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Abstract 
Routinely collected population-based cancer registry stage data are crucial to inform health 
service planning and to monitor variations in cancer patients’ outcomes. However, 
incomplete stage information is a major concern due to potential biases this introduces. This 
thesis examined the reasons why a large proportion of prostate cancer cases are recorded 
as “unknown” stage in the New South Wales (NSW) Cancer Registry (NSWCR) and validated 
the multiple imputation (MI) method as an approach for dealing with the incomplete stage 
information. 
 
NSW is the most populous state in Australia, with almost one third of the total national 
population. The NSWCR is the only population-based cancer registry in Australia that has 
routinely collected stage information since its inception in 1972. The usefulness of long-
term historical cancer registry stage data when examining cancer outcomes is illustrated in 
Chapter 2, with an investigation of geographical variation in long-term survival over time. 
The research reported in Chapter 3 shows that prostate cancer cases with “unknown” stage 
differ from those with a known stage, as survival and risk of disease progression for cases 
with “unknown” stage was intermediate between those for cases with localised and 
regional disease. Several possible reasons that could contribute to why a large proportion of 
prostate cancer cases were recorded as “unknown” stage in the NSWCR are identified in 
Chapter 4. The publication included in Chapter 5 shows that MI appears to be valid for 
“unknown” stage when the MI is implemented according to the practical guidelines 
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recommended in the literature. The application of MI to the NSWCR “unknown” stage data 
reported in Chapter 6 shows that the imputed stage data appear to be reliable. 
 
These findings provide important insights into prostate cancer cases with “unknown” stage 
recorded in the NSWCR, and an understanding of the potential biases in epidemiological 
studies that use incomplete stage data. The validated MI method to handle “unknown” 
stage will help to increase the utilisation of the cancer registry data in future research. 
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Chapter overview 
This chapter includes an introduction providing the background for the research presented 
in this thesis, a summary of the literature related to this research, and the aims and specific 
objectives that are addressed in the thesis. It first provides information on the epidemiology 
of prostate cancer worldwide and in Australia, then summarises the characteristics of 
prostate cancer, including risk factors, prostate cancer management, including diagnosis and 
treatment, as well as survival outcomes. The stage of disease information that is routinely 
collected for population-based cancer registries is described, and the utilisation of this stage 
information in cancer epidemiological research, the issues caused by the incompleteness of 
stage of disease data, and a potential method to deal with this incomplete data, are also 
described. The chapter concludes with a summary of the aims of the research and an 
overview of the structure of the whole thesis.  
 
Prostate cancer was selected for analysis in this research as it is the most commonly 
diagnosed cancer in Australia after non-melanoma skin cancer, and the second most 
common cause of cancer death for men in 2015. With growing numbers of men being 
diagnosed with and living with prostate cancer there will be increasing health care demands 
for men with this disease, resulting in an additional burden on the Australian health care 
system. Stage information as recorded in population-based cancer registries is important for 
monitoring population-wide variations in the stage distribution over time and examining 
disparities in patients’ survival outcomes. The New South Wales (NSW) Cancer Registry 
(NSWCR) is the only Australian population-based cancer registry that has routinely collected 
summary stage at diagnosis since its inception in 1972. However, over 40% of prostate 
cancer cases have “unknown” stage recorded in the NSWCR, which is a much higher 
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proportion than that for other major cancer types recorded in the same registry, and could 
be a significant problem for research using these data. Understanding the reasons why cases 
are recorded as “unknown” stage is essential for identifying the “missingness mechanism” 
and is important for informing decisions about how best to handle this incomplete stage 
data, and to better account for the potential biases caused by “unknown” stage data in 
cancer research.   
 
1 Prostate cancer – epidemiological perspectives 
 
1.1  Prostate cancer worldwide 
Prostate cancer is the second most commonly diagnosed cancer for men around the world, 
and is estimated to account for 14.8% of the total cancer diagnoses among men.1 However, 
reported age-standardised prostate cancer incidence and mortality rates vary markedly 
worldwide, with data from 2012 showing that age-standardised incidence rates ranged from 
4.2 to 227.3 per 100,000 men, and mortality rates ranged from 0.7 to 58.9 per 100,000 
men.1 The developed regions with the highest incidence rates for prostate cancer are 
Australia/New Zealand and Northern America, and rates are also high across Western and 
Northern Europe, most likely due to the use of prostate specific antigen (PSA) testing that 
has become widespread in these regions.1 The lowest reported age-standardised incidence 
rates are for Asian populations, with overall estimated rates of 10.5 and 4.5 per 100,000 in 
Eastern and South-Central Asia.1 While there are likely to be many factors contributing to 
this wide variation in the reported prostate cancer incidence around the world, the variation 
in completeness and quality of cancer registry data across different countries will play a role 
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in these observed differences. Cancer registry data are defined as being of good quality if 
they have been assessed to meet a sufficiently high standard for inclusion in the Cancer 
Incidence in Five Continents (CI5) series.2 Among countries with cancer registries included in 
the CI5 series and with high population coverage (e.g. coverage greater than 50%), Australia 
has the 3rd highest prostate cancer incidence rate (Figure 1).1  
 
Figure 1. Prostate cancer incidence and mortality rates for selected countries with high 
quality population-based cancer registries and high population coverage*, 2012 
 
* Cancer registries included in the Cancer Incidence in Five Continents 2013 with greater 
than 50% population coverage. (Source of data: GLOBOCAN 20121) 
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1.2  Prostate cancer in Australia 
Prostate cancer is the most commonly diagnosed cancer in Australia after non-melanoma 
skin cancer, and the second most common cause of cancer death for Australian men.3 With 
growing numbers of men being diagnosed with and living with prostate cancer, the 
demands for cancer care for men with this disease are continually increasing and will thus 
result in a growing burden on the Australian health care system.4, 5 As shown in Figure 2, 
due to the growth and ageing of the population and widespread use of PSA testing, the 
number of newly diagnosed prostate cancer cases almost tripled in Australia over the period 
1992-2012, from 7,926 to 20,687 cases.6 Despite this increasing number, the actual age-
standardised incidence rate showed a downward trend at the end of this period, going from 
196.6 in 2009 to 167.8 per 100,000 in 2012 (age standardised to the 2001 Australian 
standard population, which is a different standard population from that used in Figure 1). It 
is likely that this was due to a reduction in the number of PSA tests conducted, as has been 
observed in NSW.7  
 
Despite this decreasing trend in incidence rate, as the most frequently diagnosed cancer, 
prostate cancer accounts for 30% of the total burden of cancer in Australia, and driven by 
the ageing Australian population, the burden of prostate cancer will remain at a high level in 
the foreseeable future. Fortunately, the age-standardised mortality rate for prostate cancer 
has decreased over time, from 41.2 deaths per 100,000 males in 1992 to 25.8 deaths per 
100,000 males in 2014.6 However, since 1992 prostate cancer has been the second most 
common cause of cancer death for Australian men and the number of deaths from prostate 
cancer increased by 33% from 2,337 in 1992 to 3,102 in 2014.6 In 2014, prostate cancer 
accounted for 13% of all cancer deaths in Australia.6 
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Figure 2. Prostate cancer incidence and mortality trends in Australia, 1982-2012 
 
* Standardised to the 2001 Australian standard population (Source of data: AIHW 20176) 
 
2 Prostate cancer disease characteristics and management 
The prostate is a walnut-sized organ at the base of the bladder that surrounds the urethra, 
and forms part of the male reproductive system.8 Prostate cancer results from the 
uncontrolled replication of abnormal cells in the prostate gland.8 While the causes of 
prostate cancer are not fully confirmed, research suggests that there are several risk factors 
associated with the development of prostate cancer including age, family history, ethnicity, 
lifestyle and environmental factors.8 As older age is associated with prostate cancer risk, 
63% of all prostate cancer cases were diagnosed in men over 65 years of age in 2013, and by 
85 years of age one in five Australian men will be diagnosed with prostate cancer.6 Some 
variations in the patterns of prostate cancer incidence have been observed in Australia, with 
males living in inner regional areas being more likely to be diagnosed with prostate cancer 
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than men in other regions (186 new cases per 100,000 males age-standardised), and those 
living in remote or very remote areas being less likely to be diagnosed with prostate cancer 
(150 per 100,000 males age-standardised) than their counterparts living in all other 
regions.8 Research has also shown that Aboriginal and Torres Strait Islander males are less 
likely to be diagnosed with prostate cancer than non-Indigenous Australian men, but have a 
similar risk of prostate cancer death.8 Compared with non-Aboriginal men, the lower 
prostate cancer incidence rates and poorer prostate cancer survival outcomes for Aboriginal 
men are likely due to differences in the rate of PSA testing, treatment patterns, population 
risk profiles and population age structures.9 Further research is required to explain the 
differences in treatment and mortality between Aboriginal and non-Aboriginal prostate 
cancer patients, and the potential over diagnosis of prostate cancer for non-Aboriginal 
men. 
2.1  Prostate cancer detection, diagnosis and management 
Australia does not have an organised population-based prostate cancer screening program, 
as there is no available test for the early detection of prostate cancer which has an 
acceptable level of accuracy.10 The PSA test and digital rectal examination (DRE) are two 
common clinical tests used by general practitioners (GPs) to detect possible signs of 
prostate cancer, but neither of these tests are diagnostic tests for prostate cancer. A 
diagnosis of prostate cancer can only be confirmed by undergoing a biopsy of the 
prostate,8 which is a procedure in which a small sample of tissue is taken using a biopsy 
needle with ultrasound guidance. The tissue sample is examined under a microscope by a 
pathologist to determine whether cancer cells are present (Figure 3).8 
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Figure 3. Flow chart of prostate cancer detection, diagnosis and management 
Source: adapted from AIHW 2013.8 
The PSA test is a blood test used to quantify the level of PSA, which is a protein produced 
within the prostate. PSA levels in the blood naturally increase with increasing age, but a 
higher PSA level than ‘normal’ for that age is considered to be an indicator of risk of 
prostate cancer.8 However, elevated PSA levels are not specific to prostate cancer and not 
all men with prostate cancer have high PSA levels.8 A DRE is a physical examination in which 
a doctor or nurse feels the surface of the prostate to check for enlargement and detect any 
signs of prostate cancer such as irregularities including hardening or lumps on the surface of 
the prostate.8 However, not all prostate tumours are able to be felt during a DRE. In general, 
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a man will be referred for a prostate needle biopsy if a high PSA level is observed or 
irregularities in the prostate are felt in a DRE (Figure 38). 
 
A number of cancer management and treatment options are available for prostate cancer in 
Australia. Localised prostate cancer treatment and management options include: no initial 
treatment, watchful waiting or active surveillance, radical prostatectomy (RP) (removal of 
the prostate), and radiotherapy (use of high energy X-rays to kill cancer cells).8, 11 Other 
treatment options for both localised and advanced prostate cancer include chemotherapy 
(use of chemicals to kill cancer cells) and androgen deprivation therapy.8, 12, 13 Many factors 
need to be considered when deciding on the appropriate management option, including age 
at diagnosis, life expectancy, general health status, the grade and stage of disease at 
diagnosis, as well as the potential impact of treatment and any potential impact on the 
patient’s quality of life.13, 14  
 
2.2  Prostate cancer survival 
Fortunately, prostate cancer survival rates in Australia are relatively high compared to those 
observed for other cancer sites. In 2007-2011 prostate cancer 5-year relative survival was 
93%, while for all other cancers combined 5-year relative survival was 66.1% (for males 
only), and ranged from 6% for mesothelioma to 98% for testicular cancer.15 The 5-year 
relative survival for men diagnosed with prostate cancer has generally increased over time 
(Figure 4).8 In the period 1986-1993 survival was stable at around 62%, then there was an 
increase in survival from 67% in 1993 to 71% in 1994, followed by a steadily increasing trend 
to 83% in 1997. Survival was then stable again at around 83% in 1997-2003, before 
increasing steadily from 85% in 2003 to 90% in 2007,8 and up to 93% in 2007-2011.15 The 
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high survival rates for prostate cancer in Australia are likely due to the common use of PSA 
testing, which has increased detection of low risk cancers that pose little risk of death. 
 
Figure 4. Yearly trends in 5-year relative survival for prostate cancer in Australia over the 
period 1986-2007 
 
Source: AIHW analysis of the Australian Cancer Database 2007; Table S5.3.8 
 
3 Stage of disease at diagnosis 
Stage of disease describes the extent of the primary tumour and whether or not cancer has 
spread to other parts of the body. Cancer stage can be defined as clinical stage or 
pathological stage depending on the information used for staging. Clinical staging refers to 
the assessment of the primary tumour prior to first definitive treatment. For prostate 
cancer, this staging is based on the information obtained from physical examinations, such 
as DRE, transrectal ultrasonography (TRUS), Gleason score, PSA level, or other imaging 
techniques. Pathological staging refers to the stage assessment after surgical treatment, 
Chapter 1 – Introduction and literature review 
which requires histological identification of the extent of the tumour and the examination of 
the resected specimen.16, 17 In general, stage of disease at diagnosis should be determined 
or used by clinicians at the time of diagnosis for treatment decisions. Clinical stage is 
important for making decisions about treatment options, and also provides some 
information about the likely prognosis, while pathological stage is useful for prognosis and 
the evaluation of disease control achieved by treatments received. For prostate cancer, it is 
not uncommon for the pathological stage to be different from the clinical stage, especially if 
the surgery reveals that the cancer has spread to the nearby lymph nodes.18 A late stage of 
prostate cancer can also be indicated by a bone scan and supported by a raised PSA level 
without the need for a pathological test. 
3.1 Staging system 
There are several different cancer staging systems used around the world, but not all are 
general or applicable to all cancer types.18 The most commonly used staging system for 
prostate cancer is the TNM system, which was introduced by the Union for International 
Cancer Control (UICC) through its Committee on Clinical Stage Classification and Applied 
Statistics (later known as the TNM Committee) in 1954. The American Joint Committee on 
Cancer (AJCC) published their 1st edition of the “Manual for Staging of Cancer” in 1977. 
However, the recommendations of these two committees regarding staging were not 
uniform. In the later revision of the “Manual for Staging of Cancer” by the AJCC, efforts were 
made to reach uniform recommendations from the two staging committee groups in order 
to achieve a consistent staging scheme.18 Some of the past major changes in the staging of 
prostate cancer by the AJCC include the publication of the third edition in 1988, where 
additional information was based mainly on results from transurethral resection of the 
Page 11 
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prostate (TURP) and clinical information, the introduction of the T1c classification by the 
AJCC in 1992 to allow for the classification of tumours identified by a needle biopsy (e.g. 
because of elevated PSA),16, 19 and the recognition of the Gleason score as the preferred 
grading system in the seventh edition in 2010.20 The TNM staging system consists of three 
components: the size of the untreated primary tumour (T), regional lymph node 
involvement (N), and distant metastases (M).16 The TNM staging system can be used for 
both clinical and pathological staging. With four degrees of T, three degrees of N, and two 
degrees of M, the TNM staging system has 24 TNM categories and provides a reasonably 
precise classification of the extent of disease.16 For the purposes of analysis and tabulation 
TNM stages are categorised into a convenient number of stage groups by the AJCC, from 
Stage 0 (carcinoma in situ) to Stage IV (distant metastases), with each stage group being 
generally homogeneous in respect to survival outcomes.16  
 
3.2 Cancer stage recorded in population-based cancer registries 
Staging of cancer is important for cancer management at a population level because staging 
sorts cancer patients into groups with similar disease characteristics so that information 
about incidence, treatment and outcomes can be compared from a local to an international 
level.18 The role of population-based cancer registries is to collect and manage data on 
cancer diagnoses from various sources to provide data coverage of the whole population. 
This population-wide data provides valuable information on cancer which is crucial to 
understanding, and therefore controlling, the impact of cancer in that population.18 Cancer 
stage as recorded in population-based cancer registries generally includes all information 
available at the end of the first course of therapy, or within four months of initial diagnosis, 
whichever is earlier.18 This will take into consideration all of the available information 
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pertaining to the degree of spread of the tumour during clinical examination, during surgery 
and the results of the pathological examination of any specimen removed.18 Cancer registry 
stage is often referred to as summary stage as it summarises stage categories into broader 
groups with a smaller number of stage categories than enumerated in the TNM staging 
system.18, 21 Relatively simplified staging systems that are widely used by population-based 
cancer registries worldwide include the Surveillance, Epidemiology and End Results (SEER) 
system in the United States of America (USA), and the systems used by the Denmark Cancer 
Registry (DCR), the New Zealand Cancer Registry (NZCR), and the NSWCR in Australia.  
 
3.3 Prostate cancer staging systems used by cancer registries 
While the different systems used for prostate cancer staging by cancer registries all 
essentially collate very similar information, there is some variation between the systems 
used.18 Two of the most recognised staging systems used by population-based cancer 
registries are the SEER staging system, which was developed by the National Cancer 
Institute of the USA,21 and the IARC staging system described in the Manual for Cancer 
Registry Personnel by the International Agency for Research on Cancer (IARC).18 The 
descriptions of prostate cancer stage groups in the SEER and IARC staging systems are 
summarised in Table 1. Both staging systems are generally compatible with the AJCC 
staging.16, 18, 21 The primary differences between the SEER and IARC staging systems are 
mainly due to the definitions of a valid data source or evidence for staging. From 1994, the 
SEER system attempted to capture both clinical and pathological stage information, and 
adapted the new policy introduced by the AJCC Manual for Staging of Cancer 4th edition, so 
that “T1c, was defined as the tumour identified by a needle biopsy (e.g., because of 
elevated PSA)”.16 However, this was not included in the IARC staging system.18  
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Table 1. Description of prostate cancer staging as defined by SEER and IARC 
SEER staging system21 IARC staging system18 
Localised (AJCC stage I and II) 
Clinically inapparent tumour (stage A; T1a, T1b, 
T1c) 
Confined to the prostate (Involvement of one lobe, 
NOS; T2a; More than one lobe involved; T2b; 
Confined to the prostate, NOS; T2, NOS) 
Arising in prostatic apex 
Extension to prostate apex 
Invasion into (but not beyond) prostatic capsule 
Intracapsular involvement only 
Stage B 
Localised, NOS 
The tumour is invasive but is still confined 
entirely to the organ of origin. 
There is no evidence of metastasis to other 
parts of the body including the regional 
lymph nodes. 
Regional (AJCC stage III) 
Regional direct extension: 
Extension beyond prostate (T3, T4, 
extracapsular extension (beyond prostatic 
capsule), NOS; periprostatic extension, 
NOS (Stage C, NOS); periprostatic tissue 
(stage C1); through capsule, NOS; stage C, 
NOS;  
No extracapsular extension, but margins 
involved 
Regional lymph nodes (including contralateral or 
bilateral nodes) 
Both direct extension and regional lymph node(s) 
involved 
Regional, NOS 
The tumour has grown beyond the organ of 
origin. It has spread to adjacent organs or 
tissues by direct extension and/or to regional 
lymph nodes. 
Extension to periprostatic tissue, 
extracapsular extension (beyond prostatic 
capsule) NOS, through capsule, NOS. 
Extension to seminal vesicles. 
There is no evidence of distant metastasis 
based on radiological and scan examinations 
of the lung, bone and liver. 
Distant (AJCC stage IV) 
Distant site(s) / lymph node(s) involved 
Skeletal muscles: levator muscles, Pelvic bone, 
Pelvic wall, Ureter, Sigmoid colon, Penis 
Other distant involvement  
Distant, lymph nodes 
Aortic (para-aortic, peri-aortic, lumbar) 
Inguinal 
Other distant nodes 
The tumour has extended beyond the 
prostate by direct extension beyond the 
adjacent organs or tissues specified as 
regional by the summary staging guide, 
metastasis to distant lymph nodes, or 
development of secondary or metastatic 
tumours in completely different organs of 
the body for example brain, liver, lung or 
bone metastasis. 
Unknown or unstageable 
Unknown if extension or metastasis (unstaged, 
unknown, or unspecified) 
Death certificate only case 
The information in the medical record is not 
sufficient to assign a stage, and/or the 
primary site is not known. 
Cases in which the diagnosis of cancer is 
based on clinical examination alone, 
especially when the primary site and regional 
lymph nodes are not accessible. 
SEER: Surveillance, Epidemiology, and End Results Program; AJCC: The American Joint Committee on 
Cancer; IARC: International Agency for Research on Cancer; PSA: prostate-specific antigen; NOS: not 
otherwise specified. 
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4 Prostate cancer in New South Wales 
NSW is the most populous state in Australia, with almost one third of the total national 
population (7.3 million residents).6, 22 There were 7,329 cases of prostate cancer diagnosed 
in NSW in 2012, accounting for more than one-third of the total number of prostate cancer 
cases diagnosed in Australia.22 The prostate cancer incidence and mortality trends observed 
in NSW are similar to those of the nation as a whole. As shown in Figure 5, and following the 
national trends shown in Figure 2, over the period 1992 to 2012 the number of newly 
diagnosed prostate cancer cases in NSW more than doubled, increasing from 2,933 to 7,329 
cases,22 and projections indicate that this increase is likely  to continue.7 As has also been 
observed nationally however, the age-standardised incidence rate of prostate cancer in 
NSW has shown a decreasing trend, falling from 197.6 per 100,000 men in 2009 to 178.9 per 
100,000 in 2012, most likely due to a reduction in the number of PSA tests being 
performed.7 As the most populous state in Australia, NSW has prostate cancer mortality 
rates that are almost identical to the national rates,6, 22 and the survival pattern for prostate 
cancer in NSW is also similar to that nationally.23 Therefore, cancer statistics for prostate 
cancer in NSW are considered to be generalisable to the whole Australian population.  
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Figure 5. Prostate cancer incidence and mortality trends in New South Wales, 1982-2012 
 
 
* Age standardised to the 2001 Australian standard population 
(Source of data: Cancer in NSW: Online Statistics Module 2012. Cancer Institute NSW22) 
 
4.1 New South Wales Cancer Registry 
The NSWCR is the only Australian population-based cancer registry that since its inception in 
1972 has routinely collected summary stage at diagnosis. The NSWCR is managed by the 
Cancer Institute NSW under an agreement with the NSW Ministry of Health. In NSW, it is 
mandatory that all cancers diagnosed, except for non-melanoma skin cancers, are notified 
to the NSWCR by institutions including public and private hospitals, multipurpose services, 
radiation oncology departments, cancer care centres, private day procedure centres, 
residential aged care facilities and pathology laboratories.24 According to the NSW Health 
policy directive, if a patient presents for a consultation or treatment at any above 
mentioned facility in NSW and has a diagnosis of cancer then the NSWCR must be notified.24 
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Variables routinely collected by the NSWCR include age at diagnosis and year of diagnosis, 
stage of disease at diagnosis, geographical location of residence, country of birth, survival 
status and cause of death.22 Prior to the establishment of a centralised clinical registry in 
2015 no clinical treatment information was available. However, researchers can obtain 
hospital treatment information through record linkage between the NSWCR data and the 
NSW Admitted Patient Data Collection (APDC) from 2001 onwards.23 Unfortunately, no 
information on out-patient non-surgical treatments could be obtained in the cancer registry 
or through linkage with APDC or other state-based data collections. Other treatments for 
prostate cancer including radiotherapy and systemic therapies are captured by the 
National Medicare Benefits Schedule and Pharmaceutical Benefits Scheme, and these data 
have not been available for record linkage. 
4.2 Stage of disease for prostate cancer recorded in the New South Wales 
Cancer Registry 
Stage of disease at diagnosis as recorded by the NSWCR is based on the spread of disease 
information available from statutory notification forms, including hospital notifications and 
pathology reports, received up to four months after the initial date of diagnosis.24 Stage of 
disease for prostate cancer is classified using the modified summary classification by IARC 
(Table 1),18 which is similar to that used by SEER.21 This system uses the classifications of 
localised (cancer contained entirely in the prostate gland), regional (cancer extended into 
tissues surrounding the prostate or to regional lymph nodes) and distant (cancer extended 
beyond regional lymph nodes, to bones or to other distant sites). For prostate cancer, the 
NSWCR requires a sufficient level of evidence to assign a stage, this includes the degree of 
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spread information reported in cancer notification forms and definitive stage assessment 
information available in a pathology report from an RP. 
 
5  The usefulness of population-based cancer registry stage data 
in epidemiological research  
Although stage information as recorded in cancer registries results in a less detailed stage 
description than that provided by the clinical TNM staging system,25 it is still widely used in 
epidemiological studies and health services research. Cancer registry stage data are useful 
for monitoring population-wide variations in the stage distribution over time, observing 
survival trends by stage at diagnosis and estimating current and future health service 
demands.4, 25, 26 In addition, stage information is important when examining disparities in 
patients’ survival outcomes by socio-economic status27 and geographical location of 
residence as stage is a strong predictor of survival.28 The main advantage of using 
population-based cancer registry data for research is that it provides near-complete 
population coverage over a long time period with large sample sizes, and so is considered to 
be representative of the population of interest. In addition, cancer registry data are 
generally collected routinely and systematically without the specific effort and costs of data 
collection that are involved in other study designs such as cohort studies. Furthermore, 
another benefit of using registry data is that the data have been collected independently of 
the particular research question, which avoids potential recall bias.29 However, one 
limitation of using routinely collected cancer registry stage data is that it is not uncommon 
for stage information to be absent or incomplete.29 Therefore, the uncertainty created by 
Chapter 1 – Introduction and literature review 
“unknown” stage is potentially a significant problem for research, and can limit the utility of 
cancer registry data.  
There have been consistent reports of geographical disparities in cancer survival in 
Australia28, 30-35 and other countries.36-43 Stage of disease is a strong predictor of survival and 
is also associated with location of residence.44-47 Therefore, stage should be included in any 
analyses that examine such disparities. The study of survival differences by geographical 
location is a good example of how long-term historical stage data need to be used in 
epidemiological studies, however, as not all cancer registries collect stage of disease 
information, there have only been a small number of population-based studies that have 
investigated disparities in prostate cancer survival by location of residence adjusted for 
stage at diagnosis (Appendix A).28, 34, 39, 42, 43 In this thesis, the analysis of geographical 
inequalities in prostate cancer survival was selected to illustrate the value of historical 
cancer stage data in epidemiological studies. 
5.1 International studies examining urban-rural inequalities in prostate 
cancer survival 
Three international studies examined survival outcomes for prostate cancer by location of 
residence after adjustment for stage at diagnosis.39, 42, 43 Two of these studies used Cox 
proportional hazards regression, one used New Zealand Cancer Registry (NZCR) data39 and 
another from the USA used data from the Texas Cancer Registry.42 The New Zealand study 
reported some evidence of an association between poorer survival from prostate cancer 
and cancer centre travel time, after adjustment for age, ethnicity, deprivation and stage at 
diagnosis. However, 73.9% of cases had “unknown” stage recorded in the cancer registry 
Page 19 
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and were excluded from the analysis. In contrast, the Texan study found that there was no 
significant difference in prostate cancer survival by location of residence for the period 
1995-2002. In this study, the location of residence was categorised into urban, large town, 
small town and rural using the Rural Urban Commuting Area Codes based on the Census 
Bureau’s urbanised area and urban cluster definitions in combination with work commuting 
information, and the approximately 20% of cases who had “unknown” stage were included 
as a separate group.42 Both studies did not take into account the differences in the intensity 
of PSA testing between geographical areas. Another study in the USA which used data from 
seven participating cancer registries focused on clinically localised prostate cancer and 
reported that there was no significant difference in prostate cancer survival by place of 
residence. However, this result was based on a bivariable model which did not take other 
factors into account.41 
 
5.2 Utilisation of Australian cancer registry stage data in epidemiological 
studies examining urban-rural inequalities in prostate cancer survival 
There are two Australian studies of disparities in prostate cancer survival which used 
NSWCR data, with the results of these studies indicating that prostate cancer patients living 
in regional areas have lower survival than their counterparts living in major cities, after 
adjustment for stage at diagnosis.28, 34 Both studies examined 5-year survival and 
categorised place of residence into groups using the Accessibility/Remoteness Index of 
Australia (ARIA) classification, but used different statistical methods and different versions 
of the ARIA classification.28, 34 The study conducted by Jong et al., estimated 5-year relative 
survival using the period method, and examined relative excess risk (RER) using a 
generalised linear model with binomial errors and log-log link, after adjustment for age and 
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stage at diagnosis.28 The main strength of this study was the use of period analysis, which is 
considered to provide up-to-date estimates of long-term survival for a recent time period. 
All cancer cases included in the period analysis were left-truncated at the beginning of the 
period of interest in addition to being right censored at the end of follow-up.48 The results 
reported by Tervonen et al., 2017, were based on Cox proportional hazards regression 
adjusted for age, socio-economic status, and stage at diagnosis.34 The main strength of this 
study was that it assessed the potential effects of excluding cases diagnosed by death 
certificate only. Both studies had quite short follow-up time though, examining only 5-year 
relative survival, which may not have been sufficient for prostate cancer. Also the 
adjustment for stage at diagnosis may not have been effective as half of the prostate cancer 
cases were recorded as “unknown” stage in the NSWCR.28 In addition, both studies did not 
take into account the differences in the intensity of PSA testing between geographical areas. 
 
6 “Unknown” stage recorded in population-based cancer 
registries 
Stage information from population-based cancer registry data is increasingly used in 
epidemiological studies, and it is a powerful predictor of disease outcomes.28, 47, 49-53 
However, the incompleteness of stage data is a critical and major concern in regard to 
potential bias this may introduce, and because the high prevalence of cancer cases with 
“unknown” stage can reduce the ability to statistically control for the effect of stage on 
patients’ outcomes.54, 55 In this thesis, “unknown stage”, “unstaged”, “non-staged” or 
“missing stage” cancer cases recorded in the population-based cancer registry database will 
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be referred to as “unknown” stage, and includes cases with insufficient information for the 
cancer registry to assign a specific stage.  
 
Previous international studies of “unknown” stage have generally focussed on major 
cancers, including prostate,26, 44, 46, 54, 56-58 breast,44, 46, 54, 56, 58-62 colorectal,44, 46, 54-56, 58-65 and 
lung cancer.46, 54, 56, 58-60, 62, 66 There is generally significant variation  in the proportion of 
patients with “unknown” stage across the cancer types, probably due to the timing and 
complexity of the relevant staging procedures.56 Therefore, the characteristics and reasons 
why a cancer is registered as ‘‘unknown’’ stage may not be generalisable across different 
cancer sites,56 and thus only studies of “unknown” stage for prostate cancer are included in 
this review. 
 
Seven international studies focussed on “unknown” stage recorded in population-based 
cancer registries and reported results for prostate cancer.26, 44, 46, 54, 56-58 Five of these studies 
were from the USA, one study was from Denmark and one recent study was from New 
Zealand. In general, each study examined the characteristics of cancer cases with 
“unknown” stage recorded in population-based cancer registries, and also explored possible 
reasons for why these patients had their stage recorded as “unknown”. Some other studies 
did not specifically focus on “unknown” stage but did report data analysis and discussions 
relevant to “unknown” stage for prostate cancer.45, 47, 64, 67, 68 The main findings from these 
studies are summarised in Appendix B and C,26, 44-47, 54, 56-58, 64, 67, 68 and these provide the 
background for Chapters 3 and 4. 
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6.1 Characteristics of “unknown” stage prostate cancer in population-
based cancer registries 
Studies of “unknown” stage prostate cancer have reported that prostate cancer cases with 
“unknown” stage recorded in the population-based cancer registries differed from cases 
with a known stage (Appendix B).26, 44-47, 54, 56-58, 64, 67, 68 Prostate cancer patients with 
“unknown” stage were more likely to be older at diagnosis26, 44, 54, 56, 57, 64, 68 and to have 
comorbid conditions,54, 57 to be diagnosed in earlier years,26, 54 to be ethnic minorities,26, 54, 
56, 68 to be living in rural areas,26, 44, 45 to have lower education or income,26, 68 or not have 
private health insurance.44, 54, 68 Compared to prostate cancer patients who were not 
married, married cancer patients were more likely to have their stage of disease recorded in 
the cancer registries.54, 68 Studies reported that cancer cases with “unknown” stage were 
more likely to have missing grade information26, 58 and missing N-stage,57 and were less 
likely to undergo surgery or radiation treatment.56 The main strength of these studies was 
that they used multivariable logistic regression to take into account other factors when 
examining the association between socio-demographic characteristics and cases having 
“unknown” stage recorded in the cancer registries. One major limitation of these studies is 
that none took into account the differences in the intensity of PSA testing, which is an 
important factor that is associated with stage at diagnosis. 
 
6.1.1 Survival outcomes for “unknown” stage prostate cancer 
Relatively few studies have examined the survival outcomes for prostate cancer patients 
with “unknown” stage recorded in cancer registries (Appendix B). The USA SEER Cancer 
Statistics reported that only 3% of prostate cancers were recorded as having “unknown” 
stage in 2003-2009, and across all age groups and races the 5-year relative survival for these 
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cases was lower than for those with regional disease but higher than that of cases with 
distant stage.69 However, this study did not adjust for any other factors. Another study in 
the USA reported 5-year relative survival for “unknown” stage prostate cancer, but this 
study did not report a comparison of prostate cancer survival for “unknown” stage patients 
with those with a known stage recorded.54 One study using NZCR data reported that the 
survival for patients with “unknown” stage was intermediate between that of patients with 
regional and distant disease.56 Two studies in Australia using data from the NSWCR reported 
that the 5-year relative survival for prostate cancer cases with “unknown” stage was 
intermediate between that for cases with localised and regional disease.47, 67 The major 
limitations of these studies were due to the short term follow-up, follow-up for 1 or 5 years 
may not have been sufficient to fully describe the survival pattern for prostate cancer. Also, 
these studies did not adjust for the intensity of PSA testing.  
 
6.1.2 Risk of progression to metastatic disease for “unknown” stage prostate 
cancer 
Estimation of the risk of progression to metastatic disease is required to provide more 
realistic estimates of the numbers of non-metastatic cases requiring more intensive 
treatment and follow-up.4 Understanding this risk and the patterns of disease progression 
will help inform decisions about patients’ treatment and follow-up protocols, and is also 
crucial for effective planning of future health services.70 Internationally there are only a 
limited number of population-based studies that have examined the progression from non-
metastatic to metastatic prostate cancer,71, 72 while  other studies of prostate cancer disease 
progression were conducted in a single institution after patients had received specific 
treatments.73-75 However, none of this research has examined the risk of progression to 
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metastatic disease for prostate cancer cases with “unknown” stage recorded in population-
based cancer registries. 
 
A method which used routinely collected population-based NSWCR data to estimate the risk 
of developing metastatic disease for cancer patients who were initially diagnosed with non-
metastatic cancer was first described by Lord et al. in 2012.70 The study reported an analysis 
of breast cancer cases using NSWCR data and the NSW Admitted Patient Data Collection 
(APDC). The main strengths of this study were that it was population-based and utilised 
routinely collected heath data, potentially allowing for long term follow-up. The limitations 
were mainly due to the limited completeness and accuracy of subsequent cancer 
notifications of metastatic disease,70 and the study did not consider death from breast 
cancer as an indicator of disease progression. In addition, the administrative health data 
used did not include information about prognostic factors such as hormone receptor status 
or treatment received.70 Nonetheless, this method is potentially applicable to examining the 
progression of prostate cancer using population-based cancer registry data. 
 
6.2 Understanding the reasons why “unknown” stage is recorded in 
population-based cancer registries 
The possible reasons for why a cancer case is registered as ‘‘unknown’’ stage in the registry 
are likely to be multifactorial and may not be generalisable across different cancer sites.56 
For prostate cancer, the primary reasons why stage is recorded as “unknown” can be 
grouped into two summary categories. Either the stage of disease was truly unknown 
because the patient did not receive the diagnostic tests or treatment which would provide 
sufficient staging information, or stage was actually known to the treating clinicians but is 
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“unknown” to the cancer registry for various reasons including coding rules or reporting 
issues (Appendix C).  
 
Cancer cases whose stage was truly unknown 
Although stage at diagnosis is important for clinicians to make treatment decisions, it is 
possible that there are situations where patients do not have their cancer staged. This may 
be because patients aren’t well enough to complete staging procedures,54 or they may 
decide not to undergo the testing or procedures required to determine stage,44, 54 or it is 
also possible that in some cases staging is not necessary for treatment decisions to be 
made.26, 44, 56 Difficulties with access to health services, or other economic or social barriers 
may prevent some patients receiving complete staging procedures.26, 44, 56 In addition, lower 
levels or limited health insurance can also reduce a patient’s ability to undergo the testing 
and examinations required for cancer staging.54  
 
Cancer cases whose stage was known to the treating clinicians but “unknown” to the 
cancer registry 
It is also possible that for some cases registered as “unknown” stage, the clinical stage was 
assessed and determined by the treating clinician, but this information was not entered in 
the hospital notifications or medical records,45 or the staging information was not sufficient 
for the cancer registry to assign a stage, as different cancer registries have different coding 
rules for staging.56 For prostate cancer specifically, patients detected due to an elevated PSA 
level would be assigned as “unknown” stage in the NZCR.56 In addition, due to the four 
months reporting window generally required by the cancer registry, cancer patients would 
be recorded as “unknown” stage if delayed treatment or staging meant that the stage 
information was received after this period.56 
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Understanding these potential processes is difficult, as studies of these reasons for 
“unknown” stage being registered tend not to include information about any cancer-related 
procedures received after prostate cancer diagnosis. One study from New Zealand did 
report that cancer patients with “unknown” stage were less likely to have received definitive 
surgery than those with localised or regional disease.56 However, this study did not include 
information on the type of cancer care facilities that patients attended, or location of 
residence and socio-economic status of the patients. 
 
6.3 Prostate cancer cases with “unknown” stage recorded in the New 
South Wales Cancer Registry 
The introduction of the hospital Electronic Notification System (ENS) in NSW in 1994 
resulted in a considerable increase in the proportion of prostate cancer cases being 
recorded as “unknown” stage in the NSWCR, as the field for degree of spread was not 
included in the system.25 Even after this data item was restored to the ENS in 1999, the 
proportion of prostate cancer cases with “unknown” stage in the NSWCR was still much 
higher (33%) than that recorded in the NSWCR for other major cancers (i.e. 8.9% for 
colorectal cancer, 4.6% for breast cancer and 17.6% for lung cancer) in 2009.23 In addition, 
the proportion of prostate cancer cases with “unknown” stage in the NSWCR was much 
higher than in registries in the USA SEER (5.0%), Switzerland (12.7%) and Norway (25.0%) in 
2009 (Figure 6).22, 76-83 Although across the world, in those cancer registries that collect such 
information, the proportion of prostate cancer cases with “unknown” stage ranged from 
4.6% to 76%.22, 76-83 
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Figure 6. Proportion of prostate cancer cases with “unknown” stage recorded by cancer 
registries 
 
 
* Data sources from selected cancer registries where the proportion of prostate cancer cases 
with “unknown” stage are available for at least two time period.22, 76-83  
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and cancer research which excludes cases with “unknown” stage (i.e. a complete-case 
analysis) when examining patients’ outcomes could potentially be biased.55 The risk of bias 
due to missing data depends on the statistical method used to handle the missing data and 
the mechanism for the missingness in the data.84, 85 The investigation of the characteristics 
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cancer registries will be an important step towards understanding the potential biases that 
may occur in cancer research using incomplete cancer registry stage information. 
Understanding the reasons why stage is “unknown” in the registry is essential for identifying 
the missingness mechanism and is important for informing decisions about how best to 
handle this missing data, and to better account for the potential bias caused by including 
cases with “unknown” stage in cancer research. 
 
7.1  Overview of commonly used approaches for dealing with missing data 
There are several commonly used approaches to handle missing data in epidemiological 
research studies. The easiest method is complete-case analysis, in which cases with missing 
data are excluded. The main issues with this method are that the results may be biased if 
the data are not missing completely at random, and the reduced sample size may result in 
reduced statistical power to identify significant associations.85 Another method to deal with 
missing data is single imputation, where the missing data are replaced with one plausible 
value, such as the mean of the observed data.85 As with complete-case analysis, the 
advantage of this method is that standard statistical methods can be applied to the data as 
if the data are complete. However, the replacement of missing values with a single value will 
change the distribution of that variable due to the decreased variance. The uncertainty due 
to missing data is therefore not adequately reflected.86 In contrast to the complete-case 
analysis and single imputation methods, a more complex model-based method for dealing 
with missing data is the maximum likelihood method using the Expectation-Maximisation 
algorithm. This is based on a specific assumption about the distribution of the data and the 
nature of the missing data mechanism. Maximum likelihood methods focus on the 
estimation of the parameters of the observed data, namely the mean vector and variance-
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covariance matrix. However, the complex computation of the standard errors of estimates 
and the absence of robustness limit the usefulness of the method.65, 85 Fortunately, multiple 
imputation (MI) avoids the difficulties associated with maximum likelihood methods. As MI 
is a relatively flexible method for dealing with missing data and with the development of 
suitable computing software, it is increasingly used in epidemiological studies.85, 87, 88 
Different approaches can be used to implement MI, including parametric MI using chained 
equations,89 random forest regression90 and latent class analysis.91 For simplicity and clarity, 
the remainder of the section will focus on the application of a standard parametric MI, 
which is more commonly used and is easy to implement using common statistical 
software.89 
 
7.2 A brief introduction to multiple imputation 
MI is a Bayesian approach used to replace the missing values with a set of plausible values 
from the posterior predictive distribution of missing data, and reflect the uncertainty caused 
by the missing data.84, 85, 92, 93 MI has become increasingly popular due to the development 
of statistical software packages that implement the method.84, 88 MI has many advantages 
when correctly implemented under specific missing data mechanisms.93 First, MI generates 
multiple imputed datasets by imputing missing values multiple times, and retains the ability 
to use a standard statistical analysis method to analyse each imputed dataset. Second, the 
imputation model is based on the observed data, therefore it has the ability to utilise the 
knowledge involved in data collection when handling the missing data. Last but not least, MI 
reflects the uncertainty about the reasons for missingness, which consists of two types of 
uncertainties: sampling variation and the variation due to non-response.93 However, the 
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validity of the MI method depends on the specification of an imputation model which is 
based on appropriate assumptions about the mechanism for the missingness. 
 
7.2.1 Missing data mechanism 
Missingness mechanisms are generally grouped into three broad categories:85 data missing 
completely at random (MCAR), data missing at random (MAR), and data missing not at 
random (MNAR). If data are MCAR (i.e. there are no systematic differences between the 
observed data and the missing data), a complete-case analysis can provide unbiased 
estimates. However, this approach will lead to a loss of statistical power if a large proportion 
of the data are missing. When data are MAR (i.e. there are systematic differences between 
the observed data and the missing data, and the differences can be explained by the 
observed values), a complete-case analysis can produce biased results. In this situation, MI 
is an appropriate method for handling the incomplete data.84 If data are MNAR (i.e. there 
are systematic differences between the observed data and the missing data, and the 
differences cannot be explained by the observed values), the results from MI can be 
sensitive to the effects of unobserved factors.89, 94 
 
7.2.2 Implementation of multiple imputation 
The validity of using MI not only depends on the missing data mechanism, but also depends 
on the imputation model having been appropriately defined and performed.84, 89 In brief, MI 
is often described as a two-step process involving an imputation step (to develop an 
imputation model to impute missing values multiple times and generate multiple imputed 
datasets), and a data analysis step (which involves performing the intended statistical 
analysis using each of the imputed datasets generated in the imputation step).84, 87 The 
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imputation process is illustrated in Figure 7 (adapted from Lee & Simpson 201487) and is 
further described below. 
 
In the imputation step, the missing data are replaced with ‘plausible’ values multiple times 
(i.e. m times) using an imputation model appropriate for the observed data. Therefore, the 
first step is to investigate the missing data mechanism and select variables for inclusion in 
the imputation. The imputation model must include all covariates and outcomes that will be 
included in the planned data analysis, and all variables predictive of the missing data.89 The 
statistical model to be used needs to be correctly defined based on the type of variable to 
be imputed.89 The selected imputation model is then used to generate m imputed datasets. 
It is suggested that the number of imputations (m) should be at least equal to the 
percentage of cases with missing data.89, 95, 96 
 
In the data analysis step, the analysis of choice (e.g. survival analysis) is conducted 
separately for each of the imputed datasets as if each imputed dataset is a real, complete 
dataset. The m sets of results from the analyses are then combined to produce one mean 
estimate and total standard error using Rubin’s rules,92, 97 which take into account the 
variability between the imputed datasets, thus reflecting the uncertainty due to the missing 
data.92, 93 It is necessary to justify the plausibility of the MAR assumption by investigating all 
the possible reasons for the missing data,84, 88, 89 and assessing the differences between the 
results from MI and a complete-case analysis.84, 88, 89 Furthermore, it is recommended that 
details of the imputation process should be provided when reporting the results from 
analyses using the MI approach in epidemiological research.84, 88  
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Figure 7. Illustration of the multiple imputation approach, adapted from Lee & Simpson 
201487 
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the parameter of interest in the ith imputed dataset, ?̅?𝛽𝑀𝑀𝑀𝑀 is the pooled estimate for the parameter of 
interest obtained from MI.87 
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7.3 Validity of using multiple imputation for “unknown” stage of disease 
recorded in population-based cancer registries  
MI is a statistical method for handling missing data and has many advantages when 
correctly implemented. However, only a very limited number of studies have attempted to 
validate this method for handling “unknown” stage data in population-based cancer 
registries, as generally the “true” stages were not available for cases with “unknown” stage 
recorded in the cancer registry. The MI approach to “unknown” stage data recorded in 
population-based cancer registries has been validated by three studies using simulated 
datasets for male colorectal cancer, melanoma and female breast cancer. 86, 98, 99 These 
studies suggest that MI is potentially a practical method for handling incomplete cancer 
stage data. 86, 98, 99 The main findings from these studies are summarised in Appendix D and 
these provide the background for Chapter 5. 
 
In the study by Eisemann et al. 2011, 26.1% of female breast cancer cases and 90.4% of 
melanoma cases had “missing” stage by artificially generating “missing values” for fully 
observed data under a pre-specified missing data mechanism (e.g. they specified that the 
missing stage data were MAR, with the missingness of stage depending mostly on age at 
diagnosis, survival time, censoring and the interaction between survival time and censoring). 
Ten datasets were generated using each of the four imputation scenarios, and the 
concordance of the imputed stage with their observed values and the extent of dislocation 
was assessed.99 MI with chained equations using multinomial regression or using the 
predictive mean matching model appeared to be appropriate methods for dealing with 
missing stage data.99 Another study, using data for male colorectal cancer, also confirmed 
that a multinomial logistic regression model for stage that included the Nelson-Aalen 
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cumulative hazard estimate and an indicator variable for the event of interest provided valid 
estimates for the hazard ratios and net survival.98 The main strengths of these two studies is 
that a simulation approach allowed for comparison between the different methods for a 
known missing data mechanism. However, the missingness patterns in the real world 
cannot be confirmed by simulation studies. Moreover, there is no research that has 
examined the validity of using MI for prostate cancer with “unknown” stage recorded in a 
population-based cancer registry. 
 
Marshall et al. reported a simulation study of breast cancer to evaluate the performance of 
MI for four variables, including tumour size categorised from a continuous variable, based 
on different missing data mechanisms and the proportion of missingness.86 This study 
showed that the performance of MI depends on the proportion of missingness, and that MI 
may be preferred when fewer than half of the cases have missing data and the missing data 
are not MNAR.86 A previous population-based study65 reported a tutorial on MI using ordinal 
regression models for colorectal cancer stage under the assumption that the missing data 
are MAR. However, the results were not directly validated because, like most analyses, the 
“true” stage was not available in that study. Another study of the validity of MI for variables 
other than cancer stage which used linked ambulance records100 reported fair to good 
agreement between the imputed values for variables in a state trauma registry when 
compared with known values from an additional data source, although this study 
unfortunately did not report a formal statistical test of the MAR assumption. 
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8 Summary and aims of the research included in this thesis 
8.1 Gaps in the literature 
Research from around the world has indicated that prostate cancer patients with 
“unknown” stage recorded in population-based cancer registries differ from patients with a 
known stage recorded (Figure 8). The possible reasons for why a cancer case is registered as 
‘‘unknown’’ stage in the registry are likely to be multifactorial and suggest some potential 
disparities in accessing health services. There is currently no Australian research 
investigating issues related to “unknown” stage prostate cancer. Given the impact of 
prostate cancer in Australia, the importance of using population-based cancer registry 
stage data in epidemiological research, and that “unknown” stage is also associated with 
location of residence, the potential biases in studies of prostate cancer caused by the 
incomplete stage data are a major concern. Knowing the socio-demographic and disease 
characteristics of patients recorded as having “unknown” stage, and understanding the 
reasons why “unknown” stage is recorded in the cancer registry, are essential to better 
understanding the potential biases in epidemiological studies that use incomplete stage 
data. This understanding may also inform strategies for data quality assurance and 
contribute to more effective cancer surveillance. 
Page 36 
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Figure 8. What is currently known about “unknown” stage prostate cancer recorded in 
cancer registry data and gaps in the literature  
Findings from international studies Patients 
Not suitable for staging • Older age and/or
comorbid conditions
Did not receive staging 
assessment due to: 
• Difficulties with access to
health services.
• Economic or social barriers.
• Limited health insurance.
• No private health
insurance
• Not married
Potential reporting issues:
• Stage information was not
reported to the registry.
• Incomplete documentation.
• Ethnic minorities
• Lower education level
or income level
• Received non-surgical
treatment
Cancer notification system 
Health facilities 
Cancer registry 
Stage coding rules: 
• Insufficient evidence for
staging, cases detected due to
elevated PSA.
• Received non-surgical
treatment.
• Staging occurred after the 4-
month reporting window used
by the cancer registry.
• Living in rural areas
• Missing grade or N
stage
• Poorer survival than
localised stage
Use of registry stage data 
 • Monitoring survival and 
stage distribution.
• Informing health
service planning.
• Research on cancer
outcomes. Issues caused by “unknown” stage and gaps in the 
literature 
• There is currently no Australian research investigating
issues related to “unknown” stage prostate cancer and 
how to handle this incomplete data. 
• Potential biases caused by “unknown” stage, as
“unknown” stage was associated with survival and rural 
location of residence.
• The development and validation of an appropriate and
practical method for handling this incomplete stage
data is required.
• The term “unknown” stage is difficult to translate from
research to clinical practice or decision making.
Stage data 
Known Unknown 
Urban-rural inequalities 
in cancer survival 
Reduce disparities in 
cancer outcomes 
Improve patients’ 
outcomes 
Why is stage recorded as 
“unknown” in the cancer registry? 
Characteristics of cases 
with “unknown” stage 
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The results of several international studies suggest that the proportion of cases with 
“unknown” stage recorded in population-based cancer registries has decreased over time, 
indicating an improvement in capturing stage data in the cancer registries in more recent 
years.59 However, there is still a need to use historical cancer registry data for studies of 
patients’ outcomes that require long term follow-up, even when there is a large proportion 
of cases with “unknown” stage. Thus, the development and validation of an appropriate 
method for handling incomplete stage information is required. 
 
Stage information as recorded in population-based cancer registries is of particular 
importance for research on cancer patients’ survival outcomes.28 The most recent NSW 
study examining geographical inequalities in cancer survival presented 5-year relative 
survival using data for 1992-1996.28 With the implementation of health policies to reduce 
the observed geographical disparities and the availability of over 10 years of new data, there 
is now a need to investigate the effectiveness of the efforts made to reduce the disparities 
using more recent data with longer follow-up. Understanding and dealing with cases 
registered as “unknown” stage would ideally allow for more accurate and informed analyses 
of survival outcomes.  
 
8.2 Aims of the research in this thesis 
The aims of this research were to illustrate the usefulness of historical cancer registry stage 
data in epidemiological studies of patients’ outcomes that require long term follow-up, to 
achieve a better understanding of why a large proportion of prostate cancer cases are 
recorded as having “unknown” stage of disease in the NSWCR, and to validate a statistical 
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method to deal with the incomplete stage information. Specifically, the aims of the research 
completed for this thesis were to: 
1. Illustrate the importance of historical population-based cancer registry stage data in 
epidemiological studies by examining the geographical variation in prostate cancer 
survival with 10-years follow-up. 
2. Describe the characteristics and outcomes of men with “unknown” stage prostate 
cancer recorded in the NSWCR, including the survival outcomes and risk of 
developing metastatic disease.  
3. Investigate the possible reasons why prostate cancer cases are recorded as 
“unknown” stage in the NSWCR, and the direction of potential biases caused by 
“unknown” stage in epidemiological studies, by linking administrative data sets and 
examining the patterns of inpatient hospital cancer services for prostate cancer 
cases with “unknown” stage. 
4. Validate the use of MI as a method for handling data with “unknown” stage by using 
data from a population-based cohort study linked with a sub-set of the NSWCR data. 
5. Further evaluate the performance of the MI method for dealing with long term 
historical “unknown” stage data in the NSWCR by applying MI to NSWCR prostate 
cancer stage data for 1982-2007, and examining the impact of including imputed 
stage in analyses of patients’ outcomes. 
 
8.3 Presentation of the thesis 
Figure 9 shows an overview of the analytical framework for this thesis. This thesis comprises 
seven chapters, with four of the chapters including five papers which have been published 
in peer-reviewed journals. The main contents of each chapter are as follows:  
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Chapter 1 provides an overview of the background information of the research area and a 
review of the literature, identifies the gaps in the literature, and outlines the aims of this 
research. It also provides a brief description of the structure of this thesis.  
 
Chapter 2 includes the paper “Geographic variation in prostate cancer survival in New South 
Wales”. This study used NSWCR data to examine survival patterns for prostate cancer by 
geographical location with up to 10 years of follow-up after diagnosis. 
 
Chapter 3 consists of two papers, “Characteristics of cases with unknown stage prostate 
cancer in a population-based cancer registry” and “A population-based study of progression 
to metastatic prostate cancer in Australia”. The first paper examined the socio-demographic 
characteristics and the survival outcomes of prostate cancer patients who had their stage of 
disease at diagnosis recorded as “unknown” in the NSWCR. The second study used NSWCR 
data to examine the risk of progression to subsequent metastatic disease from non-
metastatic prostate cancer or “unknown” stage cancer after up to 14 years of follow-up. 
 
Chapter 4 includes the paper “Cancer related hospitalisations and “unknown” stage prostate 
cancer: a population-based record linkage study”. In this paper, linked NSWCR-APDC data 
were used to examine the pattern of hospitalisations relating to prostate cancer by stage of 
disease at diagnosis, and identifies possible explanations for stage at diagnosis being 
recorded as “unknown” in the NSWCR.  
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Chapter 5 contains the paper “Validity of using multiple imputation for unknown stage at 
diagnosis in population-based cancer registry data”. This study provided a unique evaluation 
of the MI method for handling “unknown” stage data in the NSWCR, using an external data 
source for stage from a population-based cohort study linked to the NSWCR data. 
 
Chapter 6 evaluates the performance of the MI approach for dealing with long-term 
historical “unknown” stage data in the NSWCR, and examines the impact of the imputed 
stage data on the assessment of patients’ outcomes, including prostate cancer specific 
survival and progression to metastatic disease. 
 
The concluding chapter, Chapter 7, provides a broad discussion and a summary of the main 
findings, and draws together recommendations from the research described in the thesis. 
 
All references are listed at the end of each chapter. 
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Figure 9. Overview of the structure of the thesis 
 
 
 
NSWCR: New South Wales Cancer Registry  
To understand the reasons why prostate cancer 
cases have “unknown” stage recorded in the NSWCR 
To investigate the missing data mechanism for 
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handle this incomplete stage data 
To evaluate the performance of multiple imputation for 
“unknown” stage in long-term historical cancer registry 
data and the impact on epidemiological studies 
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stage for cancer patients 
To illustrate the importance of using historical cancer 
registry stage data in epidemiological research 
Chapter 2 - The utilisation of historical 
population-based cancer registry stage data in 
an epidemiological study (Paper 1). 
Chapter 3 - Characteristics of cases with 
“unknown” stage prostate cancer and 
progression to metastatic prostate cancer 
(Papers 2 and 3). 
Chapter 5 - Validity of using multiple 
imputation for “unknown” stage at diagnosis 
in population-based cancer registry data 
(Paper 5). 
Chapter 6 - Application of multiple imputation 
for “unknown” stage in the NSWCR. 
Chapter 4 - The possible reasons why 
“unknown” stage is recorded in the NSWCR 
(Paper 4). 
Chapter 1 - Introduction and literature review 
Chapter 7 - Discussion 
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Appendices 
Appendix A. Summary of population-based studies examining disparities in prostate cancer patients’ survival outcomes by location of 
residence using cancer registry data adjusted for stage at diagnosis 
Author Study 
population 
Data source Method Measure of geographical 
location of residence 
Results 
Jong et al., 
200428 
New South 
Wales, 
Australia 
Data for all cancers including prostate 
cancer diagnosed in 1992-1996 followed 
up to the end of 1999 were obtained 
from the New South Wales Cancer 
Registry 
Relative survival using 
period method and the 
relative excess risk 
using log linear 
regression 
The Accessibility/Remoteness 
Index of Australia (ARIA) was 
used to determine 
remoteness 
Men in remote areas remained at increased 
excess risk of death from prostate cancer, after 
adjustment for age and stage at diagnosis. The 
51% of prostate cancer cases with “unknown” 
stage were included as a separate group. 
Haynes et 
al., 200839 
New 
Zealand 
Data for 5 cancer types, including 
prostate cancer, diagnosed in 1994-2004 
were obtained from the New Zealand 
Cancer Registry 
Cox proportional 
hazards regression 
Estimated travel time to the 
nearest general practitioner 
(GP) and travel time to the 
nearest cancer centre 
There was some evidence of an association 
between prostate cancer survival and cancer 
centre travel time, after adjustment for age, 
ethnicity, deprivation and stage at diagnosis. 
However, 73.9% of cases had “unknown” stage 
recorded in the cancer registry and were 
excluded from analysis. 
Schymura 
et al., 
201041 
Seven 
participating 
states in the 
USA 
Clinically localised prostate cancer 
patients diagnosed in 1997 were 
selected from the databases of the 
participating central cancer registries 
Cox proportional 
hazards regression 
Urban vs rural Urban-rural residence was not statistically 
significant in the bivariable model, and was not 
included in the multivariable model. 
White et 
al., 201142 
Texas, USA Data for prostate cancer cases diagnosed 
in 1995-2002 were obtained from the 
Texas Cancer Registry 
Kaplan-Meier method 
and Cox proportional 
hazards regression 
Location of residence was 
categorised into urban, large 
town, small town and rural 
No difference in survival outcome by 
geographical location was observed. This study 
adjusted for ethnicity, socio-economic status, 
tumour grade, stage at diagnosis. 
Tervonen 
et al., 
201734 
New South 
Wales, 
Australia 
Data for all cancers, including prostate 
cancer, diagnosed in 2000-2008 were 
obtained from the New South Wales 
Cancer Registry 
Cox proportional 
hazards regression 
Remoteness classified as 
major city, inner regional, 
outer regional/remote 
Survival inequality by remoteness was observed. 
This study adjusted for age, socio-economic 
status and stage at diagnosis. 
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Appendix B. Summary of studies that reported characteristics of prostate cancer patients with “unknown” stage recorded in population-
based cancer registries  
Study Study 
population 
Data source Method Findings 
* Liff et al., 
199045 
USA 
 
6 cancers, including prostate cancer, 
diagnosed in 1978-1985, using data from 
the Georgia Centre (affiliated with the 
SEER program) 
Multivariable logistic 
regression 
The proportion of cases with unknown stage was higher in rural 
areas than in metropolitan Atlanta. 
* Roetzheim et 
al., 199968 
USA 
 
4 cancers, including prostate cancer, 
diagnosed in 1994, using data from the 
Florida Cancer Data System 
Logistic regression 
models 
Cancer patients with unknown stage were more likely to be older, 
have lower education and income, to be unmarried, non-white, 
male, and to be insured by Medicare. 
* NHMRC 
200267 
New South 
Wales, Australia 
Prostate cancer diagnosed in 1973-1994 
using data from the New South Wales 
Cancer Registry 
5-year relative survival 
using cohort method 
The 5-year relative survival for prostate cancer patients with 
“unknown” stage was intermediate between that of cases with 
localised and regional disease. 
* Yu et al., 
200647 
New South 
Wales, Australia 
 
28 major cancers, including prostate 
cancer, diagnosed in 1980-1996, using 
data from the New South Wales Cancer 
Registry 
Relative survival using 
period method and 
Poisson regression 
The 5-year relative survival for prostate cancer patients with 
“unknown” stage was intermediate between that of cases with 
localised and regional disease. 
Klassen et al., 
200626 
USA 
 
Prostate cancer patients diagnosed in 
1992-1997, using data from the 
Maryland Cancer Registry 
 
Multilevel logistic 
regression; Generalized 
Linear Latent and 
Mixed Models 
(GLLAMM) 
Cancer patients with unknown stage were more likely to be older, 
black race, have missing tumour grade and live in areas with higher 
county-level median income. The proportion of cases with 
unknown stage decreased with recent year of diagnosis, higher 
blockgroup-level income and county-level rurality. 
Koroukian et al., 
200744 
USA 
 
Breast, prostate and colorectal cancer 
patients diagnosed in 2000 at age≥65 
years, using data from the Ohio Cancer 
Incidence Surveillance System and linked 
data 
Chi-squared test; 
Multivariable logistic 
regression 
Cancer patients with unknown stage were more likely to be older, 
have a moderate or high complexity of care needs, and be Medicaid 
beneficiaries. Variation by county of residence was observed, with 
the highest proportion of patients with unknown stage being in 
suburban counties. 
* Bradley et al., 
200864 
USA 
 
Patients with breast, colorectal, lung or 
prostate cancer diagnosed in 1997-2000, 
using data from the Michigan Tumour 
Registry and Medicare records 
Logistic regression Cancer patients with “unknown” stage were more likely to be older 
and have high mortality within a few months after cancer diagnosis. 
A much larger proportion of nursing home residents had “unknown” 
stage cancer than other elderly patients residing in Michigan. 
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Appendix B. Summary of studies that reported characteristics of prostate cancer patients with “unknown” stage recorded in population-
based cancer registries (continued) 
Study Study 
population 
Data source Method Findings 
Merrill et al., 
201154 
USA 
 
18 cancer types, including prostate 
cancer, diagnosed in 2000-2007, 
using data from 17 population-based 
cancer registries in the SEER program 
Multiple regression 
models; 
Relative survival using 
cohort method 
Cancer patients with “unknown” stage were more likely to be older and 
have comorbidity conditions, be black or of Spanish-Hispanic-Latino 
descent, reside in Appalachia, and have lower levels of health insurance. 
Married patients were more likely to have their stage recorded, and the 
proportion of cases having an “unknown” stage decreased over time. 
Nguyen-Nielsen 
et al., 201257 
Denmark Patients with prostate cancer 
diagnosed in 2004-2009, using data 
from the Danish Cancer Registry 
Report completeness of 
stage information 
stratified by age group 
and comorbidity index 
group 
Cancer patients with “unknown” stage were more likely to be older and 
have comorbidity conditions 
Hsieh et al., 
201258 
USA Patients with prostate, lung, 
colorectal and female breast cancer, 
diagnosed in 2004-2007, using data 
from 47 population-based cancer 
registries 
Relative importance 
analysis; 
Multiple linear regression 
Cancer patients with “unknown” stage were more likely to be diagnosed in 
2005 or to be cases reported by a non-hospital reporting source, or with 
unknown grade. 
Gurney et al., 
201356 
New 
Zealand 
 
18 cancer sites, including prostate 
cancer, diagnosed in 2006-2008, 
using data from the New Zealand 
Cancer Registry 
Logistic regression; 
Cox regression 
Cancer patients with “unknown” stage were more likely to be older, and 
less likely to have received definitive surgery than those with local or 
regional disease. Patients with “unknown” stage had 28-day and 1-year 
survival that was intermediate between that of cases with regional and 
distant disease. 
Watanabe-
Galloway et al., 
201546 
Northern 
Plains in 
USA 
 
4 cancer types, including prostate 
cancer, diagnosed in 2002-2009, 
using data from the cancer registries 
of Nebraska, North Dakota, and 
South Dakota 
Logistic regression 
 
Prostate cancer patients with “unknown” stage were more likely to be 
older, to be American Indians/Alaska Natives, living in areas with low socio-
economic status, and diagnosed in early years, but were less likely to be 
living in small urban or rural areas. 
* These studies were not focussed on “unknown” stage but have relevant discussions or data analysis for prostate cancer patients with “unknown” stage 
 
  
Chapter 1 – Introduction and literature review 
 
Page 46 
 
Appendix C. Summary of studies that reported possible reasons for ‘‘unknown’’ stage prostate cancer cases being recorded in population-
based cancer registries 
Study Study 
population 
Data source Method Possible reasons why a cancer case is registered as ‘‘unknown’’ stage  
* Liff et al., 
199045 
USA 
 
6 cancers, including prostate cancer, 
diagnosed in 1978-1985, using data 
from the Georgia Centre (affiliated 
with the SEER program) 
Multivariable logistic 
regression 
Differences in access to or utilization of early detection methods may 
contribute to the rural-urban differential in the extent of disease. 
Klassen et al., 
200626 
USA 
 
Prostate cancer patients diagnosed 
in 1992-1997, using data from 
Maryland Cancer Registry 
 
Multilevel logistic 
regression; 
Generalized Linear 
Latent and Mixed 
Models (GLLAMM) 
Less complete diagnostic assessment in prostate cancer. Older men and 
African Americans have higher rates of co-morbidities that present 
legitimate barriers to aggressive work-up and treatment for new disease. 
Economic and social barriers reduce access to work-up even when 
individual patients are good candidates for treatment. Hospitals treating 
more African American and older patients may also have greater barriers 
to cancer reporting. 
Koroukian et al., 
200744 
USA 
 
3 cancers, including prostate cancer, 
diagnosed in 2000 at age≥65 years, 
using data from the Ohio Cancer 
Incidence Surveillance 
Chi-squared test; 
Multivariable logistic 
regression 
The documentation of cancer patients with “unknown” stage implies that 
there is missing information on the extent of disease. 
Merrill et al., 
201154 
USA 
 
18 cancer types, including prostate 
cancer, diagnosed in 2000-2007, 
using data from 17 population-based 
cancer registries in the SEER program 
Multiple regression 
models; 
Relative survival using 
cohort method 
Lower levels of health insurance limits patient’s ability to undergo testing 
and examinations for cancer staging. Culture may also influence the 
patient’s willingness to consent to a diagnostic workup. In addition, a 
thorough cancer work-up is more limited among patients of poorer overall 
health status. 
Gurney et al., 
201356 
New Zealand 
 
18 cancer sites, including prostate 
cancer, diagnosed in 2006-2008, 
using data from the New Zealand 
Cancer Registry 
Logistic regression 
Cox regression 
Cancer registries require sufficient evidence to assign a stage. It is possible 
that comprehensive staging of disease is at least in part related to the 
significance of the health burden that the cancer represents in a given 
population. Patient-related factors include advancing age, comorbidity, and 
poorer access to health care services. Informal clinical staging indicates the 
patient is inoperable or clearly has advanced disease, or some patients 
refused both treatment and staging procedures. 
* These studies were not focussed on “unknown” stage but have relevant discussions or data analysis for prostate cancer patients with “unknown” stage 
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Appendix D. Summary of studies that reported validity of using multiple imputation for dealing with ‘‘unknown’’ cancer registry stage 
recorded in population-based cancer registries 
Study Cancer type Proportion of 
cases with 
missing data 
Data 
source 
Assumption Imputation model Variables included Number of 
imputations 
Findings  
*Marshall et 
al., 201086 
Female 
breast cancer 
5-75% Simulated 
missing 
data 
Missing at 
random 
Multinomial logistic 
regression model 
Age at diagnosis, lymph 
nodes, progesterone and 
oestrogen receptor, 
hormonal treatment, 
menopausal status, tumour 
grade, Nelson-Aalen 
estimate of the cumulative 
hazard of the survival time, 
or survival time and event 
status. 
20 The performance of MI depends 
on the proportion of missingness, 
and MI may be preferred when 
fewer than half of the cases have 
missing data and the missing data 
are not MNAR 
Eisemann et 
al., 201199 
Female 
breast 
cancer, 
melanoma 
26.1% for 
breast cancer 
and 90.4% for 
melanoma 
Simulated 
missing 
data 
Missing at 
random 
Chained equations 
using multinomial 
regression 
Age at diagnosis, survival 
time, censoring and the 
interaction between survival 
time and censoring. 
10 Multiple imputation appeared to 
be appropriate method for 
dealing with missing stage data. 
Falcaro et 
al., 201598 
Male 
colorectal 
cancer 
30% Simulated 
missing 
data 
Missing at 
random 
Multinomial logistic 
regression model 
Age at diagnosis, event 
indicator, deprivation, 
Nelson-Aalen estimate of the 
cumulative hazard 
30 Imputation models with a 
multinomial logistic regression 
and the Nelson-Aalen estimate of 
the cumulative hazard perform 
best. 
* The imputed variable is tumour size categorised from a continuous variable. 
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Chapter overview 
Stage information as recorded in population-based cancer registries is widely used in 
epidemiological studies and cancer research, and can be crucial when examining the 
disparities in cancer survival outcomes by location of residence. In this thesis, the analysis of 
geographical inequalities in prostate cancer survival was selected to illustrate the need for 
the use of valuable historical cancer stage data in epidemiological studies, as there have 
been consistent reports of geographical disparities in cancer survival in Australia28, 30-35 and 
other countries,36-43 and stage of disease as a strong predictor of survival is also associated 
with location of residence.44-47 This chapter illustrates the importance of cancer registry 
stage data using an epidemiological study that examined urban-rural inequalities in prostate 
cancer survival which was reported in the published paper Geographic variation in prostate 
cancer survival in New South Wales. The New South Wales Cancer Registry (NSWCR) data for 
prostate cancer diagnosed in 1982-2007 were analysed to assess the disparity in prostate 
cancer survival according to geographical location of residence at the time of diagnosis in 
NSW. The period method was used to estimate the relative survival after up to 10 years of 
follow-up, and multivariable Poisson regression models were used to examine geographical 
variation in relative survival, adjusted for other factors. This study identified disparities in 
prostate cancer survival by place of residence, and there was no evidence of a reduction in 
geographical disparities in prostate cancer survival over time. However, over 40% of 
prostate cancer patients in this study were recorded as “unknown” stage in the NSWCR, and 
were included as a separate group in the analyses, which may result in residual confounding 
and potential biases. In addition, while “unknown” stage is a specific term as defined for use 
in population-based cancer registries, it is not of relevance in other settings, and has little 
Chapter 2 – Utilisation of historical cancer registry stage data in an epidemiological study 
 
Page 62 
 
meaning for clinicians, patients or policy makers. As a result, it is difficult to translate 
research that categorises “unknown” stage as a group to clinical practice or health policy 
decision making. Further investigations of the characteristics of, and reasons for, Australian 
prostate cancer cases being registered with “unknown” stage, and validation of the use of 
multiple imputation (MI) to handle this incomplete data are presented in Chapters 3-5. In 
Chapter 6, the analysis reported in this chapter is repeated and the results are assessed 
after applying the MI method for “unknown” stage.  
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Geographic variation in prostate cancer 
survival in New South Wales
Abstract
Objectives: To determine whether the previously reported urban–rural 
diff erential in prostate cancer survival remains after adjusting for demographic 
and clinical factors, and to investigate temporal trends in this diff erential.
Design, setting and participants: Retrospective population-based survival 
analysis of 68 686 men diagnosed with prostate cancer from January 1982 to 
December 2007 in New South Wales.
Main outcome measures: Survival rate and relative excess risk (RER) of death 
over 10 years of follow-up in relation to geographic remoteness after adjusting 
for other prognostic factors.
Results: Overall, 10-year survival increased during the study period, increasing 
from 57.5% in 1992–1996 and 75.7% in 1997–2001 to 83.7% in 2002–2007. 
The increasing trends were also observed across categories of geographic 
remoteness and socioeconomic status. Urban–rural diff erentials were signiﬁ cant 
(P < 0.001) after adjusting for ﬁ ve important prognostic factors, with men living 
outside major cities having higher risk of death from prostate cancer (RER, 1.18 
and 1.32 for inner regional and rural areas, respectively). Socioeconomic status 
was also a signiﬁ cant factor (P < 0.001) for prostate cancer mortality, with 
the risk of dying being 34% to 40% higher for men living in socioeconomically 
disadvantaged areas than those living in least disadvantaged areas. There was 
no evidence that this inequality is reducing over time, particularly for men living in 
inner regional areas.
Conclusions: Despite the increasing awareness of urban–rural diff erentials in 
cancer outcomes, little progress has been made. Appropriately detailed data, 
including details of tumour characteristics, treatment and comorbid conditions, 
to help understand why these inequalities exist are required urgently so 
interventions and policy changes can be guided by appropriate evidence.
There have been consistent reports of disparities in cancer survival according to place of 
residence at diagnosis in Australia.1-5 
Patients living in rural and remote 
areas of New South Wales have 
poorer survival from several major 
cancers, including prostate cancer, 
than their city counterparts.6 With 
increasing attention from stake-
holders and the media, and with the 
implementation of health policies and 
programs designed to reduce urban–
rural in equality,7 the differential in 
outcomes from prostate cancer may 
have reduced.
A recent national study compared 
prostate cancer incidence, mortality, 
prostate-specifi c antigen (PSA) test-
ing and survival for men living within 
and outside Australian capital cities.1 
It reported that the survival differen-
tial increased over time, so that men 
living outside the capital cities who 
were diagnosed with prostate cancer 
were 24% more likely to die within 5 
years of being diagnosed. However, 
these results were not adjusted for 
stage at diagnosis. The same study 
showed that rates of PSA screening 
were higher in capital cities.1
It has also been reported that rates 
of advanced prostate cancer are higher 
in rural NSW,6 so the inequality in 
survival could be explained by higher 
proportions of men in capital cities 
being diagnosed with asymptomatic 
cancers with a low propensity to prog-
ress further.
For this reason we expanded the 
initial NSW study,6 which accounted 
for spread of disease at diagnosis (as 
an indication of stage), to see whether 
data for an additional 11 years would 
show a reduction in urban–rural 
inequalities in prostate cancer sur-
vival. This information will help in 
assessing whether policies to reduce 
health inequalities in Australia7 have 
been effective.
Methods
We obtained data from the NSW 
Central Cancer Registry (CCR) on all 
fi rst primary prostate cancers that were 
diagnosed in patients aged 18–84 years 
from 1 January 1982 to 31 December 
2007 and that were prevalent cases 
between 1992 and 2007. We excluded 
cases that were reported through 
death certifi cate only or fi rst identi-
fi ed postmortem.
Study variables
The outcome variable was all-cause 
survival time after a diagnosis of 
prostate cancer. Survival status was 
obtained through record linkage of 
the cancer cases in the CCR with the 
death records from the NSW Register 
of Births, Deaths and Marriages and 
the National Death Index. All eligi-
ble patients were followed up until 31 
December 2007, the most recent data 
available to us.
The primary study variable was 
place of residence, based on local 
government area. We categorised 
place of residence into major cities, 
inner regional and “rural” (a group-
ing of outer regional, remote and very 
remote) areas based on the Australian 
Standard Geographic Classifi cation 
Remoteness Structure8 (Appendix 1; 
online at mja.com.au).
We included two additional area-
based measures. First, we used age-
standardised prostate cancer incidence 
rates as a surrogate for PSA test-
ing activities, because much of the 
urban–rural variation in prostate can-
cer incidence rates may refl ect differ-
ences in the intensity of PSA screening 
between geographic areas.9 Second, 
we used the Index of Relative Socio-
economic Disadvantage by local gov-
ernment area (LGA), derived from the 
2001 Census, as a measure of area-
level socioeconomic status (SES).10 For 
each LGA, these two measures were 
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ranked and then grouped into three 
levels (high, medium and low), with 
the cut-points chosen to ensure sim-
ilar sized populations in each group.
Additional variables included were 
age at diagnosis, categorised into three 
groups (18–64 years, 65–74 years and 
75–84 years) and spread of disease 
at diagnosis categorised into three 
groups (localised, non-localised and 
unknown).
Ethics approval
Ethics approval was obtained from the 
NSW Population and Health Service 
Research Ethics Committee (reference 
number: 2009/03/139).
Statistical analysis
Survival relative to the general pop-
ulation was calculated using period 
analysis,11 with cancer cases under 
observation in each of three “at-risk” 
periods — 1992–1996, 1997–2001 and 
2002–2007. We estimated expected 
survival for each at-risk period and 
degree of geographic remoteness using 
data on all-cause mortality and num-
bers of males in the NSW population 
by age in years, LGA and calendar 
year provided by Australian Bureau 
of Statistics. A publicly available set 
of STATA syntax programs were used 
for estimating relative survival (http://
www.pauldickman.com/survival/strs.
pdf).
To adjust for other prognostic fac-
tors, we used a Poisson regression 
model12 to examine geographic vari-
ation in relative survival. The relative 
excess risk (RER) of death derived from 
this model is the ratio of the excess 
risk of death in a given region to that 
of the reference (major cities in this 
study) after controlling for other fac-
tors including age, spread of disease at 
diagnosis, prostate cancer incidence, 
at-risk period, year of follow-up (up to 
10 years) and SES. A two-sided, log-
likelihood ratio test result with a P 
value < 0.05 indicated statistical signif-
icance. An absolute measure — num-
ber of excess deaths5 — was calculated 
as the difference between the num-
ber of excess deaths observed and the 
number expected if all patients with 
prostate cancer in NSW had the same 
probability of survival as those in the 
major cities or the least disadvantaged 
SES group.
We conducted several further 
analyses:
• we added an interaction term
between the geographic remote-
ness and at-risk period to the model 
to allow the effect of geographic
remoteness to change over time
and then used a likelihood ratio test 
between the nested models to assess 
if this interaction was signifi cant;
• we compared two models (one
including SES and another with-
out) to examine the effect of SES
on the geographic variation in sur-
vival over time;
• we performed a sensitivity anal-
ysis by assuming all cases with
unknown stage had localised can-
cers, or non-localised cancers to
examine the effect of unknown
stage on geographic variation in
outcomes; and
• we estimated age-standardised
prostate cancer mortality rates over 
1992–2007 by geographic location
to consider the possible impact of
lead-time bias on survival intro-
duced by urban–rural differences
in the intensity of PSA testing, as
lead-time bias does not affect mor-
tality rates.
Analyses were performed using 
Stata statistical software, version 11.1 
(StataCorp).
Results
There were 68 959 men aged 18–84 
years diagnosed with prostate cancer 
from 1 January 1982 to 31 December 
2007; 273 cases were excluded because 
they had been reported to the CCR 
through death certificate only or 
identifi ed postmortem. Of the 68 686 
men included in this study, over two-
thirds (67.8%) lived in major cities 
and about a quarter (23.9%) in inner 
regional areas; 47.7% had localised 
disease and the stage was unknown 
in 42.5%. Bivariate analysis showed 
that all demographic and clinical fac-
tors were highly associated with geo-
graphic remoteness (Box 1). Patients 
living in inner regional or rural areas 
were less likely to have localised dis-
ease and more likely to be diagnosed 
with cancer of an unknown stage than 
those in major cities. Incidence rates 
were higher in inner regional and rural 
areas than in major cities.
The 10-year relative survival rate 
for men diagnosed with prostate can-
cer increased during the entire study 
1  Characteristics of New South Wales patients aged 18–84 years diagnosed with prostate cancer from 
1 January 1982 to 31 December 2007, by geographic remoteness
Geographic remoteness*
Characteristic Total Major cities Inner regional Rural P†
Number of patients 68 686 46 545 16 431 5 710
Age at diagnosis < 0.001
< 65 years 20 227 (29.4%) 30.1% 27.9% 28.3%
65–74 years 29 255 (42.6%) 42.1% 43.8% 43.2%
75–84 years 19 204 (28.0%) 27.8% 28.3% 28.5%
Spread of disease < 0.001
Localised 32 774 (47.7%) 49.5% 44.3% 43.4%
Non-localised 6 749 (9.8%) 9.9% 9.4% 10.8%
Unknown 29 163 (42.5%) 40.7% 46.3% 45.8%
Incidence rate‡ < 0.001
Low 15 894 (23.1%) 25.2% 18.1% 20.7%
Moderate 22 977 (33.5%) 36.8% 30.8% 13.6%
High 29 815 (43.4%) 37.9% 51.1% 65.8%
Socioeconomic status < 0.001
Least disadvantaged 23 498 (34.2%) 46.5% 10.1% 3.0%
Middle group 22 807 (33.2%) 28.2% 45.6% 38.4%
Most disadvantaged 22 381 (32.6%) 25.3% 44.3% 58.6%
* Based on patients’ place of residence at diagnosis using the remoteness classiﬁ cation with the rural category representing 
outer regional, remote and very remote areas. † Based on χ 2 test. ‡ Directly age-standardised to the 2001 Australian standard 
population. 
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period, from 57.5% in 1992–1996 and 
75.7% in 1997–2001 to 83.7% in 2002–
2007. The increased survival over time 
was also observed across categories 
of geographic remoteness and SES 
(Box 2).
The results of our multivariate anal-
ysis show that, before adjusting for 
other prognostic factors, the RER of 
death was higher for men living out-
side major cities (1.36 for inner regional 
and 1.66 for rural; Appendix 2, online 
at mja.com.au). Each step of further 
adjustment for potential prognos-
tic factors, fi rst at-risk period and age 
group, then disease spread and inci-
dence rates and, fi nally, SES, progres-
sively reduced the RER of death from 
1.36 to 1.18 for inner regional areas 
and from 1.66 to 1.32 for rural areas 
(compared with major cities). However, 
geographic remoteness remained a sig-
nifi cant factor (P < 0.001). The results 
in our Model 3 (Appendix 2), which 
adjusts for the potential prognostic 
factors above, suggest that these fac-
tors explain some of the urban–rural 
variation in prostate cancer survival 
but not all.
SES was also a signifi cant prognos-
tic factor, with men living in the middle 
and most disadvantaged areas having 
higher mortality risks (RER, 1.34 and 
1.40, respectively) than those living in 
affl uent areas (P < 0.001).
Of the total 7291 deaths attributa-
ble to prostate cancer, 709 (10%) could 
have been avoided if the urban–rural 
disparity was eliminated, and 1908 
(26%) could have been avoided if the 
SES disparity was eliminated.
Results over time showed that geo-
graphic variation was significant 
across all three at-risk periods (Box 3). 
In each period, the adjusted RER was 
signifi cantly higher for patients liv-
ing in inner regional and rural areas 
than for those in major cities, with 
an upward trend for patients in inner 
regional areas, while the RER in rural 
areas increased and then decreased 
slightly. The interaction between geo-
graphic remoteness and at-risk period 
was marginally signifi cant before 
adjusting for SES (P = 0.09), indicat-
ing that the urban–rural differential 
had changed over time. Adjusting for 
SES made the interaction become non-
signifi cant (P = 0.13), but the patterns 
of change in RER remained the same.
The sensitivity analyses found that 
the urban–rural disparities remained 
significant for both assumptions 
(P < 0.001) regarding those with 
unknown spread of disease (data not 
shown). Mortality rates were consist-
ently lower for men living in major 
cities over the whole study period 
1992–2007 (Appendix 3; online at mja.
com.au).
Discussion
Our fi ndings show that, although 
the overall survival outlook for men 
diagnosed with prostate cancer has 
improved over time, there is still a con-
tinuing (and some suggestion of a wid-
ening) inequality by place of residence, 
particularly in inner regional areas 
compared with major cities. Overall, 
men living outside major cities of NSW 
had poorer survival outcomes.
Recent studies have shown that PSA 
testing is more prevalent in urban areas 
of Australia.1 Thus, urban men may 
be more likely to be diagnosed with 
low-risk cancers through PSA testing, 
which would infl ate the observed sur-
vival in this group. The large propor-
tion of prostate cancers with unknown 
spread of disease (43%) may have cam-
oufl aged the true impact of disease 
spread on the geographic differential. 
However, the signifi cance of this dif-
ferential remained unchanged in our 
sensitivity analyses.
We could not determine a precise 
reason for the higher incidence of 
prostate cancer in regional and rural 
areas of NSW. Geographic patterns 
of PSA testing in NSW may be differ-
ent from previously published national 
patterns.1 Also, the increased risk of 
advanced prostate cancers in regional 
areas, which are more likely to be 
detected because of symptoms rather 
than PSA screening, might override 
the lower PSA testing rate. While we 
have tried to account for the impact 
of PSA testing by adjusting for pros-
tate cancer incidence rates, this may 
still leave some residual confound-
ing, especially for the small propor-
tion of men (< 5%) who were diagnosed 
before PSA testing was introduced on 
the Medicare Benefi ts Schedule.
In addition, as was observed nation-
ally,1 we found that mortality rates 
for prostate cancer in NSW were 
2 Relative survival (95% CI) from prostate cancer in New South Wales by 
geographic remoteness and socioeconomic status for each of the three at-risk 
periods* in the period analysis, 1992–2007
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consistently higher for men living in 
regional and rural areas (Appendix 3; 
online at mja.com.au). Therefore, even 
if the large proportion of prostate can-
cers with unknown spread of disease 
conceals a disproportionate amount 
of over-diagnosis of prostate cancer in 
urban areas, there remains a mortality 
inequality that suggests the survival 
differential was genuine and not sim-
ply the result of lead-time bias.
As our results were adjusted for 
spread of disease at diagnosis, it is 
unlikely that the urban–rural differ-
ential can be explained by different 
diagnostic practices. This increases 
the likelihood that there were dif-
ferences in management practices 
or other factors that contributed to 
the survival differences. Our study 
did not examine treatment, but 
the evidence for improved survival 
from any one management strat-
egy in men with localised prostate 
cancer is equivocal.13 Current rec-
ommendations for localised disease 
are based on informed choice,14 tak-
ing into account factors such as clin-
ical characteristics, life expectancy, 
quality of life and personal prefer-
ences15,16 rather than an expectation 
of increased survival. Differences in 
access to follow-up services could be 
one explanation, with several studies 
suggesting that men with metastatic 
or recurrent disease who are identifi ed 
and given salvage treatment earlier 
have better survival.17
A previous study has shown that 
men living in rural NSW and diag-
nosed with prostate cancer between 
1993 and 2002 are less likely to have 
a radical prostatectomy after taking 
account of age and disease spread;18 this 
is consistent with reports from Western 
Australia,19 Queensland20 and nation-
ally.1 Disease stage is more consistently 
recorded in patients who undergo sur-
gery, and this may partly explain why 
the spread of disease was less likely to 
be unknown in major cities.21
Some of the urban–rural survival 
differential can be explained by soci-
oeconomic disadvantage, with the size 
of the urban–rural differential being 
smaller, but still signifi cantly raised, 
when area disadvantage was included 
in the model. This fi nding is consist-
ent with those of international studies 
showing that socioeconomically disad-
vantaged men diagnosed with pros-
tate cancer have poorer survival22 and 
higher mortality from prostate cancer.23
Despite increasing awareness of 
and efforts to reduce the urban–rural 
inequalities in cancer outcomes over 
the past decade, our study suggests 
that there is no evidence that urban–
rural inequalities in prostate cancer sur-
vival have reduced over time. While 
the lack of data on tumour characteris-
tics, treatment and comorbid conditions 
make precise interpretation diffi cult, it 
remains possible that reduced access 
to general practitioners and specialist 
cancer care in regional areas may have 
contributed to this disparity.
A longer follow-up interval may be 
needed to observe the impact of recent 
changes in patterns of prostate can-
cer diagnosis and management.24,25 
However, there is still a lack of appro-
priately detailed data to investigate 
geographic inequalities in the pat-
terns of management of men diag-
nosed with prostate cancer and their 
use of health services. In the absence 
of clear guidelines on optimum man-
agement for prostate cancer, these data 
are required urgently to redress the sig-
nifi cant divide in survival outcomes for 
men diagnosed with prostate cancer in 
New South Wales.
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Appendix 1: Local government areas classified by remoteness in New South Wales* 
* Based on the Australian Standard Geographic Classification Remoteness Classification,1 which has
been recognised as a nationally consistent measure of geographic remoteness, and that uses the
physical road distance to the nearest town or service centre.
1 Australian Bureau of Statistics. ASGC Remoteness Classification: purpose and use. Canberra: Commonwealth of Australia, 
2003.
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Appendix 2: Relative excess risk of death (RER) after a diagnosis of prostate cancer during the first 10-years of follow-up, 1992-2007, New South Wales 
Model01 Model11 Model21 Model31 
RER 95% CI RER 95% CI RER 95% CI RER 95% CI 
Geographic remoteness p<0.001 p<0.001 p<0.001 p<0.001 
Major cities 1.00  1.00 1.00 1.00 
Inner regional 1.36 (1.25 -1.47) 1.31 (1.22 -1.41) 1.31 (1.23 -1.41) 1.18 (1.10 -1.27) 
Rural 1.66 (1.49 -1.86) 1.61 (1.46 -1.77) 1.52 (1.38 -1.68) 1.32 (1.19 -1.46) 
‘At risk’ period 
1992-1996 1.00 1.00 1.00 
1997-2001 0.53 (0.49 -0.57) 0.64 (0.59 -0.69) 0.64 (0.60 -0.69) 
2002-2007 0.34 (0.32 -0.37) 0.46 (0.42 -0.49) 0.46 (0.43 -0.50) 
Age at diagnosis (year) 
<65 1.00 1.00 1.00 
65-74 1.19 (1.10 -1.29) 1.40 (1.29 -1.51) 1.39 (1.28 -1.50) 
75-84 2.23 (2.04 -2.43) 2.95 (2.72 -3.20) 2.92 (2.69 -3.17) 
Spread of disease
Localised 1.00 1.00 
Non-localised 10.76 (9.72 -11.92) 10.63 (9.62 -11.76) 
Unknown 2.12 (1.91 -2.35) 2.06 (1.86 -2.29) 
Incidence rate 2
Low 1.00 1.00 
Middle 0.81 (0.75 -0.87) 0.83 (0.77 -0.90) 
High 0.67 (0.62 -0.72) 0.74 (0.68 -0.80) 
Socio-economic status
Least disadvantaged 1.00 
Middle group 1.34 (1.23 -1.46) 
Most disadvantaged 1.40 (1.29 -1.53) 
Test for the interaction between geographic 
remoteness and ‘at risk’ period 
p=0.03 p=0.09 p=0.13 
1 Model 0 does not adjust for other prognostic factors; Models 1-3 adjust for other prognostic factors in 3 steps. 
2 Prostate cancer incidence directly age-standardised to 2001 Australian standard population. 
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Appendix 3: Time trends in age-standardised prostate cancer mortality rates by 
geographic remoteness, New South Wales 1992 to 2007 
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Appendix 4: Sensitivity analysis from multivariable model for relative excess risk of 
death (RER) after a diagnosis of prostate cancer during the first 10-years of follow-up, 
1992-2007, NSW 
 
  "Unknown" stage as a separate group   
"Unknown" stage 
coded as localised 
stage   
"Unknown" stage 
coded as non-
localised stage 
  HR 95% CI HR 95% CI HR 95% CI 
Geographic remoteness p<0.0001 
 
p<0.0001 
 
p<0.0001 
Major cities 1.00  
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1.00  
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1.32 (1.19 -1.47) 
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At risk' period    
 
   
 
   
1992-1996 1.00  
 
1.00  
 
1.00  
1997-2001 0.64 (0.60 -0.69) 
 
0.65 (0.60 -0.70) 
 
0.50 (0.46 -0.54) 
2002-2007 0.46 (0.43 -0.50) 
 
0.46 (0.42 -0.49) 
 
0.34 (0.31 -0.37) 
Age at diagnosis (year) p<0.0001 
 
p<0.0001 
 
p<0.0001 
<65 1.00  
 
1.00  
 
1.00  
65-74 1.39 (1.28 -1.50) 
 
1.42 (1.31 -1.55) 
 
1.08 (1.00 -1.17) 
75-84 2.92 (2.69 -3.17) 
 
3.19 (2.94 -3.47) 
 
1.81 (1.66 -1.97) 
Spread of disease p<0.0001 
 
p<0.0001 
 
p<0.0001 
Localised 1.00  
 
1.00  
 
1.00  
Non-localised 10.63 (9.62 -11.76) 
 
7.23 (6.78 -7.70) 
 
3.43 (3.11 -3.79) 
Unknown 2.06 (1.86 -2.29) 
 
   
 
   
Incidence rate 2 p<0.0001 
 
p<0.0001 
 
p<0.0001 
Low 1.00  
 
1.00  
 
1.00  
Middle 0.83 (0.77 -0.90) 
 
0.84 (0.78 -0.91) 
 
0.82 (0.76 -0.89) 
High 0.74 (0.68 -0.80) 
 
0.72 (0.67 -0.78) 
 
0.76 (0.70 -0.83) 
Socio-economic status p<0.0001 
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1.00  
Middle group 1.34 (1.23 -1.46) 
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1.25 (1.14 -1.37) 
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Chapter overview 
This chapter includes two papers published in a peer-reviewed international journal: 
Characteristics of cases with “unknown” stage prostate cancer in a population-based cancer 
registry, and A population-based study of progression to metastatic prostate cancer in 
Australia. The previous chapter reported the results of an epidemiological study using 
population-based New South Wales Cancer Registry (NSWCR) data which illustrated the 
importance of historical cancer registry stage data, and identified that there is cause for 
concern due to the large number of prostate cancer cases recorded as having "unknown" 
stage at diagnosis in the NSWCR. In the first paper in this chapter, the socio-demographic 
and disease characteristics of prostate cancer patients with “unknown” stage recorded in 
the NSWCR were examined. The findings from this study suggest that prostate cancer cases 
with “unknown” stage recorded in the NSWCR differ from cases with known stage recorded. 
Differences in the completeness of stage data by location of residence and socio-economic 
status were also observed. The study showed that prostate cancer cases with “unknown” 
stage had a significantly higher risk of death from prostate cancer than cases with initial 
localised stage, but a lower risk of death than those initially diagnosed with regional stage. 
In the second paper in this chapter, the risk of progression to subsequent metastatic disease 
up to 14 years after diagnosis with non-metastatic prostate cancer or “unknown” stage 
cancer was examined. The results indicate that the risk of developing metastatic disease for 
those with “unknown” initial stage is intermediate between that for cases with localised and 
regional disease. Together these two papers shed some light on the characteristics and 
outcomes of prostate cancer patients who have “unknown” stage recorded in the NSWCR 
and the possible impact on epidemiological studies using these data.
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Characteristics of cases with unknown stage prostate cancer
in a population-based cancer registry
Qingwei Luo a,b,*, Xue Qin Yu a,b, Claire Cooke-Yarborough c,
David P. Smith a,d, Dianne L. O’Connell a,b,e,f
aCancer Research Division, Cancer Council New South Wales, P.O. Box 572, Kings Cross, NSW 1340, Australia
b Sydney School of Public Health, University of Sydney, NSW 2006, Australia
cNew South Wales Central Cancer Registry, Cancer Institute NSW, P.O. Box 41, Alexandria, NSW 1435, Australia
dGrifﬁth Health Institute, Grifﬁth University, Gold Coast, QLD 4222, Australia
e School of Medicine and Public Health, University of Newcastle, Callaghan, NSW 2308, Australia
f School of Public Health and Community Medicine, University of New South Wales, NSW 2052, Australia
1. Introduction
Summary stage in population-based cancer registries reﬂects
the degree of spread at diagnosis as ascertained from hospital
notiﬁcations, pathology reports and other sources. Stage informa-
tion is useful for monitoring population-wide variations in stage
distribution and survival trends, estimating health service
demands, and evaluating the effectiveness of programs for early
detection or screening [1–3]. For prostate cancer, registry recorded
stage information is particularly important for evaluating the
potential effects of over-diagnosis due to PSA testing, and,
conversely, the beneﬁts associated with reductions in diagnosis
of later stage disease. However, the prevalence of cancer cases with
‘‘unknown’’ stage reduces the ability to control statistically for the
effect of stage on patient outcomes [4]. As a result, the
incompleteness of stage data is a critical and major concern in
regard to potential bias [5,6].
Not all cancer registries collect stage of disease at diagnosis, and
even where they do it is common for stage information to be absent
or incomplete. For this study, cancer cases with insufﬁcient
information for the cancer registry to assign a stage are referred to
as having ‘‘unknown’’ stage. It is, however, important to note that a
classiﬁcation of ‘‘unknown’’ stage in a cancer registry does not
Cancer Epidemiology 37 (2013) 813–819
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imply that clinical stage was not determined or used by the
clinicians at the time of diagnosis for treatment decisions. The
proportion of prostate cancer cases recorded as ‘‘unknown’’ stage
by those cancer registries that do collect stage information has
been found to range from 3% to 76% in different countries [2,7–14].
The proportion of prostate cancer cases with ‘‘unknown’’ stage in
the New South Wales (NSW) Central Cancer Registry (CCR) was
much higher (41%) than in state-based registries in the United
States of America (USA), Germany, Switzerland and Norway. The
variation in completeness of stage information between countries
and registries suggests that there may be methods for improving
the completeness of prostate cancer stage data in the NSW CCR.
New South Wales is the most populous state in Australia with
almost one third of the total national population [15]. It is a
mandatory requirement that all cancers diagnosed in NSW, except
for non-melanoma skin cancers, are notiﬁed to the NSW CCR by
institutions including public and private hospitals, multipurpose
services, radiation oncology departments, cancer care centres,
private day procedure centres, residential aged care facilities and
pathology laboratories [16]. The NSW CCR is the only Australian
population-based cancer registry that routinely collects summary
stage at diagnosis.
Studies from other countries using registry data for different
cancer types have found that cases registered with ‘‘unknown’’
stage tended to be older patients, residents of rural areas, of lower
education or income levels, or without private health insurance
[2,5,6,8,13,17–20]. This implies that epidemiological and health
services research that excludes cases with ‘‘unknown’’ stage when
assessing health outcomes could potentially be biased [5]. As there
is as yet no equivalent Australian research, the investigation of the
characteristics and outcomes of Australian cancer cases registered
with ‘‘unknown’’ stage is an important step towards understanding
the potential biases involved in research based on incomplete
stage information.
To investigate the characteristics and outcomes of registered
prostate cancer cases with ‘‘unknown’’ stage recorded in the NSW
CCR, we examined the associations between ‘‘unknown’’ stage and
sociodemographic and disease characteristics, area-based mea-
sures related to cancer service provision, and prostate cancer
speciﬁc survival.
2. Patients and methods
This study was approved by the NSW Population and Health
Services Research Ethics Committee in April 2009 (Reference:
HREC/09/CIPHS/16).
2.1. Data sources
Data were obtained from the NSW CCR database. All ﬁrst
primary prostate cancer cases diagnosed from 1999 to 2007,
resident in NSW at the time of diagnosis and reported to the
registry, were selected based on the International Classiﬁcation of
Diseases for Oncology (ICD-O) third edition codes for prostate
cancer (C61) [21]. After excluding 350 cases that were notiﬁed
post-mortem, or through death certiﬁcate only, 315 cases that
were diagnosed and died in the same month, and four cases that
were aged 100 years or older at diagnosis [7], a total of 39 852
prostate cancer cases remained for analysis.
2.2. Outcome variables
The outcome of interest was summary stage of disease at
diagnosis as recorded by the NSW CCR based on statutory
notiﬁcation forms and pathology reports. It is classiﬁed using a
modiﬁed summary classiﬁcation [22], similar to that used by SEER
[23], of localised (cancer contained entirely in the prostate gland),
regional (cancer extended into tissues surrounding the prostate or
to regional lymph nodes), distant (cancer extended beyond
regional lymph nodes, to bones or to other distant sites) and
‘‘unknown’’ (where information in the notiﬁcations was insufﬁ-
cient to assign stage). For some analyses, stage at diagnosis was
further grouped into a dichotomous variable indicating ‘‘un-
known’’ or ‘‘known’’ stage.
Survival status and cause of death were obtained from the NSW
CCR. People with cancer were matched against death records from
the State Registry of Births, Deaths, and Marriages and the National
Death Index. All eligible cases were followed up to the end of 2007.
The survival time was calculated from the date of ﬁrst prostate
cancer diagnosis to the date of death from prostate cancer. Those
who did not die from prostate cancer were censored at the date of
death from other causes or at 31 December 2007 if they were still
alive.
2.3. Patient characteristics
Variables used in this analysis included age at diagnosis, year of
diagnosis, country of birth, Area Health Service (as deﬁned in 2005)
and socio-economic status of residence at diagnosis. Country of
birth was obtained from hospital notiﬁcations and therefore was
unknown for those cases without a hospital notiﬁcation. Cases
with known country of birth other than Australia were further
categorised into two groups according to the English proﬁciency
groups in 2001 [24]: born in overseas countries with high English
proﬁciency (English proﬁciency index rating  98.5%) and coun-
tries with moderate or low English proﬁciency (English proﬁciency
index rating < 98.5%).
Public sector health services in NSW were administered by
eight Area Health Services during the study period. Area Health
Services were considered to be important in the study as they are
the major sources of cancer notiﬁcations. Four of these areas
include parts of the Sydney metropolitan area, and the remaining
four are strictly rural [25]. All study cases were allocated to an Area
Health Service (as deﬁned in 2005) based on their residential
address at the time of diagnosis.
The Index of Relative Socio-economic Disadvantage (IRSD)
derived from the 2001 census was used as an area-based summary
measure of socio-economic status (SES). A more disadvantaged
area with a lower IRSD score would, for example, have a larger
proportion of people with low income and low educational
attainment, a higher proportion of unemployed adult residents,
and more dwellings without motor vehicles than other areas [26].
In this study, Local Government Area (LGA) (as deﬁned in 1991)
was used as the basic geographical unit for the place of residence.
The IRSD scores for each LGA in NSW were ranked and aggregated
into SES quintiles with similar population sizes. Prostate cancer
cases were assigned a SES quintile based on the LGA of their place
of residence at diagnosis.
2.4. Statistical analysis
Multivariable binary logistic regression was used to examine
the associations between cases’ characteristics and area-level
variables, and the odds of a prostate cancer case being recorded as
having ‘‘unknown’’ stage.
Cox proportional hazards regression models were used to
examine the differences in prostate cancer speciﬁc survival
between prostate cancer cases with ‘‘unknown’’ stage and known
stages, after adjusting for age at diagnosis, year of diagnosis (as a
continuous variable by subtracting 1999 which is the ﬁrst year of
the study period), socio-economic quintile, Area Health Service of
residence and country of birth. Trend tests were performed to test
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linearity on the log odds scale for ordinal variables [27]. The
proportional hazards assumption was satisﬁed based on testing
the interaction of the variables included in the regression with
survival time and visual inspection of the Schoenfeld and scaled
Schoenfeld residuals [28].
Several ﬁrst-order interactions were statistically signiﬁcant in
the logistic regression model and the Cox proportional hazards
model due to the large sample size. However, there was no
evidence of real effect modiﬁcation as the associations between the
factor and outcome of interest did not vary substantially across
strata of the third variable. Interaction terms were therefore
excluded in the ﬁnal models. Analyses were performed using
STATA (version 11.1) [29].
3. Results
Of the 39 852 prostate cancer cases included in the study, 96%
had histopathological conﬁrmation, 41.8% had disease stage
recorded as ‘‘unknown’’, 48.7% had localised disease and 9.5%
had regional or distant spread of disease. Sociodemographic and
clinical characteristics of all cases and the proportions with
‘‘unknown’’ stage are shown in Table 1.
Results from the multivariable logistic regression are presented
in Fig. 1. All variables included in the model were signiﬁcantly
associated with ‘‘unknown’’ stage (all p-values < 0.0001). The
proportion of cases with ‘‘unknown’’ stage signiﬁcantly increased
with age at diagnosis from 29.3% for the 18–64 year old age group
to 43.6% for the 65–74 year old age group (adjusted OR = 1.77, 95%
CI: 1.68–1.87) and 53.9% for the age group > 74 years old (adjusted
OR = 2.66, 95% CI: 2.52–2.82). The proportion of cases with
‘‘unknown’’ stage also signiﬁcantly increased with socio-economic
disadvantage from 31.8% for cases living in the least disadvantaged
areas to 46.6% for those from the most disadvantaged areas
(adjusted odds ratio range: 1.26–1.43), with a noticeable levelling
of risk after the middle quintile. We also found that compared to
cases born in Australia, cases born in overseas countries with
moderate or low English proﬁciency were more likely to have
‘‘unknown’’ stage (adjusted OR = 1.08, 95% CI: 1.01–1.16), and
82.6% of cases with unknown country of birth also had ‘‘unknown’’
stage. The proportion of cases with ‘‘unknown’’ stage declined from
46.7% in 1999–2002 to 37.5% in 2006–2007 (adjusted OR = 0.63,
95% CI: 0.60–0.67), and the likelihood of a case having ‘‘unknown’’
stage varied signiﬁcantly across Area Health Services, with cases
from the Hunter-New England (adjusted OR = 1.69, 95% CI: 1.55–
1.85) and North Coast areas (adjusted OR = 1.79, 95% CI: 1.62–1.98)
being more likely to be recorded with ‘‘unknown’’ stage.
The unadjusted and adjusted hazard ratios comparing the risk
of dying from prostate cancer for cases with ‘‘unknown’’ and
known stages are presented in Table 2. After adjusting for age at
diagnosis, year of diagnosis, country of birth, socio-economic
status and Area Health Service, compared with cases with
‘‘unknown’’ stage, the risk of death from prostate cancer was
signiﬁcantly lower for cases with localised stage (adjusted
HR = 0.42, 95% CI: 0.39–0.46), and signiﬁcantly higher for those
Table 1
Characteristics of 39 852 prostate cancer cases and proportions with ‘‘unknown’’ stage in New South Wales, Australia, 1999–2007.
Characteristic Number of cases Unknown stagea
n (%)b n (%)c
Age at diagnosis
18–64 years 13 371 (33.6) 3915 (29.3)
65–74 years 14 921 (37.4) 6505 (43.6)
>74 years 11 560 (29.0) 6232 (53.9)
Year of diagnosis
1999–2002 13 872 (34.8) 6482 (46.7)
2003–2005 14 430 (36.2) 5839 (40.5)
2006–2008 11 550 (29.0) 4331 (37.5)
Country of birth
Australia 24 858 (62.4) 8824 (35.5)
Countries – high English proﬁciency 3702 (9.3) 1223 (33.0)
Countries – moderate/low English proﬁciency 5658 (14.2) 1953 (34.5)
Unknown 5634 (14.1) 4652 (82.6)
Socio-economic statusd
Least disadvantaged 9070 (22.8) 2881 (31.8)
2nd quintile 7128 (17.9) 2805 (39.4)
3rd quintile 8482 (21.3) 3987 (47.0)
4th quintile 8995 (22.6) 4099 (45.6)
Most disadvantaged 6177 (15.5) 2880 (46.6)
Area Health Serviced
Sydney metropolitan area
South Western Sydney 5664 (14.2) 2329 (41.1)
South Eastern Sydney-Illawarra 7412 (18.6) 2706 (36.5)
Western Sydney 4962 (12.5) 2115 (42.6)
Northern Sydney-Central Coast 7129 (17.9) 2362 (33.1)
Rural NSW
Hunter-New England 5514 (13.8) 2914 (52.9)
North Coast 3497 (8.8) 1943 (55.6)
Greater Southern 3608 (9.1) 1434 (39.8)
Greater Western 2066 (5.2) 849 (41.1)
Total 39 852 (100.0) 16 652 (41.8)
Notes:
a Unknown stage recorded by the NSW Central Cancer Registry.
b Percentage within total.
c Percentage within each category.
d Area Health Service and socio-economic status were based on the case’s place of residence at diagnosis.
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with regional (adjusted HR = 1.29, 95% CI: 1.12–1.49) and distant
stage (adjusted HR = 10.85, 95% CI: 9.98–11.79).
4. Discussion
This is the ﬁrst study in Australia to systematically examine the
characteristics of prostate cancer cases recorded with ‘‘unknown’’
stage in a population-based cancer registry. The results from this
study provide evidence of systematic patterns in cases with
‘‘unknown’’ stage, so that patients with known stage prostate cancer
differed from those with ‘‘unknown’’ stage of disease. In brief,
patients with ‘‘unknown’’ stage prostate cancer were more likely to
be older, diagnosed in earlier years, living in more socio-economi-
cally disadvantaged areas, or from Area Health Services in non-
metropolitan NSW. The survival of cases with ‘‘unknown’’ stage
prostate cancer was signiﬁcantly poorer than those with localised
stage, but better than those with regional or distant stage. These
results indicate that the large proportion of prostate cancer cases
with ‘‘unknown’’ stage recorded in the NSW CCR represents a special
sub-population, meaning that population-based studies could
potentially be biased if cases with ‘‘unknown’’ stage were excluded
or were simply grouped with a speciﬁc known stage category.
Fig. 1. Adjusted odds ratios and 95% conﬁdence intervals (CIs) for associations between sociodemographic and clinical characteristics and unknown stage prostate cancer in
New South Wales, Australia, 1999–2007. Odds ratio adjusted for all the variables included in the ﬁgure with all p-values < 0.0001.
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There are a number of possible explanations for why stage was
‘‘unknown’’ to the cancer registry, and these explanations are not
mutually exclusive. First, restrictions in deﬁning a valid data
source for staging in different cancer registries can impact on the
completeness of summary stage data [8,22,30]. For prostate cancer
speciﬁcally, if the registry received a pathology report for a core
biopsy only, it is possible that an ‘‘unknown’’ stage would be
assigned as there would be insufﬁcient information to assign a
deﬁned stage [7]. Second, it is possible that the cases did not have
their cancer staged as they were not well enough [5,6,31,32] or
chose not to [6,18–20,31] undergo the medical workup required to
determine stage, or that staging was not necessary for decisions
about treatment to be made [2,5,19,20]. Third, cases may not have
been fully staged due to economic or social barriers [2,19], or
because cases did not have access to comprehensive health
services and all the necessary staging investigations [2,18–20].
Fourth, it is possible that the stage was known to the treating
clinician, but was not recorded in the hospital or clinic medical
records [17,31], or that the stage was known and was recorded in
the medical records, but the information was not reported to the
cancer registry due to an issue with reporting procedures [19], or
was not accurately coded. A further investigation focusing on why
‘‘unknown’’ stage is commonly recorded in the NSW CCR might
achieve a better understanding of the direction of bias in
epidemiological studies using such stage data, and also may
inform strategies for data quality improvement.
Consistent with previous studies of prostate cancer and other
cancer types in the USA, this study conﬁrmed that the proportion of
cases with ‘‘unknown’’ stage decreased over time, suggesting that
the clinical workup and quality of data being provided to the
cancer registry has improved [2,6]. This study also conﬁrmed that
older cases were more likely to have ‘‘unknown’’ stage recorded
than younger cases. Possible explanations for this pattern are that
older cases were more likely to have medical conditions that made
them unsuitable for further staging [5], or that they may have
received an incomplete diagnostic evaluation [19]. This study also
found that country of birth was signiﬁcantly associated with
‘‘unknown’’ stage, with cases born in countries other than Australia
being more likely to have ‘‘unknown’’ stage than those born in
Australia. This may be due to less comprehensive diagnostic
evaluations being undertaken due to cultural or language barriers.
There was also a strong association between unknown country of
birth and ‘‘unknown’’ stage, mainly because country of birth is
obtained from the in-patient hospital notiﬁcation form which is
also one of the main data sources for disease stage in the NSW CCR.
This special group of cases had an extremely low risk of dying from
prostate cancer (online resource 1), suggesting that they were
likely to have localised disease and were not hospitalised for cancer
treatment.
Two area-level based measures, Area Health Service and socio-
economic status, were found to be signiﬁcantly associated with the
recording of ‘‘unknown’’ stage. The differences in the proportion of
prostate cancer cases with ‘‘unknown’’ stage across the Area Health
Services may reﬂect disparities in diagnostic evaluation, and may
indicate a potential area of improvement for the health service
system. We also found that prostate cancer cases living in more
Table 2
Associations between prostate cancer speciﬁc survival and sociodemographic and clinical characteristics in New South Wales, Australia, 1999–2007.
Variables Cases/deaths Unadjusted hazard ratio (95% CI) Adjusted hazard ratioa (95% CI)
Stage at diagnosis Overall p-value < 0.0001 Overall p-value < 0.0001
Unknownb 16 652/1594 1.00 1.00
Localised 19 406/774 0.44 (0.40–0.47) 0.42 (0.39–0.46)
Regional 2282/234 1.13 (0.98–1.29) 1.29 (1.12–1.49)
Distant 1512/960 15.39 (14.19–16.71) 10.85 (9.98–11.79)
Age at diagnosis p-value for trend < 0.0001 p-value for trend < 0.0001
18–64 years 13 371/553 1.00 1.00
65–74 years 14 921/1053 1.63 (1.47–1.81) 1.50 (1.35–1.66)
>74 years 11 560/1956 4.68 (4.26–5.14) 3.76 (3.41–4.15)
Year of diagnosis p-value < 0.0001 p-value < 0.0001
One year increase 0.92 (0.91–0.94) 0.97 (0.95–0.99)
Country of birth Overall p-value < 0.0001 Overall p-value < 0.0001
Australia 24 858/2610 1.00 1.00
Countries-high English proﬁciency 3702/413 1.07 (0.96–1.18) 1.17 (1.05–1.30)
Countries-moderate/low English proﬁciency 5658/516 0.83 (0.76–0.91) 0.95 (0.86–1.05)
Unknown 5634/23 0.04 (0.02–0.06) 0.03 (0.02–0.05)
Socio-economic statusc p-value for trend < 0.0001 p-value for trend = 0.001
Least disadvantaged 9070/643 1.00 1.00
2nd quintile 7128/595 1.19 (1.06–1.33) 1.12 (0.99–1.27)
3rd quintile 8482/797 1.36 (1.22–1.51) 1.21 (1.06–1.38)
4th quintile 8995/911 1.50 (1.35–1.66) 1.18 (1.04–1.34)
Most disadvantaged 6177/616 1.47 (1.32–1.64) 1.29 (1.12–1.48)
Area Health Servicec Overall p-value < 0.0001 Overall p-value < 0.0001
South Western Sydney 5664/506 1.00 1.00
South Eastern Sydney-Illawarra 7412/552 0.84 (0.74–0.94) 0.95 (0.84–1.09)
Western Sydney 4962/368 0.86 (0.75–0.98) 1.12 (0.97–1.29)
Northern Sydney-Central Coast 7129/592 0.97 (0.86–1.09) 1.15 (1.00–1.32)
Hunter-New England 5514/631 1.51 (1.34–1.70) 1.48 (1.30–1.69)
North Coast 3497/409 1.43 (1.26–1.63) 1.30 (1.13–1.50)
Greater Southern 3608/301 0.96 (0.83–1.11) 1.06 (0.91–1.23)
Greater Western 2066/203 1.11 (0.95–1.31) 1.14 (0.96–1.36)
Notes:
a Adjusted for all variables in this table.
b Unknown stage recorded by the NSW Central Cancer Registry.
c Area Health Service and Socio-economic status were based on the case’s place of residence at diagnosis.
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socioeconomically disadvantaged areas were more likely to have
‘‘unknown’’ stage than those living in areas of higher socio-
economic status. This is possibly attributable to the associations
between lower socio-economic status and less frequent access to
comprehensive health services, and therefore to a less complete
diagnostic workup [11]. This is supported by previous internation-
al studies that have indicated that higher socio-economic status is
associated with more frequent PSA testing [33,34], a lower stage of
disease at diagnosis [35,36], and lower risk of death after a prostate
cancer diagnosis [11]. Interestingly, we did ﬁnd that the likelihood
of having ‘‘unknown’’ stage levelled off after the middle quintile of
socio-economic status, but we do not yet have any clear
explanation for this pattern.
This study demonstrates that prostate cancer cases with
‘‘unknown’’ stage had a signiﬁcantly higher risk of death from
prostate cancer than those with localised disease, but lower risk
than those with regional or distant disease. This survival pattern is
consistent with results from previous studies in NSW [1,37].
However, because of differences in the way cancer stage is
collected, coded and reported by different registries international-
ly, comparison of NSW data with other countries is difﬁcult. For
example, in the USA SEER database only 3% of prostate cancers are
recorded as having ‘‘unknown’’ stage and the relative survival is
lower than those with regional disease [9]. The USA SEER system,
unlike that used in NSW and New Zealand (NZ), classiﬁes tumours
identiﬁed by a needle biopsy (e.g., because of elevated PSA) as
localised stage [30]. A recent publication from NZ reported that the
1-year mortality hazards for cases with ‘‘unknown’’ stage prostate
cancer were between those for cases with regional and distant
spread, with the difference between regional and ‘‘unknown’’ stage
prostate cancer not reaching statistical signiﬁcance [8]. In addition,
in the NZ data 73% of prostate cancer cases were recorded as having
‘‘unknown’’ stage compared with 41% in NSW, which indicates that
there may be differences in staging systems between the two
cancer registries.
As previously noted, the reasons why a cancer case is registered
as ‘‘unknown’’ stage are likely to be multifactorial. Previous studies
that have examined the characteristics of prostate cancer cases
with ‘‘unknown’’ stage have reported quite varied results, with a
lack of consistency in associations between ‘‘unknown’’ stage and
cancer outcomes. All studies have, however, found that the survival
for such a heterogeneous group was different to that of a speciﬁc
stage group. This implies that the cases with ‘‘unknown’’ stage are
likely to be a mixture of stages, and that the composition of this
special group probably varies across cancer registries and
countries. Further investigations are therefore needed to under-
stand the composition of the group with ‘‘unknown’’ stage prostate
cancer in NSW, and to achieve accurate estimates of potential
biases caused by incomplete stage data.
Researchers using these data to study outcome disparities
should consider how these cases with ‘‘unknown’’ stage may
inﬂuence their ﬁndings. For example, when using cancer registry
data to estimate health service demands, excluding cases with
‘‘unknown’’ stage will substantially underestimate the cancer
burden. Therefore the size of the patient group requiring initial
curative treatment or active surveillance for prostate cancer is
likely to be underestimated if cases with ‘‘unknown’’ stage are
excluded. When comparing survival estimates between stages, if
cases with ‘‘unknown’’ stage were grouped with localised, regional
or distant stage, estimated differences between stages will be
biased towards the null, as ‘‘unknown’’ stage is likely to be a group
with a mixture of stages.
This study has some limitations. First, it is limited to prostate
cancer in NSW, and ﬁndings may not be generalizable to other
cancer types or other jurisdictions. Second, only an area-level
indicator of socio-economic status based on the case’s place of
residence was available and some individuals may have been
misclassiﬁed or inferences at the area level may not directly apply
to individuals. However, several studies have demonstrated the
importance of area-based socio-economic indicators in measuring
health inequalities in Australia [38] and in the USA [39], so we
believe this analysis is still of interest.
In conclusion, we found a large proportion of prostate cancer
cases were recorded as having ‘‘unknown’’ stage in the NSW
population-based cancer registry, and that this follows a system-
atic pattern, which implies that population-based studies could
potentially be biased if cases with ‘‘unknown’’ stage were excluded
or grouped with a speciﬁc stage category. The characteristics
associated with ‘‘unknown’’ stage identiﬁed in this study point to
potential health disparities associated with accessibility to health
services, insufﬁcient diagnostic workup, or incomplete notiﬁcation
procedures. This study also indicates that the prostate cancer
patients with ‘‘unknown’’ stage are likely to be a mixture of stages.
A more detailed exploration of the reasons for having ‘‘unknown’’
stage cancer recorded in the cancer registry, and the composition
of this group is necessary, so that data completeness can be
improved and the utility of research studies using data on cancer
stage is increased.
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1. Introduction
Prostate cancer is the most common cancer diagnosed in
Australia (excluding non-melanoma skin cancers), and the second
most common cause of cancer death in men [1]. With growing
numbers of men diagnosed and living with prostate cancer the
health care demands of men with this disease will increase
substantially, resulting in a growing burden on the Australian
health care system [2]. Information on the risk of developing
metastatic disease is needed to provide realistic estimates of
prevalent cases requiring follow-up and active treatment [2].
Understanding this risk and the patterns of progression will help
inform future effective health service planning.
The majority of men diagnosed with prostate cancer are detected
at an early stage, and while localised prostate cancers are believed to
have an indolent course, local progression and distant metastasis
can develop over the long term [3]. The proportion of men who
progress to metastatic disease is not well documented, and only a
few studies have examined clinical metastatic progression in
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selected cases [3,4] or after a single speciﬁed treatment in single
institutions or selected groups [4–7]. A new method using
population-based cancer registry data or routinely collected health
data to estimate rates of progression to metastatic breast cancer was
described by Lord et al. [8], but to our knowledge there have not yet
been any population-wide studies that describe and quantify
prostate cancer progression to subsequent metastatic disease after
sufﬁcient follow-up.
In this study we used population-based cancer registry data to
describe the patterns of progression to metastatic disease in men
resident in NSW who had an initial diagnosis of non-metastatic
prostate cancer.
2. Materials and methods
This study was approved by the NSW Population and Health
Services Research Ethics Committee in April 2009 (Reference:
HREC/09/CIPHS/16).
2.1. Data sources
Data for all primary non-metastatic prostate cancer cases (ICD-
O-3 C61) [9] diagnosed from 1993 to 2002 were obtained from the
New South Wales (NSW) Central Cancer Registry (CCR). NSW is the
most populous state in Australia with almost one-third of the total
national population [10]. The CCR is the only Australian popula-
tion-based cancer registry that routinely records summary stage of
disease. According to the NSW Health policy directive, if a patient
presents for a consultation or treatment at any facility in NSW and
has a diagnosis of cancer then the CCR must be notiﬁed [11]. The
stepwise inclusion and exclusion of patients for analysis is
illustrated in Fig. 1. Excluded cases comprised those that were
notiﬁed post-mortem or through death certiﬁcate only, cases that
were initially diagnosed with distant metastatic disease, cases
that died within four months of initial diagnosis so that we were
thus unable to determine their initial stage at diagnosis and cases
that were aged 90 years or older at diagnosis (due to the unreliable
assignation of cause of death for very elderly patients). This
resulted in a total of 32,643 non-metastatic prostate cancer cases
being included. This cohort of cases was then followed-up for a
notiﬁcation of distant metastatic progression or prostate cancer
death to the end of 2007.
2.2. Summary stage of disease
Stage of disease was identiﬁed at two time points in the course
of the prostate cancer: initial stage at diagnosis was determined
based on the highest stage of disease reported within four months
of the initial diagnosis, and subsequent metastatic disease was
determined by notiﬁcations dated more than four months after the
initial diagnosis. The summary stage of disease provided by the
CCR was based on the stage information available from statutory
notiﬁcation forms, including hospital notiﬁcations and pathology
reports. Using a modiﬁed summary classiﬁcation [12] that is
similar to that used by SEER [13], the CCR classiﬁes stage of disease
as: localised (cancer contained entirely in the prostate gland),
regional (cancer extended into tissues surrounding the prostate or
to regional lymph nodes), distant (cancer extended beyond
regional lymph nodes, to bones or to other distant sites) and
‘‘unknown’’ (where information in the notiﬁcations was insufﬁ-
cient for the cancer registry to assign stage). As a previous study
provided evidence that prostate cancer cases with ‘‘unknown’’
stage at diagnosis differed from those with known stage and so
excluding cases with ‘‘unknown’’ stage could therefore cause bias
[14], cases with ‘‘unknown’’ stage were included in this study as a
separate stage category.
2.3. Study endpoints
Metastatic disease progression was identiﬁed by subsequent
metastatic disease episode notiﬁcations (hereafter referred to as
‘‘episode notiﬁed’’ cases), or by notiﬁcations of prostate cancer
death (hereafter referred to as ‘‘prostate cancer death notiﬁed’’
cases). As distant metastatic disease progression is considered to
be on the pathway to prostate cancer death, we assumed that men
developed metastases at some time before prostate cancer death
[4,5]. As information up to four months after diagnosis was used by
the CCR to determine cancer stage at diagnosis, the time to
metastatic disease notiﬁcation was calculated from the date four
months after prostate cancer diagnosis to either the earliest date of
subsequent metastatic notiﬁcation, or to the date of prostate
cancer death, if it occurred more than four months after initial
diagnosis [15]. Survival status and the cause of death to the end of
2007 were obtained from the CCR by matching cancer cases against
death records from the State Registry of Births, Deaths, and
Marriages and the National Death Index. Those who were not
recorded as having developed metastatic disease were censored at
the date of death from other causes or 31st December 2007 if they
were still alive.
2.4. Study variables
Variables used in this analysis included stage of disease at
diagnosis, age at diagnosis, year of diagnosis, geographical
location, socio-economic status (SES) and age-standardised
prostate cancer incidence rate (ASR) by local government area
(LGA) of residence at diagnosis. Geographical location of residence
at diagnosis was categorised into major cities, inner regional, rural
(including outer regional, remote and very remote areas) using the
Australian Standard Geographic Classiﬁcation (ASGC) Remoteness
Structure [16]. This Remoteness Structure is recognised as a
nationally consistent measure of geographic remoteness, based on
the physical road distance to the nearest town or service centre.
Index of Relative Socio-economic Disadvantage (IRSD), derived
from the 2001 Census, was used as a measure of area-level socio-
economic status (SES) [17].
Fig. 1. Inclusion and exclusion of prostate cancer patients in NSW 1993–2002,
Australia.
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This study cohort included men diagnosed with prostate cancer
during the years in which prostate-speciﬁc antigen (PSA) testing
was introduced and became widespread in Australia. As cases of
asymptomatic disease diagnosed through PSA testing may be less
likely to progress than other cases, the level of PSA testing in a
population could affect the overall risk of disease progression. Data
on PSA testing prevalence were not available at either the
individual or area level. It has, however, been found that the
number of PSA tests conducted within a population is highly
correlated with the number of new prostate cancer cases
diagnosed in the population [18,19]. Thus, in the absence of data
on small area PSA testing rates, we instead used the 5-year period
ASR for each LGA as a marker for the rate of PSA testing. For each
LGA in NSW, ASRs and IRSD scores were ranked and then grouped
into three levels (high, medium and low) with the similar sized
populations in each group.
2.5. Statistical analysis
To describe the patterns of disease progression of prostate
cancer from non-metastatic to metastatic disease, the Kaplan–
Meier method was used to estimate the cumulative incidence rate
and the log-rank test was used to test for differences in time to
metastatic prostate cancer by initial stage at diagnosis. The annual
metastatic prostate cancer hazard as the rate of failure within one-
year intervals by initial stage at diagnosis was graphically
represented using gauss kernel smooth. Cox proportional hazard
regression models were used to identify risk factors associated
with progression to metastatic disease. We estimated median
survival after a notiﬁcation of metastatic disease to provide further
information about the potential issue of cases living with
metastatic prostate cancer that was not notiﬁed to the CCR.
Testing of the interaction of the variables included in the
regression with survival time, and visual inspection of the
Schoenfeld and scaled Schoenfeld residuals, indicated that the
proportional hazards assumption was satisﬁed [20]. All analyses
were performed using STATA (version 13.1, STATA Corporation,
College Station, TX).
3. Results
Of the 32,643 men with non-metastatic prostate cancer at
diagnosis, 43.1% had localised disease, 5.1% regional spread and
51.9% had unknown stage of disease (Table 1). The median age at
diagnosis was 70 years, and two-thirds of patients were resident in
major cities at the time of initial diagnosis. After a median of 6.8
years (range: 0.1 to 14.7 years) of follow-up, a total of 6708 cases
(20.6%) had developed subsequent distant metastases. Of these,
63.4% were identiﬁed by metastatic episode notiﬁcations and
36.6% were identiﬁed by prostate cancer death. The overall median
time to notiﬁcation of metastatic disease was 3.6 years. The
median survival after a notiﬁcation of metastatic prostate cancer
was 6 months.
Cases with regional or unknown stage at diagnosis had higher
cumulative incidence of metastatic disease than those with
localised disease (Logrank test p < 0.0001, Fig. 2). The 10-year
cumulative incidence rates for cases with localised, regional and
unknown stage at diagnosis were 17.1, 33.9, and 30.8% respec-
tively. For all initial stages, the trends in the cumulative incidence
of metastatic disease appeared to be still increasing after 14 years
of follow-up.
Fig. 3 shows the trends for the annual hazard for progression to
metastatic disease by the number of years of follow-up. We found
that the annual hazards for cases with regional and ‘‘unknown’’
stage were higher than those with localised initial stage of disease.
Over time the hazard of developing metastatic disease for cases
with unknown initial stage decreased continuously and appeared
Table 1
Baseline characteristics of men with non-metastatic prostate cancer by stage at initial diagnosis in New South Wales, Australia 1993–2002.
Characteristics Stage at diagnosis Total number of cases Metastatic progression
Localised Regional Unknowna
n (% within categories) n (% within total) % within categories
Age at diagnosis (Years)
Mean (Standard deviation) 68.2 (8.5) 65.6 (8.5) 71.7 (8.2) 69.9 (8.6)
Year of diagnosis
1993–1997 7075 (42.2) 752 (4.5) 8941 (53.3) 16,768 (51.4) 24.5
1998–2002 6985 (44.0) 907 (5.7) 7983 (50.3) 15,875 (48.6) 16.4
Geographical locationb
Major cities 10,121 (45.5) 1162 (5.2) 10,953 (49.3) 22,236 (68.1) 19.7
Inner regional 2957 (38.1) 348 (4.5) 4466 (57.5) 7771 (23.8) 21.9
Rural 982 (37.3) 149 (5.7) 1505 (57.1) 2636 (8.1) 23.9
Socio-economic statusb
Least disadvantaged 5413 (48.4) 681 (6.1) 5101 (45.6) 11,195 (34.3) 18.2
Middle tertile 4525 (41.0) 499 (4.5) 6001 (54.4) 11,025 (33.8) 21.4
Most disadvantaged 4122 (39.6) 479 (4.6) 5822 (55.9) 10,423 (31.9) 22.1
Prostate cancer incidence ratec
Lowest tertile 3232 (40.6) 357 (4.5) 4369 (54.9) 7958 (24.4) 21.6
Middle tertile 4355 (39.9) 502 (4.6) 6052 (55.5) 10,909 (33.4) 21.7
Highest tertile 6473 (47.0) 800 (5.8) 6503 (47.2) 13,776 (42.2) 19.1
Metastatic disease progression
No 12,057 (46.5) 1163 (4.5) 12,715 (49.0) 25,935 (79.5)
Yes 2003 (29.9) 496 (7.4) 4209 (62.8) 6708 (20.6)
Episode notiﬁed 1321 (31.1) 313 (7.4) 2621 (61.6) 4255 (13.0)
Prostate cancer death notiﬁed 682 (27.8) 183 (7.5) 1588 (64.7) 2453 (7.5)
Total 14,060 (43.1) 1659 (5.1) 16,924 (51.9) 32,643 (100.0) 20.6
a Unknown stage recorded by the NSW Central Cancer Registry.
b Geographical location and socio-economic status were based on the man’s place of residence at diagnosis.
c Age-standardised prostate cancer incidence rate by 5-year period in Local Government Area of the man’s residence, standardised to 2001 Australian standard population.
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to converge with that of cases originally diagnosed as localised
stage.
In a multivariable analysis (Table 2), the risk of developing
metastatic disease was signiﬁcantly increased for those with
regional (HR = 2.65, 95% CI: 2.40–2.93) or unknown initial stage
(HR = 1.70, 95% CI: 1.61–1.80), for cases diagnosed at an older age
(65–74 years: HR = 1.43, 95% CI: 1.33–1.53; >74 years: HR = 2.73,
95% CI: 2.55–2.93), those living in inner regional (HR = 1.11, 95% CI:
1.04–1.18) or rural areas (HR = 1.24, 95% CI: 1.14–1.36), and those
living in more disadvantaged areas (middle tertile: HR = 1.09, 95%
CI: 1.02–1.16; most disadvantaged: HR = 1.12, 95% CI: 1.04–1.19).
The risk of developing metastatic disease decreased with year of
diagnosis (HR = 0.98, 95% CI: 0.97–0.99 per year) and medium or
high age-standardised prostate cancer incidence rate (middle
tertile: HR = 0.91, 95% CI: 0.85–0.97; highest tertile: HR = 0.85, 95%
CI: 0.79–0.90).
4. Discussion
To our knowledge, this is the ﬁrst population-based study to
examine the patterns of prostate cancer progression from non-
metastatic to metastatic disease. After a median follow-up of 6.8
years more than 1 in 5 men initially diagnosed with non-
metastatic prostate cancer developed distant metastases. As NSW
is the most populous state in Australia, with almost one-third of
the total national population [10], and has cancer mortality rates
that are almost identical to the national rates [1], we believe that
our results may be generalised to the whole Australian population
Fig. 2. Cumulative incidence of metastatic prostate cancer by stage at initial
diagnosis in NSW 1993–2002 followed up to the end of 2007.
Fig. 3. Annual hazard of metastatic prostate cancer by stage at initial diagnosis in
NSW 1993–2002, followed up to the end of 2007.
Table 2
Bivariable and multivariable analyses of association between risk factors and development of metastatic prostate cancer after diagnosis of non-metastatic disease in NSW
1993–2002 followed up to the end of 2007.
Characteristic Total number of cases
(% of Metastatic progression)
Bivariable model Multivariable modela
HR 95% CI p-value HR 95% CI p-value
Stage at diagnosis <0.0001 <0.0001
Localised 14,060 (14.2) 1.00 1.00
Regional 1659 (29.9) 2.31 (2.09–2.55) 2.65 (2.40–2.93)
Unknownb 16,924 (24.9) 2.02 (1.92–2.13) 1.70 (1.61–1.80)
Age at diagnosis <0.0001 <0.0001
<65 years 8466 (14.2) 1.00 1.00
65–74 years 14,106 (19.6) 1.48 (1.39–1.59) 1.43 (1.33–1.53)
>74 years 10,071 (27.2) 2.95 (2.76–3.16) 2.73 (2.55–2.93)
Year of diagnosis <0.0001 <0.0001
One year increase 0.97 (0.96–0.98) 0.98 (0.97–0.99)
Geographical locationc <0.0001 <0.0001
Major cities 22,236 (19.7) 1.00 1.00
Inner regional 7771 (21.9) 1.16 (1.10–1.23) 1.11 (1.04–1.18)
Rural 2636 (23.9) 1.30 (1.20–1.42) 1.24 (1.14–1.36)
Socio-economic statusc <0.0001 0.004
Least disadvantaged 11,195 (18.2) 1.00 1.00
Middle tertile 11,025 (21.4) 1.23 (1.16–1.31) 1.09 (1.02–1.16)
Most disadvantaged 10,423 (22.1) 1.29 (1.21–1.37) 1.12 (1.04–1.19)
Prostate cancer incidence rated <0.0001 <0.0001
Lowest tertile 7958 (21.6) 1.00 1.00
Middle tertile 10,909 (21.7) 0.94 (0.89–1.01) 0.91 (0.85–0.97)
Highest tertile 13,776 (19.1) 0.83 (0.78–0.89) 0.85 (0.79–0.90)
a Adjusted hazard ratio from multivariable model including all variables listed in the table.
b Unknown stage recorded by the NSW Central Cancer Registry.
c Geographical location and socio-economic status were based on the man’s place of residence at diagnosis.
d Age-standardised prostate cancer incidence rate by 5-year period in Local Government Area of the man’s residence, standardised to 2001 Australian standard population.
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and to other countries with similar health care systems. We found
that men with regional or ‘‘unknown’’ initial stage, those aged 65
years and older at diagnosis, men living in inner regional or rural
areas, and those living in disadvantaged areas were at greater risk
of progressing to metastatic prostate cancer than other men.
Previous international studies have reported a wide range in
rates of progression to metastatic prostate cancer, with the
variation likely to be due to the selection of cases, different lengths
of follow-up, and in some cases, a focus on progression after a
single speciﬁed treatment. The rate of progression to metastatic
disease we observed (20.6%) was higher than the rate (12.8%) from
a single county cancer registry in the USA (Seattle, Washington)
[4]. This difference may be due to the younger age of the men in the
USA study (median age 58 years), or because metastatic
progression was self-reported in the American study. A study
from Sweden reported a slightly lower rate of metastatic
progression (18.4%) in localised prostate cancer cases diagnosed
in the period prior to the introduction of PSA testing (mean age 72
years, mean time to metastatic progression 9.2 years) [3]. Other
studies [5–7] have tended to focus on rates of metastatic
progression after patients in a single institution have received
speciﬁc treatments, and have generally reported a wide range of
metastatic progression rates (3.4–21.0%) due to the selection of
cases from low-risk or high-risk groups. The rate of progression
after long-term follow up that we reported was an overall estimate
for the population of cases with non-metastatic prostate cancer
regardless of the treatment received, so it is difﬁcult to compare
results from these studies.
Our study found that men with ‘‘unknown’’ stage at diagnosis
recorded in the CCR had a signiﬁcantly higher risk of developing
metastatic disease than those initially diagnosed with localised
stage, but a lower risk than those initially diagnosed with regional
disease. This pattern of progression to metastatic disease by initial
stage at diagnosis is consistent with the pattern observed for
prostate cancer speciﬁc survival, and conﬁrms that the cases with
‘‘unknown’’ stage at diagnosis recorded in the CCR are likely to
actually be a mixture of stages [14]. National and international data
does, however, suggest that the proportion of prostate cancer cases
initially diagnosed with metastatic disease is generally very low. The
USA SEER Cancer Statistics Review reported that in the period 1992–
2001 5–6% of all prostate cancer cases were initially diagnosed with
distant stage (3–4% for men aged less than 65 years) [21]. As the use
of PSA testing is similarly high in men in the USA and Australia [22],
we may expect a similar stage distribution for prostate cancer in the
two populations, with only a very low proportion of prostate cancer
cases initially diagnosed with metastatic disease. This pattern is
generally conﬁrmed by the results of the population-based NSW
Prostate Cancer Care and Outcome Study (PCOS) of men aged up to
70 years diagnosed in 2000–2002. In PCOS 12% of cases were initially
diagnosed with non-localised disease [23], and only 3.8% of all
prostate cancer cases were diagnosed with distant stage (unpub-
lished data). As previously noted, in our study population, 5.2% of all
prostate cancer cases were excluded as they were initially diagnosed
with distant metastasis, so it is unlikely that a large proportion of the
group with ‘‘unknown’’ stage had metastatic disease at diagnosis.
Therefore, we would expect the effect of possible misclassiﬁcation of
metastatic prostate cancer in the group with ‘‘unknown’’ stage to be
minimal. In addition, the men with more aggressive prostate cancer
were likely to develop metastatic disease or die in the early years of
follow-up, so that in the later years of follow-up the remaining
patients would mainly be those with localised disease. This may
explain the apparent convergence of the annual hazard rate for the
group with ‘‘unknown’’ stage towards that for localised stage as
observed in this study.
We also found evidence that the risk of progressing to
metastatic prostate cancer was signiﬁcantly higher for men living
in inner regional or rural areas than for those living in major cities,
and higher for men living in areas of low SES compared to men in
areas of high SES. A previous study using linked cancer registry and
hospital records found that men living in rural NSW or in areas of
low SES were less likely to receive a radical prostatectomy than
those in urban or high SES areas [24]. The higher risk of progression
to metastatic prostate cancer observed for men living in inner
regional, rural or more disadvantaged areas may be partly
attributed to differences in patterns of care due to difﬁculties
associated with the access and provision of cancer services. The
geographical variation in the risk of progression to metastatic
prostate cancer is consistent with that reported in a previous study
in survival differences by geographical location and SES [25].
As this study cohort included prostate cancer patients
diagnosed in the period in which PSA testing was introduced
and became widespread in Australia, it is possible that men living
in areas with high PSA testing rates were more likely to be
diagnosed with low-risk cancers identiﬁed through PSA testing,
and in turn were at lower risk of developing metastatic disease. To
control this possibility we used the age-standardised prostate
cancer incidence rate as a marker for PSA testing activity, and
found that cases in areas with higher incidence rates were less
likely to develop metastatic disease.
Although prostate cancer is generally a relatively slow-growing
cancer, distant metastases can develop over the long term, even
among patients considered to have low risk at diagnosis [3]. Our
study found continuously increasing trends in the cumulative
incidence rates of metastatic disease progression for all initial
stages of prostate cancer. A follow-up period of at least 15 years is
necessary when investigating patterns of metastatic disease
progression, as this allows for the identiﬁcation of cases
experiencing late progression, which is not a rare event. For this
reason population-based studies are considered to be a cost-
effective method for investigating prostate cancer metastatic
disease progression and can provide useful information for
planning prostate cancer services and surveillance management.
This study has some limitations. Although the accuracy of the
CCR data on primary cancer events is known to be high [26], the
completeness and accuracy of subsequent metastatic disease
notiﬁcations have not been formally investigated. It is therefore
possible that due to the issue of incomplete episode data the rate of
progression to metastatic disease found in this study is an
underestimate of the true rate [27,28]. However, as prostate
cancer death was included as one source of information on disease
progression this possible under-estimation should be minimised.
Previous research suggests that the recording of data on cancer
deaths is very complete at the CCR and that cause of death is well
ascertained [29,30]. Given that the median survival after a
notiﬁcation of metastasis was low (6 months), we believe that
the number of men living with metastatic prostate cancer who
were not notiﬁed to the CCR or died from prostate cancer after
disease progression is likely to be small. Another limitation is the
possibility of misclassiﬁcation of initial stage. Fortunately the
effect of such misclassiﬁcation appears to be minimal, as it is
suggested that the proportion with metastatic disease at diagnosis
is low and they were excluded from the analysis. The results may
also be limited because only an area-level indicator of SES based on
the man’s place of residence was available and some individuals
may have been misclassiﬁed. However, a number of studies have
demonstrated the importance of area-level socio-economic
indicators in measuring health inequalities in Australia [31] and
in the USA [32], indicating that this method is sufﬁciently robust in
these circumstances.
The study has many strengths, as we have undertaken a
statewide population-based study adopting a method using
routinely collected cancer registry data [8], which is more
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representative and comprehensive than any previous study on this
topic. Furthermore, this method provided long-term follow-up of
cases, so that we were able to assess the progression of prostate
cancer to metastatic disease over an extended time period, and we
used clinical progression to metastatic disease as the endpoint
rather than biochemical failure, recognising that biochemical
failure has limitations in predicting prostate cancer death [4,33].
Our methods may be applicable elsewhere and could help to
increase the utilisation of data from other cancer registries.
In conclusion, the rate of progression to metastatic prostate
cancer estimated in this statewide population-based study
provides important and previously unavailable information on
patient outcomes over an extended time period. The continuously
increasing trends in metastatic disease progression each year up to
14 years of follow-up conﬁrmed that distant metastasis can
develop over the long term, and the estimated overall risk of
developing metastatic disease in the population should help to
inform health services planning. Moreover, the disparities identi-
ﬁed in the progression to metastatic disease based on accessibility
to health care suggest that the development of future cancer care
services could be better targeted to areas of need.
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Chapter overview 
This chapter includes the paper Cancer related hospitalisations and “unknown” stage 
prostate cancer: a population-based record linkage study, which was previously published in 
a peer-reviewed international journal. In the previous chapter, the characteristics of 
prostate cancer cases with “unknown” stage recorded in the New South Wales Cancer 
Registry (NSWCR) were examined, and it was found that “unknown” stage prostate cancer 
cases differed from cases with a known stage recorded. This implies that population-based 
studies using NSWCR prostate cancer stage data could potentially be biased. In this chapter, 
record linkage between the NSW Admitted Patient Data Collection (APDC) and NSWCR was 
used to examine the pattern of hospitalisations relating to prostate cancer by stage of 
disease at diagnosis, and identifies possible explanations for stage at diagnosis being 
recorded as “unknown” in the NSWCR. Results suggest that about two-thirds of “unknown” 
stage prostate cancer cases can be explained by a lack of hospitalisation with a prostate 
cancer diagnosis recorded, or admission for prostate cancer care after the four-month 
reporting window used by the NSWCR. Therefor due to the importance of using historical 
cancer registry data in cancer research, the development and validation of an appropriate 
method for handling incomplete stage information is required and this is described in the 
next chapter. 
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ABSTRACT
Objectives: To identify reasons for prostate cancer
stage being recorded as ‘unknown’ in Australia’s
largest population-based cancer registry.
Design: Prospective population-based cohort.
Setting: New South Wales (NSW) is the most
populous state in Australia, with almost one third of
the total national population.
Participants: NSW Cancer Registry (NSWCR) records
for prostate cancer cases diagnosed in 2001–2009
were linked to the NSW Admitted Patient Data
Collection (APDC) for 2000–2010. All patients in this
study had a minimum of 12 months follow-up in the
hospital episode records after their date of diagnosis
as recorded by the NSWCR.
Main outcome measures: Incidence of ‘unknown’
stage prostate cancer and cancer-specific survival.
Results: Of 50 597 prostate cancer cases, 39.9% were
recorded as having ‘unknown’ stage. Up to 4 months
after diagnosis, 77.2% of cases without a hospital-
reported cancer diagnosis were recorded as having
‘unknown’ stage. Among those patients with a
hospital-reported cancer diagnosis, stage was
‘unknown’ for 7.6% of cases who received a radical
prostatectomy (RP) and for 34.0% of cases who had
procedures other than RP. In the latter group, the
factors that were related to having ‘unknown’ stage
were living in disadvantaged areas (adjusted OR (aOR)
range: 1.13 to 1.20), attending a private hospital (aOR
range: 1.25 to 2.13), having day-only admission for
care (aOR=1.23, 95% CI 1.11 to 1.36), or having
procedures other than multiple procedures with
imaging (eg, biopsy only, aOR range: 1.11 to 1.45).
Conclusions: Over half of ‘unknown’ stage prostate
cancer cases did not have a hospital-reported prostate
cancer diagnosis within the 4 months after initial
diagnosis. We identified differences in the likelihood of
cases being recorded as ‘unknown’ stage based on
socioeconomic status and facility type, which suggests
that further investigation of reporting practices in relation
to diagnostic and treatment pathways is required.
INTRODUCTION
Data on cancer stage at diagnosis as recorded
in population-based cancer registries is an
important factor in population-wide cancer
monitoring. It is a powerful predictor of sur-
vival1 and is important for estimating health
service demands,2 and for evaluating the
effectiveness of cancer screening pro-
grammes and other early detection initia-
tives.3 For prostate cancer, registry-recorded
stage information is particularly important in
the evaluation of the potential effects of over-
diagnosis due to prostate-speciﬁc antigen
(PSA) testing and, conversely, the beneﬁts
associated with a reduction in cases present-
ing with later stage disease.4 Unfortunately,
however, a high proportion of ‘unknown’
stage cases signiﬁcantly reduces the ability to
statistically control for the effect of disease
stage on patient outcomes,5 limits interpret-
ation of the appropriateness of prostate
cancer care based on disease stage and can
cause potential bias if cases with ‘unknown’
stage are excluded from analyses.4
The New South Wales Cancer Registry
(NSWCR) is the only Australian population-
based cancer registry that has routinely col-
lected summary stage at diagnosis, doing so
since its inception in 1972. The proportion
Strengths and limitations of this study
▪ The first systematic examination of hospital
inpatient cancer services and ‘unknown’ stage at
diagnosis using population-based linked records
from routinely collected administrative data sets.
▪ There are numerous advantages to using admin-
istrative data, and record linkage between data
sets can add further value to these resources,
with their population coverage ensuring that the
results are representative.
▪ The Admitted Patient Data Collection captured
90% or more of all radical prostatectomies, only
systematically missing a small number of
patients treated interstate.
▪ Our study was restricted to patients with prostate
cancer recorded in the NSW Cancer Registry, so
findings might not be generalisable to other
population-based cancer registries, nor will they
be representative of other cancer types.
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of prostate cancer cases with ‘unknown’ stage in the
NSWCR (41% in 1999–2007) has been reported to be
much higher than in similar registries in the USA,
Germany, Switzerland and Norway.4 Investigations focus-
ing on why ‘unknown’ stage is recorded in the cancer
registry will provide a better understanding of the direc-
tion of bias in epidemiological studies that use these
stage data and may also inform strategies for data quality
assurance.
There are a number of possible reasons why a prostate
cancer case may be registered as being of ‘unknown’
stage, including patients not being healthy enough or
deciding not to undergo the medical workup required
to determine stage,3 4 6–8 that there is a determination
that staging is not necessary for decisions about treat-
ment to be made,8 that economic or social barriers, or a
lack of access to comprehensive health services that have
the capacity to complete all necessary staging investiga-
tions means cases are not fully staged,3 6 8 or that stage
is known to the treating clinician, but is not recorded in
the hospital medical records.9 It is also likely that restric-
tions in deﬁning a valid data source for cancer registry
staging can affect the completeness of stage data.4 6
There is currently no published research that has system-
atically examined the reasons why ‘unknown’ stage at
diagnosis is recorded by Australian registries.
By linking administrative data sets for a cohort of pros-
tate cancer cases recorded in the NSWCR, the aim of
this descriptive study of the patterns of inpatient hospital
cancer services was to identify possible reasons for
‘unknown’ stage being recorded.
METHODS
Data sources
Cancer registry data
Data for all men with a ﬁrst diagnosis of prostate cancer
in New South Wales, Australia in 2001–2009 (the most
recent year for which cancer registry data were available)
were identiﬁed and extracted from the NSWCR using the
International Classiﬁcation of Diseases for Oncology 3rd
Edition (ICD-O-3) topography code of C61.10 It is a man-
datory requirement that all cancers diagnosed in NSW,
except for non-melanoma skin cancers, are notiﬁed to
the NSWCR by institutions, including public and private
hospitals, public multipurpose health services, radiation
oncology departments, cancer care centres, private day
procedure centres, residential aged care facilities and
pathology laboratories.11 However, mandatory notiﬁers do
not include the private consulting rooms of individual
general practitioners or specialists (including urologists).
Month and year of diagnosis were available for analysis.
After excluding 430 cases who were notiﬁed postmortem,
or through death certiﬁcate only, 398 cases who were
diagnosed and died in the same month, and four cases
who were aged 100 years or older at diagnosis,12 a total of
50 597 prostate cancer cases remained for analysis (see
online supplementary resource 1).
Hospital data
The NSW Admitted Patient Data Collection (APDC)
contains information on all inpatient separations (dis-
charges, transfers and deaths) from all public, private
and repatriation hospitals, and private day facilities in
NSW. This information is recorded as ‘episodes of care’
and includes disease diagnosis codes and procedure
codes.13 In this study, the APDC data from 2000 to 2010
were linked to the NSWCR records to identify prostate
cancer-speciﬁc procedures and prostate cancer diagno-
ses within each episode of care.
Record linkage
Record linkage between NSWCR and APDC records was
undertaken by the Centre for Health Record Linkage
(CHeReL) using probabilistic linkage and best practice
privacy-preserving protocols. Each person in the
NSWCR and APDC was assigned a unique project
person number to allow matching of individuals across
the two data sets. All uncertain matches were reviewed
clerically, together with a sample of ‘certain’ matches
and non-matches, with an estimated 0.4% false-positive
and <0.5% false-negative linkages.14 All patients in this
study had a minimum of 12 months follow-up in the hos-
pital episode records after their date of diagnosis as
recorded by the NSWCR.
Outcome variables
The outcome of interest was stage of disease at diagnosis
(referred to as degree of spread at diagnosis in the
NSWCR15), reﬂecting the highest degree of spread
reported within 4 months of diagnosis as ascertained
from mandatory notiﬁcations from private and public
hospitals, pathology laboratories, and inpatient and out-
patient treatment facilities.11 Stage recorded in the
NSWCR uses a modiﬁed classiﬁcation by the
International Agency for Research on Cancer (IARC)16
similar to that used by SEER,17 with the stage categories
of localised (cancer contained entirely in the prostate
gland), regional (cancer extended into tissues surroun-
ding the prostate or to regional lymph nodes), distant
(cancer extended beyond regional lymph nodes, to
bones or to other distant sites) and ‘unknown’ (where
information in the notiﬁcations was insufﬁcient for the
cancer registry to assign stage). For some analyses, stage
at diagnosis was further grouped into a dichotomous
variable, indicating ‘unknown’ or known stage.
We also investigated survival outcomes by stage at diag-
nosis and the cancer-related procedures received.
Survival status and cause of death were obtained from
the NSWCR. People with cancer were matched against
death records from the State Registry of Births, Deaths,
and Marriages and the National Death Index. All eli-
gible cases were followed up to the end of 2008, the
most recent year for which death data were available.
The survival time was calculated from the date of pros-
tate cancer diagnosis to the date of death from prostate
cancer. Those who did not die from prostate cancer
2 Luo Q, et al. BMJ Open 2017;7:e014259. doi:10.1136/bmjopen-2016-014259
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were censored at the date of death from other causes or
at 31 December 2008 if they were still alive. As survival
status was not available after 2008, cases diagnosed in
2009 were excluded from the survival analysis.
Hospital health service characteristics
Hospital-reported prostate cancer diagnosis
According to the NSW Health Policy Directive, the
NSWCR must be notiﬁed if a patient presents for a con-
sultation or treatment at any notifying facility in NSW
and has a diagnosis of cancer, where the cancer is the
principal or an additional diagnosis for the prostate
cancer-related episode of care.11 Those cases with a
hospital-reported prostate cancer diagnosis, regardless of
the care received, should have generated an electronic
or paper hospital notiﬁcation, in a uniform format with
speciﬁc ﬁelds for degree of cancer spread. Therefore, in
this study, hospital-reported prostate cancer diagnosis in
the APDC was used as a ﬂag that a hospital notiﬁcation
should have been sent to the NSWCR. Hospital notiﬁca-
tion is considered to be a signiﬁcant source of stage
information, as it should contain this information col-
lected from any of the several different prostate cancer
procedures, as well as any clinical stage information col-
lected from urologists’ referrals. Up to 55 diagnosis
codes using the International Classiﬁcation of Diseases
10th revision Australian Modiﬁcation (ICD-10-AM)18
recorded in each episode of care were scanned for a
diagnosis of prostate cancer (C61). In this study, the
median number of diagnosis codes recorded at each
episode of care was 5 (range 0–44).
Hospital prostate cancer procedures
As a single patient could have multiple episodes of care
and multiple procedures recorded in the APDC, we
developed a hierarchical classiﬁcation system (see online
supplementary resource 2) to identify the key hospital
cancer care activity for prostate cancer treatment experi-
enced. This hierarchical classiﬁcation system is based on
the likelihood that the procedure will provide stage infor-
mation that could contribute to staging in the cancer
registry,11 as well as taking into account general clinical
practice for prostate cancer diagnosis and initial treat-
ment, and acknowledging that not all stage information is
notiﬁable to the NSWCR (ﬁgure 1). All relevant proced-
ure codes in the Medicare Beneﬁts Schedule-Extended
classiﬁcation of the ICD-10-AM18 for prostate cancer-
related treatment and procedures were identiﬁed and
categorised into groups: radical prostatectomy (RP),
imaging (includes bone scans, abdominal/pelvic MRI
and CT), other prostate cancer treatment (includes exter-
nal beam radiotherapy, brachytherapy and bilateral orch-
iectomy), other prostate surgery (includes other
prostatectomy, cryoablation of the prostate and
Figure1 Diagnostic and initial
treatment pathways for prostate
cancer in New South Wales,
Australia.
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endoscopic destruction of a lesion of the prostate).19
Transurethral resection of the prostate (TURP) postdiag-
nosis, TURP for benign prostatic hyperplasia before
prostate cancer diagnosis and prostatic biopsy do not
provide any deﬁnitive stage information (see online
supplementary resource 2). Up to 51 procedure codes
could be recorded for each episode of care. The median
number of procedure codes recorded at each episode of
care was 5 (range 0–50).
For cases with multiple procedures at the same level in
the hierarchy, the hospital type and day stay status of the
earliest episode of care was selected for analysis. The
time interval in months from the month of prostate
cancer diagnosis recorded in the NSWCR to the month
of the selected procedure or hospital-reported prostate
cancer diagnosis in the APDC was used as a proxy for
time to cancer notiﬁcation to the NSWCR. For some
analyses, the procedures were further grouped into
mutually exclusive categories (RP, procedures other than
RP, no procedure) or ﬁve categories (multiple proce-
dures with imaging, imaging only, TURP only, biopsy
only, others) based on the nature of the procedures in
relation to providing stage information. For cases who
had received prostate cancer procedures in hospital, the
number of episodes of care with one or more cancer-
related procedures up to 4 months after initial diagnosis
was categorised into three groups (1, 2 and 3+).
Hospital characteristics
Hospitals were grouped by hospital type (principal refer-
ral public, other public, major private, other private hos-
pitals). Day stay status indicates whether or not for that
episode of care the patient was admitted and separated
from hospital on the same day.13 In NSW the procedures
for reporting to the NSWCR vary across different health
service facilities. Public facilities submit notiﬁcation forms
electronically via the Health Information Exchange data-
base, while private hospitals and procedure centres notify
the cancer registry electronically via the Secure
Notiﬁcation Portal or by paper notiﬁcation forms.11
Comorbidities
Comorbidities were coded according to a slightly
adapted version of the Charlson comorbidity index,20
excluding prostate cancer and metastatic tumors. This
index was derived from ICD-10-AM diagnostic codes as
recorded in any hospital separation within 6 months
prior to and 6 months after the prostate cancer diagno-
sis. For each individual in the linked data set a
comorbidity score was calculated by multiplying esti-
mated condition weights by comorbid indicators and
summing over the 16 relevant conditions.20
Patients’ sociodemographic characteristics
Previous work by the authors4 suggested that certain
sociodemographic characteristics—age at diagnosis, year
of diagnosis, country of birth and socioeconomic status
(SES) of place of residence at diagnosis—were
associated with the likelihood of a patient with prostate
cancer being recorded as ‘unknown’ stage at diagnosis,
so we included these as study factors. Country of birth
was categorised into Australia and other countries
according to the English proﬁciency groups.21 Country
of birth was obtained from hospital notiﬁcations and,
therefore, was unknown for those cases without a hos-
pital notiﬁcation. The Index of Relative Socioeconomic
Disadvantage derived from the 2001 Australian census
was used as an area-based summary measure of SES.22
An additional area-based summary measure was geo-
graphic location of place of residence at diagnosis using
the Australian Standard Geographic Classiﬁcation
Remoteness Structure,23 which has been recognised as a
nationally consistent measure of geographic remoteness
based on the physical road distance to the nearest town
or service centre. Recognising that patients can receive
cancer care in neighbouring states in Australia and that
there is an agreement between the cancer registries in
different states to exchange cancer reporting informa-
tion, a patient living close to an interstate border was
ﬂagged as potentially having treatment interstate. For
some analyses, living near state borders was combined
with the remoteness of location and grouped into ﬁve
categories (major cities, inner regional areas near state
borders, other inner regional, rural areas near state
borders and other rural areas).
Statistical analysis
The analyses were divided into three parts: (a) descriptive
data analysis to examine the distribution of cases with
‘unknown’ stage at diagnosis by hospital prostate cancer
diagnosis and procedures, to identify possible explana-
tions for ‘unknown’ stage in relation to prostate cancer
care in hospitals; (b) for cases where no clear explanation
was found in part (a), logistic regression was used to
examine the associations between study factors and a case
being recorded as ‘unknown’ stage in the NSWCR; (c)
cancer speciﬁc survival by stage at diagnosis and types of
cancer-related procedure using the Kaplan-Meier
method. All analyses were performed using STATA
(V.13.1) (Stata Statistical Software: Release 13 [program].
13 version: College Station, Texas, USA: StataCorp LP.,
2013).
RESULTS
Of the 50 597 men registered in the NSWCR database
with a ﬁrst diagnosis of prostate cancer between 2001
and 2009, 96.5% were histopathologically conﬁrmed.
Half of these men had localised disease, 10.1% had
regional or distant spread, and 39.9% had ‘unknown’
stage of disease (table 1). The median age at diagnosis
was 68 years, with a younger median age for cases with
localised (66 years) and regional spread (65 years) com-
pared to those with distant (77 years) and ‘unknown’
stage (72 years). Two-thirds of patients were living in a
major city at the time of diagnosis. There were 48 757
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(96.4%) cases linked with at least one APDC episode up
to the end of 2010, and 9.4% had a comorbidity score
≥1 recorded in the time period of 6 months prior to
6 months after the prostate cancer diagnosis (table 1).
Figure 2 shows the distribution of cases with
‘unknown’ stage at diagnosis by hospital-reported pros-
tate cancer diagnosis and procedures. Of the total study
cohort, 29.4% of cases (n=14 890) did not have a
hospital-reported prostate cancer diagnosis, and the
majority of these cases did not receive any cancer-related
procedures. Of these 14 890 cases, 77.2% were recorded
as ‘unknown’ stage at diagnosis, which accounted for
57.0% of the total number of cases with ‘unknown’
stage. Only 30 of these cases received RP within
4 months, and 10 of these 30 cases were recorded as
‘unknown’ stage.
Within 4 months of the initial diagnosis, 70.6% of the
study cohort (n=35 707) had a hospital-reported prostate
cancer diagnosis, and 24.3% of these cases were recorded
as ‘unknown’ stage at diagnosis (ﬁgure 2). High concord-
ance was found between cancer-related procedures and
hospital-reported cancer diagnosis, with 97.3% of cases
who received cancer-related procedures also having a
hospital-reported prostate cancer diagnosis. In this group
of cases, 13 177 received RP and 19 864 received a pros-
tate procedure other than RP within 4 months after diag-
nosis, and a relatively small number of the patients
received RP (n=951) and other procedures (n=192) after
4 months. Among men who received procedures within
4 months of diagnosis, the proportion with ‘unknown’
stage was the lowest for cases who had an RP (7.6%), and
highest for the 19 864 cases with a prostate procedure
Table 1 Characteristics of 50 597 men with prostate cancer and distribution of cancer registry recorded stage at diagnosis in
New South Wales, Australia, 2001–2009
Localised Regional Distant Unknown All stages
Characteristics Per cent within categories n (%)*
Year of diagnosis
2001–2005 48.1 5.8 4.1 42.0 23 885 (47.2)
2006–2009 51.8 6.9 3.3 38.0 26 712 (52.8)
Age at diagnosis
Median age (years) 66 65 77 72 68
18–64 61.1 8.7 1.7 28.5 17 490 (34.6)
65–74 49.7 6.6 2.6 41.0 18 656 (36.9)
75–99 37.0 3.3 7.6 52.1 14 451 (28.6)
Country of birth
Australia 50.7 6.5 3.7 39.1 36 090 (71.3)
High English proficiency countries 52.7 7.3 3.8 36.2 5300 (10.5)
Moderate English proficiency
countries
52.1 6.0 3.5 38.5 2998 (5.9)
Low English proficiency countries 47.8 5.7 4.5 42.0 5430 (10.7)
Unknown 8.5 1.5 0.6 89.3 779 (1.5)
Geographical location†
Major cities 50.9 6.6 3.8 38.7 33 509 (66.2)
Inner regional 48.6 5.8 3.7 41.9 12 916 (25.5)
Rural 47.8 6.2 3.4 42.5 4172 (8.2)
Socioeconomic status†
Least disadvantaged 57.8 8.3 2.7 31.1 12 695 (25.1)
Middle group 48.0 6.0 4.1 42.0 24 213 (47.9)
Most disadvantaged 46.5 5.3 4.1 44.2 13 689 (27.1)
Lived near state borders
No 50.6 6.5 3.7 39.2 46 312 (91.5)
Yes 44.5 5.4 3.5 46.7 4285 (8.5)
Cases linked with APDC
No 24.1 3.3 1.5 71.1 1840 (3.6)
Yes 51.0 6.5 3.8 38.7 48 757 (96.4)
Comorbidity score‡
No record in time range 19.3 2.4 1.4 76.9 9027 (17.8)
None 57.8 7.5 3.5 31.2 36 826 (72.8)
1+ 48.0 5.6 9.6 36.8 4744 (9.4)
Total 50.0 6.4 3.7 39.9 50 597 (100)
*Percentage within total.
†Geographical location and socioeconomic status were based on the men’s place of residence at diagnosis.
‡Diseases in the Charlson comorbidity index excluding prostate cancer and metastases within 6 months before and 6 months after diagnosis.
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other than RP (34.0%). The proportion of cases with a
comorbidity score ≥1 was found to be lower, and median
age at diagnosis was younger, for men who had an RP
compared with men who had prostate procedures other
than RP (ﬁgure 2). The Kaplan-Meier survival estimates
by stage at diagnosis stratiﬁed by the type of cancer-
related procedure (ﬁgure 3) suggested a similar survival
outcome for ‘unknown’ stage as localised stage for cases
who received cancer-related procedures. For cases who
did not receive cancer-related procedures, on average,
Figure 2 Distribution of men with ‘unknown’ stage at diagnosis by hospital-reported prostate cancer diagnosis and procedures,
New South Wales, Australia, 2001–2009 (n=50 597).
Figure 3 Prostate cancer specific survival by stage at diagnosis recorded in the NSWCR stratified by cancer-related
procedures, New South Wales, Australia, 2001–2008, followed up to the end of 2008 (n=43 368).
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the survival outcome for ‘unknown’ stage was similar to
that for regional stage.
The 19 864 cases with a hospital-reported prostate
cancer diagnosis and prostate procedures other than an
RP within 4 months of diagnosis accounted for a large
proportion of this study cohort. The most common pro-
cedures received included imaging (58.2%), biopsy
(62.6%) and TURP before diagnosis (32.0%), and small
proportions with other treatments, TURP post diagnosis
and other surgery (see online supplementary resource 3).
The procedures are not mutually exclusive and most of
the patients who received imaging also received another
procedure. About two-thirds of all procedures were per-
formed in private facilities. Most TURP or other prostate
surgical procedures had overnight episodes of care,
while the majority of biopsy and imaging procedures
were recorded as day-only admissions. Results from
bivariable and multivariable logistic regression analysis
for these cases are presented in online supplementary
resource 4 and ﬁgure 4. The odds of a case having
‘unknown’ stage were signiﬁcantly higher for men who
were older at diagnosis (adjusted OR (aOR) ranged
from 1.12 to 1.30), or for cases from more socio-
economically disadvantaged areas compared with those
from the least disadvantaged areas (aOR ranged from
1.13 to 1.20), or from inner regional areas not close to
state borders compared with those who live in major
cities (aOR=1.10, 95% CI 1.01 to 1.20). Compared with
cases who had undergone multiple procedures plus
imaging, all other procedure groups were signiﬁcantly
more likely to be recorded as ‘unknown’ stage at diagno-
sis (eg, imaging only, TURP only or biopsy only, aOR
ranged from 1.11 to 1.45). Having ‘unknown’ stage was
also more common for cases who were admitted to
Figure 4 Associations between
patients’ characteristics and
‘unknown’ stage prostate cancer
for patients with a
hospital-reported prostate cancer
diagnosis and prostate
procedures other than radical
prostatectomy ≤4 months after
diagnosis, New South Wales,
Australia, 2001–2009 (n=19 864).
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private hospitals (aOR ranged from 1.25 to 2.13 com-
pared with principal referral hospital) and those with
day-only admission (aOR=1.23 compared with overnight
admission, 95% CI 1.11 to 1.36). The proportion of
cases with ‘unknown’ stage fell with the number of epi-
sodes of care recorded (aOR ranged from 0.54 to 0.79),
and was lower for cases who lived in inner regional areas
close to state borders than for those who lived in major
cities (aOR: 0.82, 95% CI 0.71 to 0.96).
DISCUSSION
Our ﬁndings show that a considerable proportion of the
‘unknown’ stage prostate cancers arises because of a lack
of deﬁnitive staging evidence or clinical stage made
available to the NSWCR. This particularly occurs when
this information has been collated by non-notifying facil-
ities such as private consulting rooms (ﬁgure 1). Over
half of the total cases with ‘unknown’ stage prostate
cancer in our study did not have a hospital-reported
prostate cancer diagnosis and did not receive a hospital-
based cancer-related procedure within 4 months after
diagnosis. For patients who had a hospital-reported pros-
tate cancer diagnosis within 4 months of the initial diag-
nosis, RP is the most important prostate cancer
procedure for providing deﬁnitive stage information
that allows the NSWCR to assign a stage. Prostate proce-
dures other than RP provide only limited stage informa-
tion and the NSWCR rarely assigns stage based on a
pathology report from a biopsy or TURP. We found that
patients with prostate cancer who had procedures other
than RP were older and more commonly had comorbi-
dities than patients who had an RP. These ﬁndings
suggest that advancing age and the presence of
comorbidities were associated with more conservative
treatment with less complete diagnostic assessment,
which is then associated with ‘unknown’ stage.3 6 7
Among the group of patients who received prostate pro-
cedures other than RP and had a hospital-reported pros-
tate cancer diagnosis within 4 months of the initial
diagnosis, those who were older at diagnosis, lived in
socioeconomically disadvantaged areas, had prostate
procedures other than multiple procedures plus
imaging, who were admitted to private hospitals, or who
had a day-only admission were more likely to have
‘unknown’ stage recorded in the NSWCR.
The main strength of our study is that it is the ﬁrst sys-
tematic examination of hospital inpatient cancer services
and ‘unknown’ stage at diagnosis using population-based
linked records from routinely collected administrative
data sets. There are numerous advantages to using
administrative data, and record linkage between data
sets can add further value to these resources, with their
population coverage ensuring that the results are repre-
sentative. Our study was restricted to patients with pros-
tate cancer recorded in the NSWCR, so ﬁndings might
not be generalisable to other population-based cancer
registries, nor will they be representative of other cancer
types. Our study was limited to inpatient hospital ser-
vices and does not capture all prostate cancer services. A
previous study reported that the APDC captured 90% or
more of all RPs, only missing a small number of patients
treated interstate, but it underenumerated non-surgical
treatment.19 Comorbidities also tend to be underenum-
erated in the APDC.24 25
To assign stage, the NSWCR requires a sufﬁcient level
of evidence, such as the degree of spread reported in
hospital notiﬁcation forms, or deﬁnitive stage informa-
tion provided in a pathology report of an RP. If this evi-
dence is not available, a patient’s stage is recorded as
‘unknown’.12 This is an effective quality control
measure, which aims to ensure that the assigned stage is
based on the most complete information available. For a
cancer such as prostate, however, where over 70% of
patients may not receive surgical treatment, or 30% of
patients may not receive active treatment within
4 months after diagnosis, the absence of clinical infor-
mation appears to result in a relatively high proportion
of cases being recorded as ‘unknown’ stage. We found
that 95% of patients with prostate cancer with
‘unknown’ stage received no surgical treatment and that
half of these patients received no other active treatment
up to 4 months after diagnosis. The relatively good sur-
vival and low proportion of cases with comorbidities
among this group of patients suggests that it is likely that
they were primarily low-risk cases who were diagnosed by
a core needle biopsy alone due to elevated PSA levels,
and who did not receive any further staging assessment
within 4 months of diagnosis, or some of these patients
had a bone scan or imaging outside a hospital and then
went onto watchful waiting or androgen deprivation
therapy (ﬁgure 1). For these cases, the only notiﬁcation
to the NSWCR is likely to be the pathology report con-
ﬁrming the cancer diagnosis. The staging system used by
the NSWCR does not allow for stage to be assigned from
a needle biopsy alone, so low-risk patients diagnosed by
a core needle biopsy alone due to elevated PSA, unlike
that used in the USA SEER system (classiﬁed as T1c
stage),26 will be recorded as ‘unknown’ stage by the
NSWCR. Unfortunately, the NSWCR could not adopt
this staging system due to the absence of clinical infor-
mation provided by the notifying institutions.
For patients who received a cancer-related procedure
other than RP within 4 months of diagnosis, we found a
higher proportion of cases with ‘unknown’ stage among
patients admitted to private hospitals compared to
patients treated in public hospitals, after adjusting for
the cancer-related procedures received. This may be due
to potential issues related to documentation in the
cancer notiﬁcation process, resulting in the available
stage information not being received by the NSWCR. A
large proportion of biopsy and imaging procedures were
conducted during day-only admissions, but even after
adjusting for the cancer-related procedures undertaken,
patients with day-only admissions were still more likely to
be recorded as having ‘unknown’ stage at diagnosis in
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the NSWCR than patients who were admitted overnight.
It is possible that this is because the stage information
was not available at the time of reporting for those
day-only admissions.
We observed some differences in the proportions of
cases with ‘unknown’ stage by place of residence. Cases
living in more socioeconomically disadvantaged areas or
inner regional areas away from state borders were more
likely to be recorded as ‘unknown’ stage, even after
accounting for hospital cancer services and other
factors. This is possibly related to the differences
between hospital services in different socioeconomic
areas, although with the data available to us it is not pos-
sible to be sure of the reasons for these differences. We
also found that after adjusting for other factors, patients
who lived in inner regional areas near state borders
were less likely to be recorded as ‘unknown’ stage than
those living in major cities. This may be because these
patients were treated at interstate health services, and
there is a general agreement between the cancer regis-
tries in different states to exchange information for
patients who seek treatment from the neighbouring
state, but this hypothesis could not be conﬁrmed based
on the data available for this study.
Cancer stage as a prognostic indicator is essential for
researchers using cancer registry data to study outcome
disparities. Our previous research in this area,4 and the
results of this current study, suggest that because prostate
cancer cases with ‘unknown’ stage consisted of either
patients who did not receive deﬁnitive staging due to
treatment decisions based on older age or the presence
of comorbidities, or patients who had low-risk disease
diagnosed by a core biopsy only, the ‘true’ stage of
patients recorded as having ‘unknown’ stage is likely to
be a mixture of stages.4 The composition of this mixture
of stages may vary by the type of cancer-related proce-
dures received; however, the relatively good survival
among this group of patients with ‘unknown’ stage sug-
gests that the majority of these cases are likely to have
early stage disease. Also, the USA SEER Cancer Statistics
Review reported that in the period 2003–2009, 81% of
all prostate cancer cases were diagnosed with localised
stage.27 As the patterns of PSA testing in Australia are
similar to those in the USA,28 we may expect a similar
stage distribution among Australian patients with pros-
tate cancer, which does suggest that the majority of
those with ‘unknown stage’ stage are likely to have loca-
lised disease. Understanding the reasons why stage was
‘unknown’ to the cancer registry is an important step
towards understanding the potential biases that may be
caused by the incomplete stage information. For
example, as the proportion of cases with ‘unknown’
stage is higher among cases living in more socio-
economically disadvantaged areas, when examining the
socioeconomic disparities in patients’ outcomes adjust-
ing for incomplete stage data, the estimated differences
may be biased. The direction of bias can be towards or
away from the null, depending on the variation in the
composition of this mixture of stages by SES for cases
with ‘unknown’ stage recorded in the NSWCR. In addi-
tion, complete-case analysis as the default option in most
statistical software can provide biased estimates and lead
to a considerable loss in statistical power. Multiple imput-
ation is a ﬂexible statistical method for dealing with
missing data, and has been increasingly used in epi-
demiological studies.29 Further research focusing on the
validity of using MI for ‘unknown’ stage and the true
stage distribution for cases with ‘unknown’ stage is
warranted.
IMPLICATIONS AND CONCLUSIONS
This study found that hospital cancer services are import-
ant determinants of the availability of cancer stage at
diagnosis in the cancer registry for prostate cancer. Over
half of ‘unknown’ stage prostate cancer cases do not have
a hospital-reported prostate cancer diagnosis within the
cancer registry’s 4-month reporting window. Men living in
more disadvantaged areas or those attending private facili-
ties were more likely to be recorded as having ‘unknown’
stage, even after adjustment for other factors. The results
reﬂect the nature of the investigative and follow-up path-
ways for prostate cancer, and reveal a problem for patients
with prostate cancer who are managed outside notifying
healthcare facilities by treating clinicians or by private
facilities. We speculate that to reduce the variation in
practice and reporting would improve the completeness
of stage data in the NSWCR. The recent establishment of
the NSW Prostate Clinical Cancer Registry which intends
to collect grade, TNM stage and PSA levels directly from
clinicians’ notes may alleviate problems in the future
when reporting prostate cancer stage information for the
NSW population. If successful, this will allow much ﬁner
gradation of prognostic categorisation than is currently
available in the NSWCR data. Nonetheless, the clinical
registry will not revise clinical stage for cases diagnosed
prior to 2015, so a clear understanding of ‘unknown’
stage disease as recorded in the NSWCR remains import-
ant. Furthermore, this study provided clues on the direc-
tion of the possible bias due to cases with ‘unknown’
stage in epidemiological studies using this important his-
torical data to investigate survival outcomes. Further
studies to explore the composition of ‘unknown’ stage
and develop a valid method to manage this incomplete
stage data are necessary and could help us to increase the
usage of these valuable cancer registry data.
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Online resource 1. Inclusion and exclusion of prostate cancer patients in New South 
Wales 2001-2009, Australia 
All prostate cancer cases diagnosed 
in 2001-2009 
n=51429  
Prostate cancer cases 
n=50999 
Prostate cancer cases 
n=50601 
Prostate cancer cases included in 
this study 
n=50597 
Excluded: cases who were notified 
post-mortem or through death 
certificate only 
n=430 (0.8%) 
Excluded: cases aged >99 years 
n=4 (0.0%) 
Excluded: cases who died in the 
same month as their initial diagnosis 
n=398 (0.8%) 
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Online resource 2. Hierarchy of classification of prostate cancer procedures in 
relation to stage at diagnosis
Radical prostatectomy 
Imaging (bone scans, abdominal/pelvic magnetic resonance 
imaging and computed tomography) 
Other prostate cancer treatment (external beam radiotherapy, 
brachytherapy, and bilateral orchiectomy) 
Other prostate surgery (other prostatectomy, cryoablation of 
prostate and endoscopic destruction of lesion of prostate) 
Transurethral resection of the prostate (TURP) post diagnosis 
TURP before diagnosis 
Prostatic biopsy 
More 
Less 
Stage 
information
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Online resource 3: Composition of prostate cancer procedures and individual hospital characteristics for men who had a hospital-
reported cancer diagnosis and prostate procedures other than radical prostatectomy within four months of initial diagnosis 
(n=19864) 
Prostate related procedure within 4 months (not mutually exclusive) 
Imaging 
Other 
treatments* 
Other 
surgery† 
TURP‡ post 
diagnosis 
TURP before 
diagnosis Biopsy 
n % n % n % n % n % n % 
Procedure groups 
Multiple procedures plus Imaging  10491 90.7 1057 66.6 596 70.1 536 55.2 1183 18.6 9612 77.2 
Imaging only 1075 9.3 
TURP only 317 32.6 4772 75.2 
Biopsy only 2247 18.1 
Other procedures 530 33.4 254 29.9 118 12.2 392 6.2 584 4.7 
Hospital type of the procedure 
Principal referral 1414 12.2 253 10.4 38 4.5 121 14.2 1024 16.1 1004 8.1 
Other public 1380 11.9 155 12.0 32 3.8 190 23.0 1398 22.0 1153 9.3 
Major private 3535 30.6 791 55.0 652 76.7 338 27.6 2015 31.7 4283 34.4 
Other private 5237 45.3 388 22.6 128 15.1 322 35.2 1910 30.1 6003 48.2 
Day stay status of the procedure 
Overnight admission 2852 24.7 1200 85.0 698 82.1 964 99.3 6300 99.3 1653 13.3 
Day-only admission 8714 75.3 387 15.0 152 17.9 7 0.7 47 0.7 10790 86.7 
Total 11566 100.0 1587 100.0 850 100.0 971 100.0 6347 100.0 12443 100.0 
Percentage within 19864 cases 58.2 8.0 4.3 4.9 32.0 62.6 
* Other treatment includes external beam radiotherapy, brachytherapy and bilateral orchiectomy.
† Other surgery includes other prostatectomy, cryoablation of prostate and endoscopic destruction of lesion of prostate.
‡ TURP: Transurethral resection of the prostate.
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Online resource 4: Associations between patients’ characteristics and “unknown” stage prostate cancer for patients with a 
hospital-reported prostate cancer diagnosis and non-RP procedures ≤4 months after diagnosis, New South Wales, Australia, 
2001-2009 (n=19864) 
Characteristics No of cases 
% of unknown 
stage 
Bivariable model Multivariable model† 
OR 95% CI OR† 95% CI 
Age at diagnosis 
 
p<0.0001 p<0.0001 
18-64 years 4338 31.4 1.00 1.00 
65-74 years 7172 33.3 1.09 1.01 1.18 1.12 1.03 1.22 
75-99 years 8354 35.9 1.22 1.13 1.32 1.30 1.20 1.41 
Year of diagnosis
 
p=0.5 p=0.6 
One year increase 1.00 0.98 1.01 1.00 0.98 1.01 
Country of birth
 
p=0.003 p=0.3 
Australia 14473 34.7 1.00 1.00 
Countries-high English proficiency 2089 32.0 0.88 0.80 0.98 0.95 0.86 1.05 
Countries-moderate English proficiency 1117 30.6 0.83 0.73 0.95 0.97 0.84 1.11 
Countries-low English proficiency 2185 33.0 0.93 0.84 1.02 1.07 0.97 1.19 
Geographical location
 
p<0.0001 p=0.0007 
Major cities 12838 32.3 1.00 1.00 
Inner regional - near state borders 983 33.5 1.05 0.92 1.21 0.82 0.71 0.96 
Other inner regional 4539 38.7 1.32 1.23 1.42 1.10 1.01 1.20 
Rural - near state borders 339 33.9 1.07 0.86 1.35 1.03 0.81 1.31 
Other rural 1165 34.5 1.10 0.97 1.25 0.92 0.80 1.07 
Socio-economic status
 
p<0.0001 p<0.0001 
Least disadvantaged 5074 31.0 1.00 1.00 
Middle group 9488 35.4 1.22 1.14 1.32 1.20 1.11 1.30 
Most disadvantaged 5302 34.3 1.17 1.07 1.27 1.13 1.02 1.25 
Comorbidity score
 
p=0.001 p=0.8 
0 17189 34.4 1.00 1.00 
1+ 2675 31.2 0.86 0.79 0.94 0.99 0.90 1.08 
Number of episodes of care
 
p<0.0001 p<0.0001 
1 14522 36.5 1.00 1.00 
2 3825 29.7 0.73 0.68 0.79 0.79 0.73 0.86 
3+ 1517 20.6 0.45 0.40 0.51 0.54 0.47 0.62 
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Online resource 4: Associations between patients’ characteristics and “unknown” stage prostate cancer for patients with a 
hospital-reported prostate cancer diagnosis and non-RP procedures ≤4 months after diagnosis, New South Wales, Australia, 
2001-2009 (n=19864) (continued) 
Characteristics No of cases 
% of unknown 
stage Bivariable model Multivariable model† 
Prostate cancer procedures 
 
p<0.0001 p<0.0001 
Multiple procedures with imaging 10491 33.5 1.00 1.00 
Imaging only 1075 27.7 0.76 0.66 0.88 1.25 1.07 1.47 
TURP* only 5035 35.8 1.11 1.03 1.19 1.34 1.20 1.49 
Biopsy only 2247 35.4 1.09 0.99 1.20 1.11 1.01 1.23 
Other procedures 1016 33.7 1.01 0.88 1.16 1.45 1.25 1.70 
Hospital type of key procedure 
 
p<0.0001 p<0.0001 
Principal referral 2693 25.8 1.00 1.00 
Other public 3050 25.2 0.97 0.86 1.09 0.94 0.82 1.06 
Major private 6240 30.2 1.24 1.12 1.37 1.25 1.12 1.40 
Other private 7881 43.2 2.18 1.98 2.40 2.13 1.91 2.38 
Day stay status of key procedure 
 
p<0.0001 p<0.0001 
Overnight admission 9112 32.0 1.00 1.00 
Day-only admission 10752 35.7 1.18 1.11 1.25 1.23 1.11 1.36 
* TURP: Transurethral resection of the prostate
† Multivariable model adjusted for all variables listed
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Chapter overview 
This chapter includes the paper Validity of using multiple imputation for "unknown" stage at 
diagnosis in population-based cancer registry data, which was published in a peer-reviewed 
international journal. In this study, the knowledge obtained from the research described in 
Chapters 3 and 4 was used to develop a multiple imputation (MI) model to impute stage for 
those with “unknown” stage recorded in the NSWCR. The availability of the population-
based NSW Prostate Cancer Care and Outcomes Study (PCOS) linked to New South Wales 
Cancer Registry (NSWCR) data allowed a unique evaluation of the MI method. The validity of 
MI relies on the postulate that the imputed variable is missing at random (MAR), which is 
impossible to formally verify, as the missing data mechanism commonly comprises both 
accessible and inaccessible factors. However, “unknown” stage recorded in a cancer registry 
does not imply that stage of disease was not determined or used to inform treatment 
decisions by clinicians at the time of diagnosis. Thus, in this study the PCOS-NSWCR linked 
data were used to evaluate the MAR assumption and the validity of using MI to deal with 
“unknown” stage recorded in the NSWCR. The results suggest that for this dataset, MI 
appears to provide valid estimates when examining patients’ outcomes. However, a 
cautious approach to the use of this method elsewhere is recommended. 
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Abstract
Background
Themultiple imputation approach to missing data has been validated by a number of simula-
tion studies by artificially inducingmissingness on fully observed stage data under a pre-
specified missing data mechanism. However, the validity of multiple imputation has not yet
been assessed using real data. The objective of this study was to assess the validity of
using multiple imputation for ªunknownºprostate cancer stage recorded in the New South
Wales Cancer Registry (NSWCR) in real-world conditions.
Methods
Data from the population-based cohort study NSWProstate Cancer Care and Outcomes
Study (PCOS) were linked to 2000±2002 NSWCR data. For cases with ªunknownºNSWCR
stage, PCOS-stage was extracted from clinical notes. Logistic regression was used to eval-
uate the missing at random assumption adjusted for variables from two imputation models:
a basic model including NSWCR variables only and an enhancedmodel including the same
NSWCR variables together with PCOS primary treatment. Cox regression was used to eval-
uate the performance of MI.
Results
Of the 1864 prostate cancer cases 32.7%were recorded as having ªunknownºNSWCR
stage. The missing at random assumption was satisfied when the logistic regression
included the variables included in the enhancedmodel, but not those in the basic model
only. The Cox models using data with imputed stage from either imputation model provided
generally similar estimated hazard ratios but with wider confidence intervals compared with
those derived from analysis of the data with PCOS-stage. However, the complete-case
analysis of the data provided a considerably higher estimated hazard ratio for the low socio-
economic status group and rural areas in comparison with those obtained from all other
datasets.
PLOSONE | https://doi.org/10.1371/journal.pone.0180033 June 27, 2017 1 / 16
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Luo Q, Egger S, Yu XQ, Smith DP,
O’Connell DL (2017) Validity of using multiple
imputation for "unknown" stage at diagnosis in
population-based cancer registry data. PLoS ONE
12(6): e0180033. https://doi.org/10.1371/journal.
pone.0180033
Editor: Caroline A. Thompson, UNITED STATES
Received: November 17, 2016
Accepted: June 7, 2017
Published: June 27, 2017
Copyright:© 2017 Luo et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in
any medium, provided the original author and
source are credited.
Data Availability Statement: The authors confirm
that, in accordance with the ethical approval for this
study, some access restrictions apply to the data
underlying the findings. We obtained the data for
the project from two sources, the NSW Cancer
Registry and the NSW Prostate Cancer Care and
Outcomes Study. The NSW Cancer Registry is the
data custodian for the population-based and linked
cancer registry data. Approved release of these
data can be obtained through an application to the
NSW Population & Health Services Research
Ethics Committee. Details are available at https://
www.cancerinstitute.org.au/data-and-statistics/
__________________________________________________________________________________________________Chapter 5 – Validity of using multiple imputation for “unknown” stage at diagnosis
Page 109
Conclusions
Using MI to deal with ªunknownºstage data recorded in a population-based cancer registry
appears to provide valid estimates. We would recommend a cautious approach to the use of
this method elsewhere.
Introduction
How to deal with missing data is a common challenge in medical and epidemiological
research. There are many statistical methods which can be used to handle missing data, but
some methods can lead to biased estimates. For example, complete-case analysis is the default
option in most statistical software, and this has been used commonly to handle missing data
by excluding cases with missing values. The risk of bias due to missing data depends on the sta-
tistical method used and the missingness mechanism, which is often broadly classified into the
following three categories [1]: data missing completely at random (MCAR), data missing at
random (MAR), and data missing not at random (MNAR). If data are MCAR the missingness
does not depend on the response variables, neither observed values nor the missing values
themselves. When data are MCAR a complete-case analysis can provide unbiased estimates. If,
however, a large proportion of the data are missing, complete-case analysis will lead to a con-
siderable loss in statistical power. If data are MAR, missingness can be explained by the
observed values and does not depend on the missing values themselves, and in this situation a
complete-case analysis can be biased. If data are MNAR the missingness depends on the miss-
ing values themselves, even after the observed data are taken into account.
Multiple imputation (MI) is a relatively flexible and increasingly popular approach to deal-
ing with missing data [2, 3]. The aim of MI is to provide unbiased estimates and valid standard
errors from the analysis of data that are MAR or MCAR, and it is implemented in several com-
monly used statistical packages. The basis of MI is explained in the published literature [4, 5].
In brief, MI replaces the missing data with `plausible'values multiple times (i.e.m times) using
an imputation model appropriate for the observed data. The validity of results obtained from
the analysis of data generated by MI depends on the imputation model being approximately
correct and appropriate under a MAR assumption. This imputation process will generatem
complete datasets, each of which can be used to perform the standard analysis of interest. The
analysis of choice (e.g. survival analysis) is conducted separately for each imputed data set as if
they were the real complete dataset. The analysis results inm sets of estimates which are then
combined to produce one mean estimate and standard error using Rubin's rules, while taking
into account the variability in estimates between the imputed datasets, thus reflecting the
uncertainty due to the missingness [4, 5].
Stage of disease information recorded in population-based cancer registries is useful for
monitoring variations in survival trends and disease progression, estimating health service
demands, and evaluating or modelling the effectiveness of programs for early detection [6±9].
The New South Wales (NSW) Cancer Registry (NSWCR) is the first Australian population-
based cancer registry to routinely record summary stage of disease, doing so since its inception
in 1972. For prostate cancer, however, it has been shown that a large proportion (41.8% in
1999±2007) of cases are recorded as ªunknownº stage in the NSWCR [6]. Previous studies
have provided evidence that data with ªunknownº stage for prostate cancer are not MCAR [6,
9, 10], so that when analysing these data the use of inappropriate strategies such as complete-
case analysis could significantly reduce the ability to statistically control for the effect of stage
Validity of usingmultiple imputation for "unknown" stage at diagnosis
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on patients' outcomes [11] and may produce biased estimates [6]. As there is a great need to
use this valuable historical cancer registry data, even with a large proportion of cases with
ªunknownº stage, an appropriate method to handle the incomplete data for stage is required.
The MI approach to missing data has been validated by a number of simulation studies by
artificially inducing missingness on fully observed stage data under a pre-specified missing
data mechanism [12, 13]. These studies have generally found that MI is potentially a practical
and convenient method to allow for less biased assessment of patients' outcomes when using
incomplete data on stage. However, the validity of the method when using real data with real-
world missing data mechanisms, has not yet been confirmed because the ªtrueº values of the
missing data are generally unknowable. It is important to note, however, that a classification of
``unknownºstage in a population-based cancer registry does not imply that clinical stage was
not determined or used by clinicians to inform treatment decisions at the time of diagnosis.
Therefore, for cases with ªunknownº stage recorded in the cancer registry, information on
stage may be available from sources other than the registry.
The NSW Prostate Cancer Care and Outcomes Study (PCOS) is a population-based cohort
study that collected clinical data for men registered in the NSWCR who were aged less than 70
years and diagnosed with prostate cancer in 2000±2002 [14]. Record linkage between PCOS and
NSWCR was undertaken after recruitment was completed. Men in this study who were recorded
as ªunknownº stage in the NSWCR were assigned a known stage in PCOS, which was consid-
ered to represent the ªtrueº stage. The availability of the ªtrueº stage for cases with ªunknownº
stage in the NSWCR enabled us to formally validate the use of MI and assess the MAR assump-
tion. The aim of this study was to assess the validity of the use of MI for dealing with ªunknownº
prostate cancer stage recorded in the NSWCR using the PCOS-NSWCR linked data.
Materials andmethods
This was a population-based retrospective cohort study which was approved by the NSW Pop-
ulation and Health Services Research Ethics Committee (formerly known as the NSWDepart-
ment of Health Ethics Committee), Cancer Institute NSW and Cancer Council NSW in April
2006 (Project No: 2005-11-017).
Data sources
Records in the population-based cohort study (PCOS) were linked with the NSWCR records
by the Centre for Health Record Linkage (CHeReL). Eligible men were aged less than 70 years
at first diagnosis of histopathologically confirmed prostate cancer in NSW between October
2000 and October 2002. Clinical data were extracted from patients' medical records by trained
field officers or by treating physicians using a data collection protocol [14, 15]. The stepwise
inclusion and exclusion of patients for analysis is illustrated in Fig 1. After excluding 17 cases
who had missing clinical stage information, 1864 prostate cancer cases were included in the
current analysis.
Stage at diagnosis from two sources of data
NSWCR stage. Summary stage at diagnosis as recorded by the NSWCR was based on stat-
utory notification forms and pathology reports, and is hereafter referred to as ªNSWCR stageº.
It is classified using a modified summary classification [16], similar to that used by SEER [17],
with spread defined as localised (cancer contained entirely in the prostate gland), regional
(cancer extended into tissues surrounding the prostate or to regional lymph nodes), distant
(cancer extended beyond regional lymph nodes, to bones or to other distant sites) and
ªunknownº (where information in the notifications was insufficient to assign stage). For some
Validity of usingmultiple imputation for "unknown" stage at diagnosis
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analyses, stage at diagnosis was grouped into a dichotomous variable indicating ªunknownº or
ªknownº NSWCR stage. For the purpose of MI, ªunknownº NSWCR stage was coded as miss-
ing data. In this study, 32.7% of men had ªunknownº NSWCR stage and this was the only vari-
able with missing values imputed using MI.
PCOS-stage. For men who had ªunknownº NSWCR stage, clinical stage based on tumour
size (T), regional lymph nodes (N) and metastases (M) was determined from the clinical infor-
mation available to the PCOS study [14]. The TNM stages were then combined to define sum-
mary stage of disease using the same classification as that used by the NSWCR. This was
assumed to represent the closest approximation to the ªtrueº stage for those cases with
ªunknownº stage recorded in the NSWCR, and is hereafter referred to as ªPCOS-stageº.
Other NSWCR variables
Survival status and survival time. Survival status and cause of death were obtained from
two sources. Men with prostate cancer were matched against death records from the NSW
Fig 1. Inclusion and exclusion of prostate cancer patients in NSWProstate Cancer Care and Outcomes Study,
Australia.
https://doi.org/10.1371/journal.pone.0180033.g001
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Registry of Births, Deaths, and Marriages and the Australian Bureau of Statistics Cause of
Death records. All eligible cases were followed up to the end of 2007 (the most recent data
available at the time). Survival time was calculated from the date of prostate cancer diagnosis
to the date of death from prostate cancer. Those who did not die from prostate cancer were
censored at the date of death from other causes or at 31 December 2007 if they were still alive.
Demographic variables. Demographic variables that were available from the NSWCR
and were used in these analyses include age at diagnosis, geographical location and socio-eco-
nomic status of local government area of residence at diagnosis. Geographical location of resi-
dence was categorised into major cities, inner regional, and rural (including outer regional,
remote and very remote areas) using the Australian Standard Geographic Classification
Remoteness Structure [18]. This Remoteness Structure is recognised as a nationally consistent
measure of geographic remoteness, based on the physical road distance to the nearest town or
service centre. The Index of Economic Resources, derived from the 2001 Census, was used as a
measure of area-level socio-economic status [19].
Primary treatment according to PCOS. Primary treatment was defined as the treatment
received up to six months after diagnosis [14] and was categorised into four groups [20]: radi-
cal prostatectomy (RP), androgen deprivation therapy (ADT) or orchidectomy (OT), external
beam radiotherapy (EBRT) or brachytherapy, and other treatments including active surveil-
lance (AS) and watchful waiting (WW).
Statistical analysis
There were three steps of analyses involved in this study, which are summarised in Fig 2 and
described in detail below. In brief, the first step focussed on investigating the missing data
mechanism and selecting variables for imputation. This step involved the selection of variables
for inclusion in imputation models for ªunknownº NSWCR stage (the statistical models in
this step are hereafter referred to as ªselection modelsº), and imputing ªunknownº NSWCR
stage using the selected models (hereafter referred to as ªimputation modelsº). This first step
generated 35 imputed datasets which were then used in the second step. The second step
involved performing the data analysis of interest using the 35 imputed datasets generated in
the first step. The statistical models in the second step are hereafter referred to as ªanalysis
modelsº. The third step consisted of two parts: assessing the MAR assumption for ªunknownº
NSWCR stage and the PCOS-stage adjusting for variables included in the two imputations
models (the statistical models in this step are hereafter referred to as ªassessment modelsº).
We evaluated prostate cancer-specific survival with Kaplan-Meier estimates and Cox propor-
tional hazards regression models, and compared these with the corresponding results from the
data with PCOS-stage and NSWCR known stage in a complete-case analysis.
Selection of variables for inclusion in imputation models for ªunknownº NSWCR
stage. Two general rules were applied when selecting variables for inclusion in the imputa-
tion models. Firstly, to avoid bias in the analysis model, the imputation model must include all
variables intended to be included in the analysis model, including the outcomes [2, 21, 22].
Secondly, multivariable binary logistic regression was used to identify auxiliary variables that
were associated with the odds of ``unknownºstage being recorded in the NSWCR but are not
included in the analysis models. In this study, we intended to use the imputed data in prostate
cancer-specific survival analyses, therefore survival status and either the Nelson-Aalen estima-
tor of the cumulative hazard to the survival time, H(T) [12] or the survival time (T) [2] were
included in the imputation models. The correlation between H(T) and survival time T was
found to be high (0.89), indicating that for these data the use of H(T) or T as a predictor for
ªunknownº stage made little difference, and the results obtained based on these two variables
Validity of usingmultiple imputation for "unknown" stage at diagnosis
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were similar. Therefore, we have only presented the results from imputation models that
included the survival time (T). Survival time and age at diagnosis were included in the imputa-
tion models as continuous variables. Auxiliary variables with p<0.05 in either a bivariable or
multivariable model were also included in the imputation models. For the purposes of com-
parison, the following two imputation models were selected:
1. Basic model: Restricted to variables that were available from the NSWCR database, includ-
ing all variables in the analysis model (age at diagnosis, geographical location, socio-eco-
nomic status, survival status and survival time). The basic model represented the observed
data that are generally available to researchers using data from population-based cancer
registries.
2. Enhanced model: Included all the variables in the basic model plus primary treatment (with
p<0.0001) obtained in the PCOS study as an auxiliary variable.
Impute ªunknownº NSWCR stage using the imputation models. As it is often suggested
that the number of imputations (m) should be at least equal to the percentage of incomplete
cases [2, 23, 24], we usedm = 35 for this study as 32.7% (n = 610) of the study cohort had
ªunknownº NSWCR stage recorded in the cancer registry and this was coded as missing data.
Stage at diagnosis is an ordered categorical variable but because it did not meet the propor-
tional odds assumption when defined as the outcome variable in ordinal logistic regression,
multinomial logistic regression [13] within the ice package in STATA [2] was used to impute
NSWCR stage. For each of the 610 cases with missing data on NSWCR stage, the imputation
procedure imputed a plausible stage category 35 times. Combining with the 1254 cases with a
Fig 2. Statistical analyses included in this study. *NSWCR, NSWCancer Registry; PCOS, Prostate Cancer Care andOutcomes Study.
https://doi.org/10.1371/journal.pone.0180033.g002
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known NSWCR stage the imputation procedures created 35 complete data sets based on each
of the selected imputation models, which is hereafter referred to as the ªimputed stageº.
Data analysis of interest±survival analysis using imputed datasets. The response of
interest in the survival analyses was time to prostate cancer death, or censoring due to other
causes of death or end of follow-up. The prostate cancer-specific survival SE(t) was estimated
in each imputed dataset using the Kaplan-Meier method, transformed using log{−log[SE(t)]}
before applying Rubin's rules to obtain a summary estimate [25, 26], and was graphically pre-
sented to allow comparisons with the survival estimates based on PCOS-stage. Cox propor-
tional hazards regression models were performed using the m`i estimate: stcox' command in
STATA to examine differences in the risk of dying from prostate cancer by patients' demo-
graphic and clinical characteristics including the imputed stage.
Assess the MAR assumption. AMAR pattern is present when missingness (i.e. missing
vs not-missing) is dependent on the observed values but not on the actual values of the missing
observations. If missingness is dependent on the actual values of the missing observations after
the observed data are taken into account then the data are said to be MNAR [1]. To evaluate
the MAR assumption for ªunknownº NSWCR stage we used multivariable binary logistic
regression to examine the association between ``unknownºNSWCR stage (vs known NSWCR
stage) and the PCOS-stage (localised, regional, distant), after adjusting for the predictor vari-
ables included in the two imputation models separately. In the current analysis, the MAR
assumption would be violated if, in a logistic regression model, the PCOS-stage predicted
ªunknownº NSWCR stage (vs known NSWCR stage) independent of other observed patient
characteristics. An example of MNAR would be where metastatic cases are more likely to be
recorded as ªunknownº stage in the cancer registry [27] independent of other observed patient
characteristics.
Evaluation of results from survival analysis using imputed data. To understand how a
variable with imputed values will behave in statistical analyses, we compared the results from
cancer-specific survival analyses using the imputed datasets with the corresponding results
from the data with PCOS-stage and results from complete-case analysis using only the 1254
cases with known NSWCR stage (the default method used by most statistical software). The
proportional hazards assumption was satisfied based on testing the interaction of the variables
included in the regression with survival time, and visual inspection of the Schoenfeld and
scaled Schoenfeld residuals [28]. We conducted sensitivity analyses by repeating the analyses
of MI data obtained from the enhanced imputation model with 100 imputations. All statistical
analyses were performed using STATA and p<0.05 was considered to denote statistical
significance.
Results
Of the 1864 eligible prostate cancer cases who participated in PCOS 84.2% had localised dis-
ease, 12.6% had regional spread and 3.3% had distant stage as recorded by PCOS (Table 1). In
the NSWCR however, 610 (32.7%) of these same patients were recorded as having ªunknownº
stage (Table 1). The median age at diagnosis was 62 years, 69.3% of patients were resident in
major cities at the time of diagnosis, and 51.8% of patients received RP. After a median of 6.2
years of follow-up (range: 0.5 to 8.0 years), 112 cases had died from prostate cancer.
Selection of imputationmodels for ªunknownºNSWCR stage
Table 2 presents the results from bivariable and multivariable binary logistic regression models
used to identify the socio-demographic and clinical factors associated with a case having an
ªunknownº NSWCR stage (vs known NSWCR stage). All covariates intended for use in the
Validity of usingmultiple imputation for "unknown" stage at diagnosis
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analysis models that were available from the NSWCR data met the criteria to be included in
the basic selection model with p<0.05 in bivariable or multivariable models. Survival time, age
at diagnosis and socio-economic status as available in the NSWCR data were the variables sig-
nificantly associated with having ªunknownº NSWCR stage in both the bivariable models and
the basic selection model. Geographical location was only significant in the bivariable model,
and survival status was included in the imputation models since it was the outcome for the
analysis models. In the enhanced imputation model, survival status and survival time available
in the NSWCR data and primary treatment taken from PCOS were the variables significantly
associated with having ªunknownº NSWCR stage. After the imputation procedure, 35 com-
plete data sets with imputed stage were generated using each selected imputation model.
Assessing the MAR assumption
Table 3 shows there was a significant association between ªunknownº NSWCR stage and
PCOS-stage independent of variables included in the basic imputation model (p = 0.0001),
indicating that the MAR assumption is violated if the imputation model only includes
Table 1. Characteristics of prostate cancer cases aged less than 70 years at diagnosis included in this study as recorded in PCOS, NSW
(N = 1864).
Cases Unknown NSWCR stage
Characteristics n %within total n % within categories
PCOS-stage
Localised 1569 84.2 504 32.1
Regional 234 12.6 68 29.1
Distant 61 3.3 38 62.3
Age at diagnosis
Median age (years) 62 63
Geographical location
Major cities 1291 69.3 385 29.8
Inner regional 466 25.0 189 40.6
Rural 107 5.7 36 33.6
Socio-economic status
High 668 35.8 177 26.5
Middle 544 29.2 163 30.0
Low 652 35.0 270 41.4
Survival status at the end of 2007
Alive 1671 89.6 538 32.2
Died from prostate cancer 112 6.0 45 40.2
Died from other causes 81 4.3 27 33.3
Years of follow-up at the end of 2007
Median follow-up time (years) 6.2 6.1
Initial primary treatment
Radical prostatectomy 965 51.8 137 14.2
ADT/OT 152 8.2 96 63.2
EBRT/Brachytherapy 453 24.3 256 56.5
AS/WW 294 15.8 121 41.2
Total 1864 100.0 610 32.7
NSWCR: NSWCancer Registry; PCOS: Prostate Cancer Care and Outcomes Study; ADT: androgen deprivation therapy; OT: orchidectomy; EBRT:
external beam radiotherapy; AS: active surveillance; WW: watchful waiting.
https://doi.org/10.1371/journal.pone.0180033.t001
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variables available in the cancer registry data. However, the corresponding association was not
statistically significant when variables from the enhanced imputation model (p = 0.50) were
included (the variables from the basic imputation model plus primary treatment as recorded
in PCOS), indicating that the MAR assumption is satisfied when the observed data includes
the additional information on treatment.
Evaluation of results from survival analysis using imputed data
Kaplan-Meier prostate cancer-specific survival estimates by stage at diagnosis for various data-
sets including the datasets with imputed stage are shown in Fig 3. Compared to the analysis of
the dataset with PCOS-stage, analysis of the dataset derived from the basic imputation model
appears to underestimate survival for patients with distant stage disease. Analysis of the dataset
Table 2. Associations between sociodemographic and clinical characteristics and ªunknownº NSWCR stage prostate cancer for PCOS cases
(N = 1864).
Variable Cases (Unknown
NSWCR stage
%)
Bivariable modelÐ
Unadjusted odds ratio (95%CI)
Multivariable modelÐ adjusted odds ratio (95% CI)
Basic selectionmodela Enhanced selectionmodelb
Survival status at
the end of 2007
p = 0.20 p = 0.40 p<0.0001
Alive 1671 (32.2) 1.00 1.00 1.00
Died from prostate
cancer
112 (40.2) 1.41 (0.96 -2.09) 0.81 (0.47 -1.39) 0.26 (0.14 -0.48)
Died from other
causes
81 (33.3) 1.05 (0.66 -1.69) 0.66 (0.36 -1.20) 0.34 (0.17 -0.66)
Survival time at the
end of 2007
One year increase 0.89 (0.82 -0.97) p = 0.007 0.85 (0.75 -0.97) p = 0.01 0.86 (0.75 -0.99) p = 0.03
Age at diagnosis
One year increase 1.04 (1.02 -1.06) p<0.0001 1.04 (1.02 -1.06) p<0.0001 1.01 (0.99 -1.03) p = 0.50
Geographical
location
p = 0.0002 p = 0.20 p = 0.08
Major cities 1291 (29.8) 1.00 1.00 1.00
Inner regional 466 (40.6) 1.61 (1.29 -2.00) 1.13 (0.86 -1.48) 1.25 (0.93 -1.69)
Rural 107 (33.6) 1.19 (0.79 -1.81) 0.76 (0.48 -1.21) 0.76 (0.46 -1.26)
Socio-economic
status
p<0.0001 p = 0.0001 p = 0.07
High 668 (26.5) 1.00 1.00 1.00
Middle 544 (30.0) 1.19 (0.92 -1.53) 1.15 (0.89 -1.50) 1.07 (0.80 -1.42)
Low 652 (41.4) 1.96 (1.55 -2.47) 1.83 (1.36 -2.45) 1.43 (1.03 -1.97)
Primary treatment p<0.0001 p<0.0001
Radical
prostatectomy
965 (14.2) 1.00 1.00
ADT/OT 152 (63.2) 10.36 (7.11 -15.09) 14.32 (9.21 -22.28)
EBRT/
Brachytherapy
453 (56.5) 7.85 (6.06 -10.18) 8.32 (6.34 -10.91)
AS/WW 294 (41.2) 4.23 (3.15 -5.67) 4.13 (3.06 -5.58)
NSWCR: NSWCancer Registry; PCOS: Prostate Cancer Care and Outcomes Study; ADT: androgen deprivation therapy; OT: orchidectomy; EBRT:
external beam radiotherapy; AS: active surveillance; WW: watchful waiting.
a. Basic selection model includes NSWCR variables survival status, survival time, age at diagnosis, geographical location, and socio-economic status.
b. Enhanced selection model includes all variables in the basic imputationmodel, plus primary treatment from PCOS.
https://doi.org/10.1371/journal.pone.0180033.t002
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derived from the enhanced imputation model provided similar survival estimates compared to
those obtained from the analysis of the dataset with PCOS-stage (Fig 3). In the multivariable
Cox proportional hazards regression models (Fig 4 and S1 Table) examining the associations
between prostate cancer-specific survival and socio-demographic factors and stage at diagno-
sis, analysis of data from both imputation models provided generally similar estimated hazard
ratios (HRs) but wider confidence intervals (CIs) compared with those derived from analysis
of the data with PCOS-stage. The complete-case analysis of the data with NSWCR stage pro-
vided similar HR estimates for stage (HR: 2.35, 95% CI: 1.28±4.31 for regional and HR: 25.71,
95% CI: 12.90±51.23 for distant stage) compared with the estimates from data with PCOS-
stage (HR: 2.91, 95% CI: 1.81±4.69 for regional and HR: 22.04, 95% CI: 14.08±34.52 for distant
stage). However, the complete-case analysis of the data provided a considerably higher esti-
mated HR for the low socio-economic status group (HR: 2.45, 95% CI: 1.25±4.79) and rural
areas (HR: 2.76, 95% CI: 1.18±6.46) in comparison with those obtained from all other datasets.
The results from sensitivity analyses with 100 imputed datasets using the enhanced imputation
model were similar to the corresponding results from 35 imputations (S1 Table).
Discussion
To our knowledge this is the first study to develop and evaluate the MI method for ªunknownº
prostate cancer stage recorded in a population-based cancer registry using external clinical
information on stage of disease through record linkage. We have shown that in a representa-
tive sample of men diagnosed with prostate cancer, MI was a valid method for dealing with
ªunknownº stage recorded in a population-based cancer registry database, and to reflect the
uncertainty associated with ªunknownº NSWCR stage. MI using the basic imputation model
comprising only those variables available in the dataset from the NSWCR appeared to produce
similar parameter estimates for all study factors included in this study, compared to the MI
using the enhanced imputation model.
MI is a statistical method for handling missing data and has many advantages when cor-
rectly implemented. The aim of MI is to provide unbiased statistical estimates while account-
ing for the uncertainty caused by the missing data when it is MAR. AlthoughMI is appealing
and has become increasingly popular due to the ease of implementation in most common sta-
tistical software packages [2, 29], an inappropriate imputation method may provide biased
estimates [1]. For researchers using MI it is important to note that the validity of the method is
Table 3. Assessment of themissing at random assumption±the associations between ªunknownº stage prostate cancer recorded in the NSWCR
and PCOS-stage, after adjusting for variables included in the imputation models (n = 1864).
Cases (Unknown stage%) Bivariable model - Multivariable modelÐadj usted odds ratio (95%CI)
Unadjusted odds ratio
(95%CI)
Basic imputation
modela
Enhanced imputation
modelb
PCOS-stage at diagnosis p<0.0001 p = 0.0001 p = 0.5
Localised 1569 (32.1) 1.00 1 1.00
Regional 234 (29.1) 0.87 (0.64 -1.17) 0.85 (0.62 -1.15) 0.94 (0.66 -1.32)
Distant 61 (62.3) 3.49 (2.06 -5.92) 3.24 (1.80 -5.82) 1.44 (0.75 -2.76)
Missing at random assumption Not satis®ed Not satis®ed Satis®ed
NSWCR: NSWCancer Registry; PCOS: Prostate Cancer Care and Outcomes Study
a. Adjusted for variables from the basic imputation model including NSWCR variables: survival status, survival time, age at diagnosis, geographical location,
and socio-economic status.
b. Adjusted for variables from the enhanced imputation model: all variables in the basic imputationmodel plus primary treatment from PCOS.
https://doi.org/10.1371/journal.pone.0180033.t003
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Fig 3. Comparison of Kaplan-Meier curves for prostate cancer-specific survival based on analyses of PCOS-
stage data, the NSWCR complete-case stage data and imputed stage data from two imputation models.
*NSWCR, NSWCancer Registry; PCOS, Prostate Cancer Care andOutcomes Study.
https://doi.org/10.1371/journal.pone.0180033.g003
Fig 4. Comparison of the estimated adjusted hazard ratios frommultivariable Cox proportional hazards regression
models for data with PCOS-stage, the NSWCR complete-case stage and imputed stage from two imputation models.
*NSWCR, NSWCancer Registry; PCOS, Prostate Cancer Care andOutcomes Study.
https://doi.org/10.1371/journal.pone.0180033.g004
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dependent on the missingness mechanism and several procedural requirements [2, 3, 22±25].
First, the correct regression method for the imputation model (linear regression, ordinal logis-
tic regression or multinomial logistic regression) must be specified based on the type of vari-
ables to be imputed [2]. Second, the imputation model must include the covariates and
outcome from the planned analysis model, and all variables predictive of the incomplete vari-
able or influencing the process causing the missing data, even if these variables are not of inter-
est in the intended analysis [2]. Third, the number of imputations should be selected based on
the statistical efficiency of the estimates, or as it is often suggested that the number of imputa-
tions (m) should be at least equal to the percentage of cases with incomplete data [2, 23, 24].
Fourth, the imputation models must be checked for any potential perfect prediction problems
when categorical variables are involved (i.e. when one or more observations has fitted proba-
bility exactly zero or one) [2]. Fifth, justification of the plausibility of the MAR assumption
must be provided through consideration of all the possible reasons for missing data [2, 3],
through assessing the differences between the results from complete-case analysis and MI [2,
3]. It is also suggested that sensitivity analyses to investigate the robustness of inferences to
estimate the parameters under MNARmechanisms are desirable, although this requires ongo-
ing research [3, 30]. Last but not least, sufficient details about the imputation methods should
be provided as supplements when reporting the results in the epidemiological literature [3].
For standard MI to be valid, the primary assumption that the data are MAR needs to be
approximately correct, but is not a property of the data [3]. In this study, the MAR assumption
was satisfied if the primary treatment received was a part of the observed data, but not if the
variable was not included in the observed data (as was the case for the basic imputation model
included only data available in the NSWCR). While treatment data was not available in the
NSWCR data, it is not uncommon for cancer registries to collect this information. The USA
SEER database, for example, has data on treatment, and the recently established NSW Prostate
Clinical Cancer Registry intends to capture cancer treatment information that will be incorpo-
rated into the NSWCR. The availability of treatment data might enable researchers to conduct
a valid MI under MAR.
With a considerably large proportion of missing data, the performance of MI can be sensi-
tive to departures from the MAR assumption [2]. There have however been some develop-
ments in methods for dealing with MNAR data [31, 32]. In addition, the standard MI model
can be extended to incorporate specific MNAR mechanisms by using a weighted approach or
by modelling speculated mechanisms for missingness [2, 4, 30]. Nevertheless, it is common for
the missing data mechanism to actually consist of both observed and unobserved factors, and
the effects of an inaccessible mechanism are often minimal in the implementation of MI [33].
Hamilton and colleagues [34] reported that MI appears reasonably robust under a MNAR
mechanism. This was confirmed in the current study using real data, as the MI implemented
under a MNAR mechanism using the basic imputation model appeared to still provide rela-
tively unbiased estimates. This may be because there is a strong association between stage at
diagnosis and cancer survival, and the survival outcomes have been included in the imputation
models. In addition, we found that cases with distant stage were more likely to be recorded as
ªunknownº stage in the NSWCR than cases with localised or regional disease. However, in this
study only a very small number of cases (less than 5% of the study cohort) were diagnosed
with distant PCOS-stage, which may be another reason why the departure from aMAR
assumption had minimal effects on the analysis models using imputed data.
Without knowing the mechanism leading to the missing data, it is difficult to interpret
comparisons of estimates from the analysis of imputed data with those from the complete-case
analysis. If the missing data are confirmed to be not MCAR, the estimates from analyses of the
imputed data may differ from those from complete-case analysis, particularly if the
Validity of usingmultiple imputation for "unknown" stage at diagnosis
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missingness is associated with both the study outcome of interest and other study factors. We
found that the complete-case analysis of the NSWCR dataset in this study provided similar
estimates for stage compared to the estimates using data with PCOS-stage and those from the
enhanced imputation model. However, the complete-case analysis appeared to overstate the
risk of dying from prostate cancer for cases from rural areas or areas with low socio-economic
status. A possible reason for this might be due to the differences between cancer services in dif-
ferent socio-economic areas or geographical locations, and insufficient recording of clinical
data affecting the NSWCR's ability to determine stage. The large proportion of cases with
ªunknownº NSWCR stage may have resulted in residual confounding by stage. The findings
from this study provide a good example of the potential for differences between estimates
from the analysis of MI data and those from complete-case analysis for a variable other than
the imputed variable. This demonstrates by way of example that comparisons of the results
obtained from complete-case analysis and those obtained fromMI should not be used to eval-
uate the performance of MI.
Consistent with two simulation studies of MI on stage of disease for male colorectal cancer,
melanoma and female breast cancer [12, 13], this validation study using real data confirmed
that MI using multinomial regression may, under certain conditions, be an appropriate
method for dealing with ªunknownº prostate cancer stage in a population-wide cancer regis-
try. Our analysis also suggests that complete-case analysis which excludes prostate cancer cases
with ªunknownº stage can produce biased estimates. Another population-based study [35]
reported a tutorial on MI using ordinal regression models for colorectal cancer stage under the
assumption that the missing data are MAR. However, the results were not directly validated
because, like most analysis, the ªtrueº stage was not available in that study. Another study of
the validity of MI for variables other than cancer stage which used linked ambulance records
[36] reported fair to good agreement between the imputed values for variables in a state
trauma registry when compared with known values from an additional data source, although
this study unfortunately did not report a formal statistical test of the MAR assumption as pre-
sented in our study.
The main strength of our study is that, unlike the many previous simulation studies of MI,
it has demonstrated the potential benefits of MI in a real-world setting using a state-wide pop-
ulation-based cohort study and record linkage. The study cohort did not differ much in age,
area of residence or socio-economic status from all patients aged less than 70 years at diagnosis
with prostate cancer registered during the recruitment period [14]. Also, the overall survival
pattern by NSWCR stage at diagnosis in PCOS is consistent with that for the whole NSW pop-
ulation of prostate cancer cases aged less than 70 years at diagnosis in 2000±2002 (S1 Fig). This
study is limited to prostate cancer in NSW, so findings might not be generalisable to other can-
cer types or other jurisdictions without reasonable justification. Also another limitation is the
potential differential misclassification due to the differences in cancer stage recorded in the
two data sources, although of the cases with known disease stage recorded in both PCOS and
the NSWCR the agreement was 82%.
In conclusion, we found that while MI should be used with care and the results interpreted
with caution, MI for data on stage recorded in a population-based cancer registry appears to
provide valid estimates when the method was correctly implemented. Using real data we dem-
onstrated that in some situations standard MI under the MNAR assumption may be valid
when the effects of an inaccessible missing mechanism are minimal, but MI under MNAR
should be used with caution as it is sensitive to the degree of departure from the MAR assump-
tion [2]. Historical cancer registry data are of great value to researchers, so it is important that
appropriate methods for dealing with unavoidable missing data are investigated and validated.
We hope that our method of validation of the MI method using population-based health data
Validity of usingmultiple imputation for "unknown" stage at diagnosis
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linked with external data sources may be applicable elsewhere, and that it will help to improve
the utilisation of data from other population-based cancer registries.
Supporting information
S1 Fig. Kaplan-Meier survival curves by NSWCR stage at diagnosis in PCOS data with the
whole NSW population of prostate cancer cases aged less than 70 years and diagnosed in
2000±2002.  NSWCR, NSW Cancer Registry; PCOS, Prostate Cancer Care and Outcomes
Study.
(TIF)
S1 Table. Comparison of the estimated adjusted hazard ratios (HRs) frommultivariable
Cox proportional hazard regression models for data with PCOS-stage, NSWCR complete-
case stage and imputed stage from two imputation models.
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Supplementary material 1: Kaplan-Meier survival curves by NSWCR stage at diagnosis in PCOS data with the whole NSW population of 
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Supplementary material 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* NSWCR, NSW Cancer Registry; PCOS, Prostate Cancer Care and Outcomes Study.  
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Supplementary material 2: Comparison of the estimated adjusted hazard ratios (HRs) from multivariable Cox proportional hazards 
regression for data with PCOS-stage, NSWCR complete-case stage and imputed stage from two imputation models 
Variables 
Multivariable model - adjusted hazard ratio (95% CI) 
PCOS-stage NSWCR complete-case stage 
Data generated by multiple imputation 
Data from basic 
imputation modela 
Data from enhanced 
imputation modelb 
Data from enhanced 
imputation modelb 
m=35 m=35 m=100 
n=1864 n=1254 n=1864 n=1864 n=1864 
    MNAR MAR MAR 
Age at diagnosis  p=0.5 p=0.6 p=0.6 p=0.6 p=0.6 
One year increase 1.01 (0.98 -1.05) 1.01 (0.97 -1.06) 1.01 (0.97 -1.05) 1.01 (0.97 -1.05) 1.01 (0.97 -1.05) 
Geographical 
location p=0.8 p=0.05 p=0.5 p=0.4 p=0.8 
Major cities 1.07 (0.64 -1.79) 1.80 (0.89 -3.67) 1.18 (0.69 -2.02) 1.22 (0.68 -2.20) 1.24 (0.70 -2.21) 
Inner regional 1.00   1.00   1.00   1.00   1.00   
Rural 1.24 (0.61 -2.55) 2.76 (1.18 -6.46) 1.57 (0.75 -3.32) 1.66 (0.76 -3.64) 1.63 (0.75 -3.56) 
Socio-economic 
status p=0.04 p=0.003 p=0.03 p=0.03 p=0.03 
High 1.00   1.00   1.00   1.00   1.00   
Middle 0.74 (0.43 -1.28) 0.73 (0.35 -1.52) 0.83 (0.47 -1.45) 0.79 (0.44 -1.41) 0.81 (0.46 -1.45) 
Low 1.48 (0.86 -2.53) 2.45 (1.25 -4.79) 1.73 (0.98 -3.04) 1.69 (0.94 -3.05) 1.75 (0.97 -3.16) 
Stage at diagnosis p<0.0001 p<0.0001 p<0.0001 p<0.0001 p<0.0001 
Localised 1.00   1.00   1.00   1.00   1.00   
Regional 2.91 (1.81 -4.69) 2.35 (1.28 -4.31) 2.31 (1.19 -4.49) 2.67 (1.42 -5.04) 2.76 (1.48 -5.13) 
Distant 22.04 (14.08 -34.52) 25.71 (12.90 -51.23) 23.54 (11.97 -46.31) 20.54 (9.55 -44.16) 20.99 (9.81 -44.92) 
a. Basic imputation model includes NSWCR variables survival status, survival time, age at diagnosis, geographical location, and socio-economic status.  
b. Enhanced imputation model includes all variables in the basic imputation model, plus primary treatment from PCOS. 
* NSWCR: NSW Cancer Registry; PCOS: Prostate Cancer Care and Outcomes Study; MNAR: Missing not at random; MAR: Missing at random.  
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Chapter overview 
This chapter presents the results of an examination of the use of multiple imputation (MI) 
for “unknown” stage prostate cancer data recorded in the New South Wales Cancer Registry 
(NSWCR). In the previous chapter, the use of MI for prostate cancer cases recorded as 
“unknown” stage in the NSWCR was validated using the population-based NSW Prostate 
Cancer Care and Outcomes Study (PCOS) data linked to 2000-2002 NSWCR data for patients 
aged less than 70 years. In the current chapter, the performance of the MI approach for 
dealing with long-term historical “unknown” stage data in the NSWCR is further evaluated 
by examining the imputed stage distribution and trends in stage-specific survival over time, 
and comparing these results with the SEER statistics from the United States of America 
(USA). To assess the impact of using imputed stage data in epidemiological studies the 
analyses reported in Chapters 2 and 3 which used the original data: (1) Geographic variation 
in prostate cancer survival in New South Wales, and (2) A population-based study of 
progression to metastatic prostate cancer in Australia were repeated using the imputed 
stage data. When MI is implemented according to the guidelines described in the literature, 
analyses using the imputed stage for prostate cancer patients of all ages provide reliable 
results. Also, there is some evidence that MI may be the preferable method for dealing with 
incomplete NSWCR prostate cancer stage data in epidemiological studies.  
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Abstract 
Background 
The use of MI as an approach for dealing with “unknown” stage data was successfully 
validated in a previous population-based cohort study, but the method has not yet been 
applied to long-term NSWCR data, nor has there been an evaluation of the effect of using 
imputed stage when examining patients’ outcomes. The aim of this study was to evaluate 
the performance of the MI method for dealing with long-term historical stage data, by 
examining the stage distribution after imputation and comparing this with the equivalent 
SEER statistics. Additional analyses were performed to illustrate the impact of the use of MI 
for “unknown” stage when adjusting for stage in the examination of urban-rural inequalities 
in survival and the patterns of progression to metastatic disease. 
Methods 
NSWCR data were extracted for all prostate cancer cases diagnosed in 1982-2007 and 
followed up for survival status or subsequent progression to metastatic disease to the end 
of 2007. MI was used to impute stage for cases with “unknown” stage. The primary 
outcomes of interest were the stage distribution and stage-specific relative survival over 
time. Outcomes of interest in the two analyses conducted to illustrate MI were relative 
survival and relative excess risk (RER) of death in relation to place of residence for all cases, 
and the risk of developing metastatic disease for non-metastatic cases diagnosed in 1993-
2002.  
Results 
Of the 76719 prostate cancer cases diagnosed in 1982-2007, 41.0% were recorded as having 
“unknown” stage. After imputation the majority of the 31455 prostate cancer cases with 
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“unknown” stage were categorised as being diagnosed with localised stage (81.8%), while 
8.7% were categorised as regional stage and 9.5% as distant stage. Imputed data for the 
period 2001-2007 showed that 84.9%, 9.9% and 5.2% of prostate cancer cases were 
diagnosed with localised, regional and distant stage respectively, which is generally 
consistent with the USA SEER Statistics for the same period (81%, 12% and 4% for localised, 
regional and distant stage, respectively). For prostate cancer cases diagnosed during 1999-
2006, with follow up to the end of 2007, the 5-year relative survival for those with localised, 
regional and distant stage at diagnosis were 98.1%, 91% and 22.8%, respectively. The overall 
5-year relative survival for all stages combined was lower in the NSW population compared 
with the USA SEER statistics (92.6% versus 99.1%, respectively). However, the survival 
pattern by stage was generally consistent with the SEER statistics for the same period (100% 
for localised and regional stages, and 30.2% for distant stage). The two re-analyses using the 
imputed stage data resulted in the same overall conclusions as the analyses using the 
original data, although there were some variations in the detailed results produced by the 
two approaches. 
Conclusions 
These analyses indicate that MI provides reliable results when implemented according to 
the guidelines recommended in the literature. It seems likely that MI is a preferable method 
for dealing with incomplete stage data when examining patients’ outcomes. 
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1 Introduction 
Missing data are unavoidable in epidemiological research, and are often particularly 
prevalent in population-based cancer registry data, including stage of disease at diagnosis.1 
Stage of disease information recorded in population-based cancer registries is useful for 
monitoring variations in survival trends, estimating health service needs, and providing 
realistic estimates of numbers of cancer patients requiring active treatment due to disease 
progression.2-5 However, not all cancer registries routinely collect stage information, and 
even when they do it is often missing for a substantial proportion of patients, and often the 
data are not missing completely at random (MCAR).2, 6 The New South Wales (NSW) Cancer 
Registry (NSWCR) was the first Australian population-based cancer registry to routinely 
record summary stage of disease, doing so since its inception in 1972.2 This historical 
information is enormously valuable, and has been widely used in cancer research examining 
patients’ outcomes.4, 7, 8 For prostate cancer, however, it has been shown that over 40% of 
cases are recorded as “unknown” stage in the NSWCR, and that these missing data follow a 
systematic pattern.2 As a result, complete-case analysis is likely to introduce some bias, and 
so may not be a valid method for analysing these data.9  
 
The use of MI for “unknown” stage data has been validated by a number of simulation 
studies.10, 11 In the research presented in Chapter 5 the MI method for “unknown” prostate 
cancer stage recorded in the NSWCR was evaluated using real data with real-world missing 
data mechanisms through record linkage in a population-based cohort study for patients 
aged less than 70 years.9 All previous research has generally found that MI is potentially a 
practical and convenient method to allow for less biased assessment of patients’ outcomes 
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when using incomplete data on stage.9-11 It is important to emphasise that the 
implementation of MI needs to be carefully customised for each jurisdiction to justify the 
possible missing data mechanism,6, 9 and comprehensive guidelines and recommendations 
on how to implement an appropriate imputation method have been emerging in the 
literature.9, 12, 13 However, there has not yet been any evaluation of the performance of the 
MI approach for dealing with long-term historical stage data for patients of all ages, nor has 
there been an evaluation of the impact of adjusting for imputed stage on analyses of 
patients’ outcomes.  
 
Disparities in prostate cancer outcomes according to the location of residence at diagnosis 
have been consistently reported in Australia.8, 14, 15 A recent population-based study using 
NSWCR data8 reported that little progress has been made in reducing the urban-rural 
differences in prostate cancer survival, and that the urban-rural inequalities are unlikely to 
be explained by different diagnostic practices.8 Moreover, results from a population-based 
study using NSWCR stage data with up to 14 years of follow-up revealed that amongst men 
diagnosed with non-metastatic prostate cancer at initial diagnosis, those living in inner 
regional or rural areas and those living in disadvantaged areas were at greater risk of 
progressing to metastatic disease than those living in urban and less disadvantaged areas.4 
In both of these studies cases with “unknown” stage were categorised into a separate group. 
However, previous studies have suggested that the group of prostate cancer cases recorded 
as “unknown” stage is actually likely to include patients with a mixture of clinical stages.2 As 
“unknown” stage is associated with both patients’ demographic characteristics and cancer 
outcomes, due to residual confounding this mixture of stages may reduce the ability to 
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statistically control for the effect of stage when comparing patients’ outcomes, and the 
potential bias caused by these incomplete stage data is of concern.  
 
The primary aim of this study was to apply MI to NSWCR prostate cancer stage data for the 
period 1982-2007, and to compare the resulting stage distribution and survival patterns 
with the equivalent SEER statistics. As the use of PSA testing is similarly high for men in the 
USA and Australia,16 and the accuracy and completeness of the SEER data are known to be 
high,17, 18  a similar stage distribution and patterns of survival would be expected. Additional 
analyses were performed to examine the impact of including imputed stage in the 
examination of patients’ outcomes. All analyses described here use the imputed stage data, 
so that the results can then be compared to the previously reported results in Chapters 2 
and 3 which included “unknown” stage cases as a separate group (referred to as the original 
data). 
 
2 Evaluation of multiple imputation for long-term historical 
“unknown” stage data 
2.1 Methods 
2.1.1 Data source 
NSWCR data were obtained for all primary prostate cancer cases diagnosed from 1982 to 
2007 who were residents in NSW at the time of diagnosis, selected using the International 
Classification of Diseases for Oncology (ICD-O) third edition codes for prostate cancer 
(C61).19 The data from 1982 onwards were used because over 83% of cases had 
histopathological confirmation, and because cancer notification by pathology laboratories 
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became compulsory in 1985. After excluding 598 cases who were notified post-mortem or 
through death certificate only, 2838 cases who had died within the month of diagnosis, 12 
cases with unknown location of residence, and 9 cases who were aged 100 years or older at 
diagnosis,20 a total of 76719 prostate cancer cases remained for analysis. 
 
2.1.2 Outcome variables 
Based on the general rules for variable selection as outlined in the literature,9, 12, 13, 21, 22 the 
imputation model needed to include all variables intended to be analysed, including the 
outcomes, and all variables that have been identified as being associated with the odds of 
“unknown” stage being recorded in the NSWCR.9 In this section the intent was to examine 
the stage distribution and stage-specific relative survival over time, and in section 3 the aim 
was to use the imputed stage data in two epidemiological studies, involving analysis of 
relative survival and the risk of progression to metastatic disease. Therefore, two types of 
outcomes were considered in the imputation model selection. 
 
Survival status and survival time  
Vital status, all-cause survival time after a diagnosis of prostate cancer, cause of death, and 
the month and year of death to the end of 2007 were obtained from the NSWCR. The 
NSWCR derives the cause of death by matching cancer cases against death records from the 
State Registry of Births, Deaths, and Marriages and the National Death Index. All eligible 
cases were followed up to the end of 2007 (the most recent data available at the time of 
this research). Survival time was calculated from the month of prostate cancer diagnosis to 
the month of death from any cause. Those who did not die were censored at 31 December 
2007. 
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Progression to metastatic disease  
Stage of disease was identified at two time points in the course of the prostate cancer: 
initial stage at diagnosis was determined based on the highest spread of disease recorded in 
notifications received by the NSWCR within four months of the initial diagnosis of prostate 
cancer, and subsequent metastatic progression was identified by metastatic disease episode 
notifications or death from prostate cancer after four months of initial diagnosis.4 Prostate 
cancer patients who were not recorded as having developed metastatic disease were 
censored at the date of death from other causes or the end of 2007 if they were still alive.4 
More detailed information on this definition of progression to metastatic disease is given in 
a previous publication and Chapter 3.4 
 
2.1.3 Demographic variables 
Previous studies have identified that several demographic variables are associated with the 
odds of “unknown” stage being recorded in the NSWCR, and therefore the imputation 
model had to include age at diagnosis, geographical location, socio-economic status (SES) 
and the age-standardised prostate cancer incidence rate (ASR) by local government area 
(LGA) of residence at diagnosis.4, 9 Geographical location of residence was categorised into 
major cities, inner regional, and rural (including outer regional, remote and very remote 
areas) using the Australian Standard Geographic Classification Remoteness Structure,8, 23 
which is recognised as a nationally consistent measure of geographic remoteness, based on 
the physical road distance to the nearest town or service centre.4 The Index of Relative 
Socio-economic Disadvantage (IRSD), derived from the 2001 Census, was used as a measure 
of area-level SES.4, 24 It has been found that the number of prostate-specific antigen (PSA) 
tests conducted within a population is highly correlated with the number of new prostate 
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cancer cases diagnosed in the population.25, 26 Thus, in the absence of data on small area 
PSA testing rates, the 5-year period ASR for each LGA was used as a surrogate for the rate of 
PSA testing.4, 8 For each LGA in NSW, IRSD scores and ASRs were ranked and then grouped 
into three levels (SES: least disadvantaged, middle tertile, and most disadvantaged areas; 
ASR: high, middle and low), with similar sized populations in each group.4, 8 
 
2.1.4 Variable with missing data – stage at diagnosis 
Stage at diagnosis as recorded by the NSWCR is based on statutory notification forms and 
pathology reports.2, 27 It is classified using a modified summary classification,28 similar to 
that used by SEER,29 with spread defined as localised (cancer contained entirely in the 
prostate gland), regional (cancer extended into tissues surrounding the prostate or to 
regional lymph nodes), distant (cancer extended beyond regional lymph nodes, to bones or 
to other distant sites) and “unknown” (where information in the notifications was 
insufficient to assign stage).2 For the MI “unknown” NSWCR stage was coded as missing data, 
and this was the only variable with missing values imputed using MI. 
 
2.1.5 Implementation of MI 
A detailed description of the MI process for “unknown” NSWCR stage can be found in the 
publication that was presented in Chapter 5.9 In brief, MI involves two stages, an imputation 
step, where the missing data mechanism is investigated, variables for imputation are 
selected and then “unknown” stage is imputed multiple times using the selected model, and 
a data analysis step, where the intended statistical analysis is performed using each of the 
imputed datasets generated in the imputation step. For this study, as it is often suggested 
that the number of imputations (m) should be at least equal to the percentage of 
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incomplete cases,12, 30, 31 and as 41.0% (19.5% to 50.4%) of the total study cohort in 1982-
2007 had “unknown” stage recorded in the cancer registry (missing data), we generated 
m=55 imputed datasets. Stage at diagnosis is an ordered categorical variable, but because it 
did not meet the proportional odds assumption when defined as the outcome variable in 
ordinal logistic regression we instead used multinomial logistic regression9, 11 within the ice 
package in STATA12 to impute stage. 
 
Selection of variables for inclusion in imputation models for “unknown” stage 
All variables included in this analysis are generally available from cancer registries. 
Multivariable binary logistic regression was used to identify variables that were associated 
with the odds of “unknown” stage being recorded in the NSWCR. It is recommended that all 
variables intended to be included in the analysis model, including the outcomes, should also 
be included in the imputation models.9, 12, 13, 21, 22 In this study it was intended that the 
imputed stage data be used in the analysis of relative survival and in the estimation of risk 
of progression to metastatic disease in section 3. As there is high correlation between 
survival status and subsequent metastatic disease progression, and between survival time 
and time to metastatic progression, it was decided that survival status and survival time, age 
at diagnosis, geographical location, SES, and ASR of prostate cancer incidence be included in 
the imputation model. Fifty-five complete datasets with imputed stage were generated 
using the selected imputation model. 
 
When performing MI for long-term historical cancer registry data, changes over time in the 
staging system and diagnostic techniques should be taken into account where possible. 
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However, the inclusion of year of diagnosis in the imputation model may account for these 
changes over time. 
 
2.1.6 Statistical analysis 
The stage distribution by 5-year period of diagnosis before and after imputation was 
compared, and the trends in the stage distribution by year of diagnosis using the imputed 
data were graphically presented. Relative survival is the ratio of the observed probability of 
survival of the prostate cancer patients and the probability of survival that would have been 
expected if the patients had the same survival probability as the general population.1, 32 In 
order to compare these results with the SEER statistics, the stage distribution and 5-year 
relative survival using the cohort method for cases diagnosed in 1999-2006 and followed up 
to the end of 2007 were also examined. Five-year relative survival was calculated for each of 
the 55 imputed datasets, and then the 55 estimates of relative survival were combined 
using Rubin’s rules to obtain a summary estimate.33-35 The formulae for the calculations are 
provided in Appendix A. All statistical analyses were performed using STATA (version 13.1, 
STATA Corporation, College Station, TX) and p<0.05 was considered to indicate statistical 
significance. 
 
2.2 Results 
Of the 76719 cases diagnosed with prostate cancer in 1982-2007, 47.7% had localised 
disease, 5.3% regional spread, 6.0% distant disease and 41.0% had “unknown” stage of 
disease recorded in the NSWCR. The median age at diagnosis was 70 years, and 68.3% of 
patients were residents in major cities at the time of diagnosis. After a median of 4.2 years 
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of follow-up (range: 0.1 to 25.9 years), 20.7% of cases had died from prostate cancer and 
23.7% had died from other causes. 
 
2.2.1 Selection of imputation model for “unknown” stage 
All available covariates intended for use in the analysis models met the criteria for inclusion 
in the imputation model, with p<0.05 in bivariable or multivariable models: vital status, 
survival time, age at diagnosis, year of diagnosis, SES, geographical location, and ASR of 
prostate cancer incidence as a surrogate for PSA testing level in the area (Appendix B). As 
reported in Chapter 5, for prostate cancer patients aged less than 70 years old the missing 
at random (MAR) assumption is satisfied if the imputation model includes additional 
information on primary treatment.4 If treatment information was omitted from the 
imputation model, cases with distant stage were more likely to be recorded as “unknown” 
stage in the NSWCR than those with localised and regional stage.9 For the NSWCR prostate 
cancer data for all patients (aged less than 100 years at the time of diagnosis) it is likely that 
a similar pattern will occur. The imputation model in the current study is consistent with the 
basic imputation model that was validated in Chapter 5 of this thesis. This means that the 
MAR assumption is likely to be violated, as primary treatment information is not available in 
the NSWCR data. However, the inclusion of the ASR of prostate cancer incidence as a 
surrogate for PSA testing behaviour may make the MAR assumption more plausible. 
 
2.2.2 Stage distribution after imputation 
After imputation the majority of the 31455 prostate cancer cases with “unknown” stage 
were categorised as being diagnosed with localised stage (81.8%), while 8.7% were 
categorised as regional stage and 9.5% distant stage (Table 1). Stage distribution over time 
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showed a decreasing trend in the proportion of prostate cancer cases diagnosed with 
distant stage from 21.5% in 1982-1986 to 5.2% in 2002-2007, and an increasing trend in the 
proportion of cases diagnosed with localised stage from 72.6% in 1982-1986 to 84.9% in 
2002-2007. Imputed data for the period 2001-2007 showed that 84.8%, 9.8% and 5.4% of 
prostate cancer cases were diagnosed with localised, regional and distant stage respectively, 
which is generally consistent with the SEER Cancer Statistics Review for the same period 
2001-2007 (81%, 12% and 4% for localised, regional and distant stage, respectively).36 
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Table 1. Prostate cancer stage distribution after multiple imputation by year of diagnosis for 1982-2007, New South Wales, Australia 
(n=76719) 
  Period of diagnosis 
Total 
 1982-1986 1987-1991 1992-1996 1997-2001 2002-2007 
  n % n % n % n % n % n % 
Original data             
Localised 3356 58.2 4427 52.5 6966 40.5 6481 40.3 15362 52.5 36592 47.7 
Regional 272 4.7 408 4.8 712 4.1 845 5.3 1867 6.4 4104 5.3 
Distant 1015 17.6 977 11.6 1014 5.9 646 4 916 3.1 4568 6 
“Unknown” 1127 19.5 2615 31 8508 49.5 8099 50.4 11106 38 31455 41 
Imputed stage for “unknown” stage 
Localised 835 74.1 2026 77.5 6840 80.4 6572 81.1 9470 85.3 25744 81.8 
Regional 65 5.8 185 7.1 695 8.2 766 9.5 1028 9.3 2738 8.7 
Distant 227 20.2 404 15.4 973 11.4 761 9.4 608 5.5 2973 9.5 
Imputed data             
Localised 4191 72.6 6453 76.6 13806 80.3 13054 81.2 24832 84.9 62336 81.3 
Regional 337 5.8 593 7 1407 8.2 1610 10 2895 9.9 6842 8.9 
Distant 1242 21.5 1381 16.4 1987 11.6 1407 8.8 1524 5.2 7541 9.8 
Total 5770 100 8427 100 17200 100 16071 100 29251 100 76719 100 
 
Chapter 6 – Application of multiple imputation for “unknown” stage data 
 
Page 142 
 
Stage-specific 5-year relative survival by period of diagnosis after imputation 
The 5-year relative survival for men diagnosed with localised and regional prostate cancer 
has generally increased over time (Figure 1). The increase was most pronounced from 1987-
1991 to 1992-1996, followed by a steadily increasing trend in survival for regional stage, 
although survival was stable after 1996 for cases with localised stage. For the period 1999-
2006 and followed up to the end of 2007, the 5-year relative survival of prostate cancer 
cases with localised, regional and distant stage at diagnosis were 98.1%, 91% and 22.8%, 
respectively. The overall 5-year relative survival for all stages combined was lower in the 
NSW population than was reported in the USA SEER statistics (92.6% versus 99.1%, 
respectively).37 However, the survival pattern by stage is generally consistent with the SEER 
statistics for the same period (100% for localised and regional stages, and 30.2% for distant 
stage).37  
 
Figure 1: Trends in prostate cancer 5-year relative survival (95% CI) by stage at diagnosis 
for 1982-2007 after multiple imputation, New South Wales, Australia 
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3 Utilisation of the imputed data in two epidemiological studies 
In order to understand the impact of “unknown” stage on epidemiological studies assessing 
patients’ outcomes, analyses using data that included “unknown” stage as a separate group 
were compared with analyses of data with imputed stage. The original data that did not 
include any imputation (hereafter referred to as the “original data”) comprise the NSWCR 
data with “unknown” stage categorised as a separate group. These are the data that were 
used in two previously published studies presented in Chapters 2 and 3.4, 8 The data 
including imputed stage derived from the MI model are referred to as the “imputed data”.  
 
3.1 Geographic variation in prostate cancer survival 
In this section, the analysis reported in Chapter 2, Geographic variation in prostate cancer 
survival in New South Wales, was repeated using the imputed data described in Section 2 of 
this chapter for all primary prostate cancer cases aged 18-84 years and diagnosed from 1982 
to 2007. The aim of this analysis was to compare the results of the two analyses for urban-
rural inequalities in survival outcomes, to provide an assessment of the impact of 
incomplete stage data. 
 
3.1.1 Methods 
A detailed description of the methods used in this section can be found in the previous 
publication which is presented in Chapter 2 of this thesis.8 The aim of the period method in 
estimating relative survival is to provide up-to-date estimates of long-term survival for a 
recent time period, where all cancer cases included in the analysis are left-truncated at the 
beginning of the period of interest in addition to being right censored at the end of follow-
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up or at death.38 The period method was used to estimate relative survival for prostate 
cancer cases in each of three “at-risk” periods (1992-1996, 1997-2001 and 2002-2007), and 
by geographical remoteness and SES.8, 39 The “at-risk” periods were when deaths were 
observed and not necessarily when the cases were diagnosed. The relative excess risk (RER) 
of death was derived from a generalised linear model (GLM) assuming a Poisson 
distribution.8, 39 The imputed data were analysed using GLM in STATA (version 13.1, STATA 
Corporation, College Station, TX). Analysis of relative survival using the period method was 
conducted for each of the 55 imputed datasets and these were then combined using Rubin’s 
rules to obtain a summary estimate, as described in Appendix A.33-35 
 
3.1.2 Results 
The results from the multivariable models using the imputed data and the original data are 
shown in Tables 2 and 3. The results from analyses using the imputed data are generally 
consistent with the results using the original data with “unknown” stage categorised as a 
separate group, although there are some differences in the detailed results between the 
two approaches. Using the imputed data, the RER was lower for inner regional and rural 
areas compared with results from the original data. For example, after adjusting for SES, RER 
of death using the original data was 1.19, 95%CI 1.09-1.29 for inner regional areas and 1.41, 
95% CI 1.27-1.57 for rural areas compared with major cities (p-value<0.0001), while RER of 
death using the imputed data was 1.14, 95% CI 1.05-1.24 for inner regional areas and 1.25, 
95% CI 1.10-1.41 for rural areas compared with major cities (p-value<0.0001). The 
interaction term between geographical remoteness and at-risk period was not statistically 
significant in either of the analyses. 
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The RER of death over the ‘at-risk’ period shows consistently lower RERs from the analysis of 
the imputed data compared with results using the original data, with the change in RER 
being smaller for cases living in inner regional areas than those living in rural areas. For 
example, during the ‘at-risk’ period 2002-2007, without adjusting for SES, the RER for cases 
living in inner regional areas was 1.31 using MI compared to 1.36 using the original data, 
while the RER for cases living in rural areas was 1.40 using imputed data compared with 1.27 
using the original data (Table 3). 
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Table 2. Relative excess risk (RER) of death during the first 10 years after prostate cancer diagnosis in New South Wales by geographical 
location, using original and imputed data for each of the three “at-risk” periodsa, 1992-2007 
  Model not adjusted for SES   Model adjusted for SES 
 Original datab   Imputed data  Original data
b   Imputed data   RER 95% CI RER 95% CI RER 95% CI RER 95% CI 
Geographical locationc p<0.0001   p<0.0001   p<0.0001   p<0.0001 
Major cities 1.00    1.00    1.00    1.00   
Inner regional 1.26 (1.17 -1.36)  1.21 (1.12 -1.31)  1.19 (1.09 -1.29)  1.14 (1.05 -1.24) 
Rural 1.54 (1.40 -1.71)  1.36 (1.21 -1.52)  1.41 (1.27 -1.57)  1.25 (1.10 -1.41) 
“At risk” perioda p<0.0001   p<0.0001   p<0.0001   p<0.0001 
1992-1996 1.00    1.00    1.00    1.00   
1997-2001 0.68 (0.63 -0.74)  0.73 (0.67 -0.80)  0.68 (0.63 -0.74)  0.73 (0.66 -0.80) 
2002-2007 0.54 (0.50 -0.59)  0.67 (0.61 -0.74)  0.54 (0.50 -0.59)  0.67 (0.61 -0.74) 
Age at diagnosis (year) p<0.0001   p<0.0001   p<0.0001   p<0.0001 
<65 1.00    1.00    1.00    1.00   
65-74 1.12 (1.03 -1.21)  1.09 (1.00 -1.19)  1.12 (1.03 -1.21)  1.09 (1.00 -1.19) 
75-84 1.66 (1.52 -1.82)  1.41 (1.28 -1.56)  1.66 (1.52 -1.81)  1.41 (1.28 -1.55) 
Stage at diagnosis p<0.0001   p<0.0001   p<0.0001   p<0.0001 
Localised 1.00    1.00    1.00    1.00   
Regional 2.96 (2.55 -3.42)  2.86 (2.47 -3.30)  2.95 (2.55 -3.41)  2.86 (2.47 -3.30) 
Distant 19.76 (17.71 -22.04)  20.22 (18.17 -22.51)  19.29 (17.31 -21.50)  19.85 (17.85 -22.07) 
“Unknown” 1.89 (1.70 -2.10)      1.85 (1.67 -2.06)     
Prostate cancer incidence ratec p<0.0001   p<0.0001   p<0.0001   p<0.0001 
Low 1.00    1.00    1.00    1.00   
Moderate 0.85 (0.78 -0.92)  0.89 (0.81 -0.97)  0.88 (0.81 -0.95)  0.89 (0.82 -0.98) 
High 0.70 (0.65 -0.76)  0.80 (0.73 -0.87)  0.75 (0.69 -0.82)  0.84 (0.77 -0.91) 
Socio-economic statusc                 p<0.0001  p=0.0001 
Least disadvantaged         1.00    1.00   
Middle tertile         1.20 (1.10 -1.31)  1.19 (1.09 -1.31) 
Most disadvantaged                 1.25 (1.13 -1.37)   1.22 (1.10 -1.35) 
Test for the interaction between 
geographical location and “at risk” period p=0.16   p=0.15   p=0.2   p=0.2 
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a. The “at-risk” periods were when deaths were observed and not necessarily when the cases were diagnosed. 
b. Cases with “unknown” stage were categorised as a separate group. 
c. Based on the patient’s place of residence at diagnosis. Prostate cancer incidence rate by 5-year period standardised to 2001 Australian standard 
population 
 
 
Table 3. Relative excess risk (RER) of death during the first 10 years after prostate cancer diagnosis in New South Wales by geographical 
location, and change over time for each of the three “at-risk” periodsa, using original and imputed data, 1992-2007 
  RER with 95% CIb 
Geographical location Without adjusting for SES  Adjusted for SES 
  Original data   Imputed data  Original data   Imputed data 
“At risk” period 1992-1997 
Major cities 1.00    1.00    1.00    1.00   
Inner regional 1.17 (1.02 - 1.34)  1.13 (0.98 - 1.31)  1.11 (0.97 - 1.27)  1.08 (0.93 - 1.24) 
Rural 1.53 (1.29 - 1.81)   1.34 (1.09 - 1.64)  1.39 (1.16 - 1.65)   1.22 (0.99 - 1.51) 
“At risk” period 1997-2001 
Major cities 1.00    1.00    1.00    1.00   
Inner regional 1.26 (1.09 - 1.45)  1.18 (1.01 - 1.37)  1.19 (1.03 - 1.37)  1.11 (0.95 - 1.29) 
Rural 1.74 (1.47 - 2.05)   1.49 (1.23 - 1.79)  1.59 (1.34 - 1.89)   1.37 (1.13 - 1.66) 
“At risk” period 2002-2007 
Major cities 1.00    1.00    1.00    1.00   
Inner regional 1.36 (1.19 - 1.54)  1.31 (1.15 - 1.49)  1.27 (1.12 - 1.45)  1.23 (1.08 - 1.40) 
Rural 1.40 (1.17 - 1.67)  1.27 (1.06 - 1.52)  1.29 (1.08 - 1.54)  1.17 (0.97 - 1.41) 
Test for time trends p-value=0.16   p-value=0.15   p-value=0.2   p-value=0.2 
a. The “at-risk” periods were when deaths were observed and not necessarily when the cases were diagnosed. 
b. Adjusted for age at diagnosis, stage at diagnosis, age-standardised prostate cancer incidence rate.  
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3.2 Progression to metastatic disease 
In this section the analysis reported in Chapter 3, A population-based study of progression to 
metastatic prostate cancer in Australia, was repeated using the imputed stage data 
described in Section 2. For the purpose of examining the patterns of disease progression 
over long term follow-up, the data for all cases with non-metastatic prostate cancer 
diagnosed in 1993-2002 and followed up to the end of 2007 for subsequent metastatic 
progression were used in this analysis, and the patterns of metastatic disease progression 
were described. 
 
3.2.1 Methods 
The Kaplan-Meier method was used to estimate the cumulative incidence rate for 
progression to metastatic prostate cancer, and the log-rank test was used to test for 
differences in time to metastasis by initial stage at diagnosis. The annual hazard for 
progression to metastatic prostate cancer was calculated as the rate of failure within one-
year intervals by initial stage at diagnosis, and was graphically presented using Gaussian 
kernel smoothing. Cox proportional hazards regression was used to identify risk factors 
associated with progression to metastatic disease.4, 40 The imputed data were analysed 
using Cox proportional hazards regression in STATA (version 13.1, STATA Corporation, 
College Station, TX). The cumulative incidence of metastases and annual hazards for 
progression to metastatic prostate cancer were estimated using each of the 55 imputed 
datasets, and were then combined using Rubin’s rules to obtain a summary estimate 
(Appendix A).33-35 
 
Chapter 6 – Application of multiple imputation for “unknown” stage data 
 
Page 149 
 
3.2.2 Results 
The characteristics of patients included in the analysis of disease progression are 
summarised in Table 4. After imputation, an average of 1613 cases with “unknown” stage in 
the original data (accounting for 9.8% of the total number of cases with “unknown stage”) 
were excluded from this new analysis as their imputed stage was distant stage at diagnosis. 
Compared to the imputed data, the original data with “unknown” stage categorised as a 
separate group resulted in a slightly higher estimate of the overall rate of developing 
metastatic disease (17.9% versus 20.6% of the study sample developed metastases using 
the imputed data and the original data, respectively).  
 
Kaplan-Meier estimates for the cumulative incidence rate for metastatic prostate cancer by 
stage at diagnosis and the trends for the annual hazard for progression to metastatic 
disease by the number of years of follow-up are shown in Figures 2 and 3. The overall 
patterns derived from both sets of data are consistent, although the original data resulted in 
a 10-year cumulative incidence rate of metastatic disease that is slightly lower than the 
estimates from the imputed data for both localised and regional stages. In addition, the 
hazard for regional stage using the imputed data was higher than that estimated using the 
original data.  
 
In the multivariable Cox proportional hazards regression examining the associations 
between metastatic prostate cancer progression and socio-demographic factors adjusted 
for stage at diagnosis, analyses of both the original data and the imputed data provided 
generally consistent results for all study factors, with overlapping 95% CIs for the adjusted 
hazard ratios (HRs) (Table 5).  
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Table 4. Baseline characteristics of men with non-metastatic prostate cancer diagnosed in 1993-2002 in New South Wales, Australia 
  Original data   Imputed data 
    Stage at diagnosis     Stage at diagnosis 
Characteristics Total  Localised Regional “Unknown”  Total  Localised Regional 
  n (% within total)   % within categories  n (% within total)   % within categories 
Age at diagnosis             
<65 years 8466 (25.9)  53.8 9.0 37.2  8277 (26.7)  85.7 14.3 
65-74 years 14106 (43.2)  44.3 4.7 51.0  13546 (43.7)  90.5 9.5 
>74 years 10071 (30.9)  32.3 2.3 65.4  9207 (29.7)  93.0 7.0 
Year of diagnosis             
1993-1997 16768 (51.4)  42.2 4.5 53.3  15789 (50.9)  90.8 9.2 
1998-2002 15875 (48.6)  44.0 5.7 50.3  15241 (49.1)  89.1 10.9 
Geographical locationa             
Major cities 22236 (68.1)  45.5 5.2 49.3  21237 (68.4)  90.3 9.7 
Inner regional 7771 (23.8)  38.1 4.5 57.5  7353 (23.7)  89.9 10.1 
Rural 2636 (8.1)  37.3 5.7 57.1  2440 (7.9)  87.4 12.6 
Social-economic statusa             
Least disadvantaged 11195 (34.3)  48.4 6.1 45.6  10754 (34.7)  89.3 10.7 
Middle tertile 11025 (33.8)  41.0 4.5 54.4  10452 (33.7)  90.5 9.5 
Most disadvantaged 10423 (31.9)  39.5 4.6 55.9  9824 (31.7)  90.0 10.0 
Prostate cancer incidence rateb             
Lowest 7958 (24.4)  40.6 4.5 54.9  7513 (24.2)  90.5 9.5 
Moderate 10909 (33.4)  39.9 4.6 55.5  10283 (33.1)  90.3 9.7 
Highest 13776 (42.2)  47.0 5.8 47.2  13234 (42.6)  89.4 10.6 
Total 32643 (100.0)   43.1 5.1 51.8   31030 (100.0)   89.9 10.1 
a. Based on the patient’s place of residence at diagnosis.  
b. Prostate cancer incidence rate by 5-year period standardised to 2001 Australian standard population.  
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Figure 2. Cumulative incidence of metastatic prostate cancer by stage at initial diagnosis using the original and imputed data in 1993-2002 
and followed to the end of 2007, New South Wales, Australia 
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Figure 3. Annual hazard of metastatic prostate cancer by stage at initial diagnosis using the original and imputed data for New South Wales, 
Australia, over the period 1993-2002 and followed to the end of 2007  
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Table 5. Comparison of estimated adjusted hazard ratios (aHRs) and 95% CIs corresponding to analysis of the original and imputed data: 
multivariable analyses of associations between risk factors and development of metastatic prostate cancer after diagnosis of non-
metastatic disease in New South Wales over the period 1993-2002 and followed to the end of 2007 
  Original data   Imputed data 
Characteristic 
Total number of cases 
(% of metastatic 
progression) 
Multivariable modela   Total number of cases 
(% of metastatic 
progression) 
Multivariable modela 
aHR 95% CI p-value   aHR 95% CI p-value 
Stage at diagnosis         <0.0001          <0.0001 
Localised 14060 (14.2) 1.00     27911 (16.3) 1.00    
Regional 1659 (29.9) 2.65 (2.40 - 2.93)   3119 (32.3) 2.82 (2.55 - 3.11)  
“Unknown” 16924 (24.9) 1.70 (1.61 - 1.80)         
Age at diagnosis      <0.0001       <0.0001 
<65 years 8466 (14.2) 1.00     8277 (12.7) 1.00    
65-74 years 14106 (19.6) 1.43 (1.33 - 1.53)   13546 (17.4) 1.68 (1.52 - 1.86)  
>74 years 10071 (27.2) 2.73 (2.55 - 2.93)   9206 (23.3) 3.83 (3.43 - 4.27)  
Year of diagnosis              
One-year increase   0.98 (0.97 - 0.99) <0.0001    0.97 (0.95 - 0.98) <0.0001 
Geographical locationb      <0.0001       0.036 
Major cities 22236 (19.7) 1.00     21237 (17.3) 1.00    
Inner regional 7771 (21.9) 1.11 (1.04 - 1.18)   7353 (19.0) 1.14 (1.03 - 1.26)  
Rural 2636 (23.9) 1.24 (1.14 - 1.36)   2440 (20.0) 1.09 (0.94 - 1.27)  
Socio-economic statusb      0.004       <0.0001 
Least disadvantaged 11195 (18.2) 1.00     10754 (16.1) 1.00    
Middle tertile 11025 (21.4) 1.09 (1.02 - 1.16)   10452 (18.6) 1.23 (1.11 - 1.36)  
Most disadvantaged 10423 (22.1) 1.12 (1.04 - 1.19)   9824 (19.1) 1.28 (1.15 - 1.42)  
Prostate cancer incidence rateb      <0.0001       0.0083 
Lowest  7958 (21.6) 1.00     7513 (18.6) 1.00    
Moderate 10909 (21.7) 0.91 (0.85 - 0.97)   10283 (18.5) 0.90 (0.81 - 1.00)  
Highest  13776 (19.1) 0.85 (0.79 - 0.90)     13234 (17.0) 0.85 (0.76 - 0.94)   
a. Adjusted hazard ratio from multivariable model including all variables listed in the table.  
b. Based on the patient’s place of residence at diagnosis. Prostate cancer incidence rate by 5-year period standardised to 2001 Australian standard 
population.  
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4 Discussion 
 
MI has been validated as a potentially practical and convenient method for handling 
incomplete stage data recorded in population-based cancer registries.9-11 However, the only 
previous validation study that used real data was the research described in Chapter 5 of this 
thesis, which included prostate cancer cases aged 70 years or younger at diagnosis.9 This 
current study extended this previous work and makes some unique contributions to the 
literature by using MI to deal with long-term historical “unknown” stage data for prostate 
cancer cases recorded in the NSWCR from 1982 onwards. The stage distribution and stage-
specific relative survival over a 25-year period were estimated, and this demonstrated that 
the patterns in the stage distribution and relative survival estimates after imputation were 
generally consistent with the SEER statistics for a similar time period. As the use of PSA 
testing is similarly high for men in the USA and Australia,16 a similar stage distribution and 
patterns of survival for prostate cancer in the two populations would be expected. Thus this 
consistency in results between the estimates based on the imputed data and the relevant 
SEER statistics provides evidence that when implemented according to the guidelines MI 
results in reliable inferences for the whole NSWCR prostate cancer dataset from 1982 
onwards including older patients.  
 
It should be noted that the overall and stage-specific 5-year relative survival were lower in 
the NSW population than was reported in the USA SEER statistics, which is likely to be due 
to the population coverage, rate of cases detected by elevated PSA levels, and patterns of 
treatment received in the two settings. The population coverage of the data from the SEER 
program is about 28% of the USA population,37 while the NSWCR has nearly whole 
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population coverage, as it is mandatory that all cancers diagnosed, except for non-
melanoma skin cancers, are notified to the NSWCR.41 Although the use of PSA testing is 
similarly high in men in the USA and Australia,16 the actual rate of cases detected by 
elevated PSA levels may still be different in the two settings. Furthermore, it is reported that 
43.4% of cases in the SEER data had received surgical treatment,42 while this proportion was 
less than 30% in NSW.43 Both Australia and the USA are developed countries with both 
public and private health care systems and medical practices. Australia has universal health 
coverage where everyone is eligible to receive high quality free public healthcare. However, 
this does not cover dental care, some allied health care and ambulance services, and about 
half of Australians choose to have private health insurance.44 Similarly, the USA has a wide 
range of healthcare systems that vary across states, with the public USA Medicare and 
Medicaid programs providing healthcare to citizens aged 65 or older and to those with 
lower income, respectively. Over 70% of the USA population are covered by private health 
insurance.45 Despite these differences, the comparison of relative survival between the SEER 
and the NSWCR data can still provide insight into the overall pattern of patients’ survival 
outcomes by stage at diagnosis after MI. 
 
As these results suggest that MI is a valid method for dealing with incomplete stage data, it 
allows for potentially reliable analyses of long-term historical cancer registry stage data. In 
this current analysis, the application of the MI approach to the NSWCR stage data for 
prostate cancer allowed for a more complete examination of changes in the stage 
distribution and stage-specific relative survival over a 25-year period than has previously 
been reported in which “unknown” stage was included as a separate group. The study also 
confirmed that the group of cases with “unknown” stage prostate cancer recorded in the 
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NSWCR actually included patients with a mixture of stages,2, 4, 9, 43 although the majority of 
these cases were likely to have localised stage.9, 43 After imputation, the stage distribution in 
the population showed a decreasing trend over time in the proportion of prostate cancer 
cases diagnosed with distant stage, and an increasing trend in the proportion of cases 
diagnosed with localised stage. These patterns reflect the changes in diagnostic practices 
that have occurred in Australia, with PSA testing becoming widely available from the early 
1990s onwards. As clinical guidelines since 2008 had recommended against population-
based PSA testing for prostate cancer diagnosis,46, 47 future research to investigate any 
potential impact of subsequent changes in PSA testing on stage migration and survival is 
warranted. 
 
The imputed historical stage data also allowed the evaluation of the impact of “unknown” 
stage on epidemiological studies by comparing the analyses of patients’ outcomes using 
imputed stage data with those using the original data with “unknown” stage as a separate 
group. The findings from this study show some differences in the results from analyses using 
the imputed data compared with previously published results using the original data in 
which “unknown” stage was a separate group, although the conclusions of the studies 
remained unchanged. For 10-year relative survival using the period method, the RER 
decreased for areas outside major cities, in particular in rural areas, after adjusting for 
imputed stage. The results from the analysis of progression to metastatic disease indicated 
that the imputed data resulted in a slightly lower estimate of the overall rate of developing 
metastatic disease compared to that from the original data with “unknown” stage as a 
separate group.  While in these two analyses it was not found that using MI changed the 
overall conclusions of the studies, it’s possible that this wouldn’t be the case in every 
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situation, so it is important that researchers or others using incomplete cancer registry stage 
data consider the potential residual confounding that could occur when including cases with 
“unknown” stage as a separate group. 
 
Despite there being no difference in the overall conclusions from the analyses using the 
original and imputed data, there were still some variations in the detailed results produced 
by the two approaches. While in the analysis of survival outcomes by location of residence, 
the RERs for SES categories were relatively stable, in the analysis of metastatic disease 
progression, the risk of developing metastatic prostate cancer varied for patients living in 
more disadvantaged areas (1.12 using the original data versus 1.28 using the imputed data). 
This is likely to be due to “unknown” stage being associated with both patients’ outcomes 
and their socio-demographic characteristics. In addition, after imputation an average of 
1613 cases with “unknown” stage in the original data were excluded from the analysis as 
they were imputed to have distant stage at diagnosis. This results in a slightly lower overall 
rate of developing metastatic disease than that estimated using the original data that 
included these 1613 cases with “unknown” stage. As the remaining cases with “unknown” 
stage were imputed as localised or regional stage, the cumulative incidence rates for 
metastatic disease for localised or regional stage were both higher than those estimated 
using the original data. Given that over 40% of prostate cancer cases are recorded as 
“unknown” stage in the NSWCR, and this group actually includes patients with a mixture of 
stages, there will always be some concern that statistical analyses that include patients with 
“unknown” stage as a separate group may fail to capture some complex relationships 
between patients’ disease and socio-demographic characteristics, particularly as both 
“unknown” stage and patients’ outcomes are associated with socio-demographic 
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characteristics. Moreover, “unknown” stage is a specific term defined in the population-
based cancer registries, but is not of relevance in other settings with little meaning for 
clinicians, patients or policy makers. As a result, it is difficult to translate research that 
categorises “unknown” stage as a group to clinical practice. For all these reasons it is likely 
that MI is a preferable method for dealing with incomplete stage data when analysing 
patients’ outcomes. 
 
This study has some limitations. First, it is limited to prostate cancer in NSW, and findings 
may not be generalisable to other cancer types or data from other cancer registries without 
sufficient justification. Second, there was no treatment information available for this study, 
as the hospital treatment information through record linkage between the NSWCR data and 
the NSW Admitted Patient Data Collection (APDC) are only available from 2001 onwards.48 
Further, the APDC can only provide complete information on surgical treatment. Other 
treatments for prostate cancer including radiotherapy and systemic therapies are captured 
by the National Medicare Benefits Schedule and Pharmaceutical Benefits Scheme, and these 
data have not been available for record linkage. In addition, as only area-level measures of 
SES and geographical location based on the patient’s place of residence at diagnosis were 
available for this study, there may be some misclassifications due to the inferences at the 
area level not being accurate for some individuals.2 However, as demonstrated by several 
studies in Australia and in the USA, area-level SES indicators are important in measuring 
health inequalities.49, 50 There is also a potential limitation with the data on subsequent 
metastatic disease, as the completeness and accuracy of subsequent metastatic disease 
notifications in the NSWCR have not been formally investigated. It is possible that if the 
episode data are incomplete, the true rate has been underestimated.4 However, as prostate 
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cancer death was used as one source of information on disease progression this possible 
underestimation should be minimised.4 
 
Despite these concerns, as this is the first study to apply MI to state-wide population-based 
cancer registry stage data in Australia, and to evaluate the potential impacts of “unknown” 
stage on epidemiological studies examining patients’ outcomes, it provides valuable and 
previously unavailable information on the performance of MI in handling “unknown” stage 
data in a real-world setting. These results could help to increase confidence in the reliability 
of results based on the analysis of incomplete stage data from population-based cancer 
registries using MI. The application of the MI approach then allowed for a more complete 
examination of changes in prostate cancer stage distribution and stage-specific relative 
survival over a 25-year period in NSW than has previously been reported, and which could 
help inform whether any future changes in clinical practice have any effect on stage 
migration.  
 
Historical cancer registry data are of great value to cancer research, so it is important that 
appropriate methods for dealing with unavoidable missing data are investigated, validated 
and carefully implemented in each data setting.9 Results presented in this study suggest that 
MI provides reliable results when implemented according to the guidelines recommended in 
the literature, so it is likely that in many situations it is the preferable approach for handling 
“unknown” stage registry data. 
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Appendix A: Rubin’s rules to combine the parameters of interest after multiple imputation 
1. Rubin’s rules without transformation  
Take the number of cases (n) by stage at diagnosis as the parameter of interest. After 
multiple imputation with m=55 imputations we have 55 imputed datasets. For each stage, 
we obtained the m estimates: 𝑛𝑛�𝑖𝑖 , 𝑖𝑖 = 1, … ,𝑚𝑚. and 𝑉𝑉[𝑛𝑛�𝑖𝑖], 𝑖𝑖 = 1, … ,𝑚𝑚. which is the estimated 
variance of 𝑛𝑛�𝑖𝑖  for each imputed dataset. 
 
The pooled estimate is defined as: 
𝑛𝑛� = 1
𝑚𝑚
�𝑛𝑛�𝑖𝑖
𝑚𝑚
𝑖𝑖=1
 
(1) 
and the total variance for this estimate is 
𝑇𝑇 = 𝑈𝑈� + �1 + 1
𝑚𝑚
�𝐵𝐵 
(2) 
in which 
𝑈𝑈� = 1
𝑚𝑚
�𝑉𝑉[𝑛𝑛�𝑖𝑖]𝑚𝑚
𝑖𝑖=1
 
(3) 
is the pooled variance and 
𝐵𝐵 = 1
𝑚𝑚− 1�(𝑛𝑛�𝑖𝑖 − 𝑛𝑛�)2𝑚𝑚
𝑖𝑖=1
 
(4) 
is the between-imputation variance. 
By definition, the 95% confidence interval for the number of cases is: 
�𝑛𝑛� − 1.96√𝑇𝑇;  𝑛𝑛� + 1.96√𝑇𝑇� 
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2. Rubin’s rules after complementary log-log transformation (adapted from Morisot et al. 
201535) 
Take the Kaplan-Meier survival as the parameter of interest. After multiple imputation with 
m=55 imputations we have 55 imputed datasets. For each imputed dataset, at each time 
𝑡𝑡𝑗𝑗 , 𝑗𝑗 = 1,⋯ , 𝐽𝐽 , we obtained the survival estimates  ?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗�, 𝑖𝑖 = 1,⋯ ,𝑚𝑚, and the estimated 
variance of ?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗�  given by 𝑉𝑉�?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗��, 𝑖𝑖 = 1,⋯ ,𝑚𝑚, for each imputed dataset. 
After complementary log-log transformation, for 𝑖𝑖 = 1,⋯ ,𝑚𝑚 and  𝑗𝑗 = 1,⋯ , 𝐽𝐽, we define 
𝑄𝑄�𝑖𝑖�𝑡𝑡𝑗𝑗� = 𝑙𝑙𝑙𝑙𝑙𝑙�−𝑙𝑙𝑙𝑙𝑙𝑙�1 − ?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗���   
We define the variance of 𝑄𝑄�𝑖𝑖�𝑡𝑡𝑗𝑗� as: 
𝑈𝑈𝑖𝑖�𝑡𝑡𝑗𝑗� = 𝑉𝑉𝑉𝑉𝑉𝑉 �𝑄𝑄�𝑖𝑖�𝑡𝑡𝑗𝑗�� = 𝑉𝑉𝑉𝑉𝑉𝑉�𝑙𝑙𝑙𝑙𝑙𝑙�−𝑙𝑙𝑙𝑙𝑙𝑙�1 − ?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗����   
In order to obtain 𝑈𝑈𝑖𝑖�𝑡𝑡𝑗𝑗� depending on 𝑉𝑉�?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗��, we use the 𝛿𝛿-method51 with: 
𝑙𝑙 �?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗�� = 𝑙𝑙𝑙𝑙𝑙𝑙�−𝑙𝑙𝑙𝑙𝑙𝑙�1 − ?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗��� 
We obtain: 
𝑉𝑉𝑉𝑉𝑉𝑉�𝑙𝑙𝑙𝑙𝑙𝑙�−𝑙𝑙𝑙𝑙𝑙𝑙�1 − ?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗���� ≈ � −1
𝑙𝑙𝑙𝑙𝑙𝑙�1 − ?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗�� × �1 − ?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗���2 × 𝑉𝑉𝑉𝑉𝑉𝑉�?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗�� 
and then: 
𝑈𝑈𝑖𝑖�𝑡𝑡𝑗𝑗� ≈
𝑉𝑉𝑉𝑉𝑉𝑉�?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗��
�𝑙𝑙𝑙𝑙𝑙𝑙�1 − ?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗�� × �1 − ?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗���2 
The pooled log-log transformation relative survival estimate is defined as: 
𝑄𝑄��𝑡𝑡𝑗𝑗� = 1𝑚𝑚�𝑄𝑄�𝑖𝑖�𝑡𝑡𝑗𝑗�𝑚𝑚
𝑖𝑖=1
 
(1) 
and the total variance for this estimate is defined as: 
𝑇𝑇�𝑡𝑡𝑗𝑗� = 𝑈𝑈��𝑡𝑡𝑗𝑗� + �1 + 1𝑚𝑚�𝐵𝐵�𝑡𝑡𝑗𝑗� (2) 
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In which 
𝑈𝑈��𝑡𝑡𝑗𝑗� = 1𝑚𝑚�𝑈𝑈𝑖𝑖𝑚𝑚
𝑖𝑖=1
�𝑡𝑡𝑗𝑗� ≈
1
𝑚𝑚
�
𝑉𝑉𝑉𝑉𝑉𝑉�?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗��
�𝑙𝑙𝑙𝑙𝑙𝑙�1 − ?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗�� × �1 − ?̂?𝑆𝑖𝑖�𝑡𝑡𝑗𝑗���2
𝑚𝑚
𝑖𝑖=1
 
 
(3) 
is the pooled variance and 
𝐵𝐵�𝑡𝑡𝑗𝑗� = 1𝑚𝑚 − 1��𝑄𝑄�𝑖𝑖�𝑡𝑡𝑗𝑗� − 𝑄𝑄��𝑡𝑡𝑗𝑗��2𝑚𝑚
𝑖𝑖=1
 
(4) 
is the between-imputation variance. 
By definition, the 95% confidence interval for the log-log transformation of survival is: 
�𝑄𝑄��𝑡𝑡𝑗𝑗� − 1.96�𝑇𝑇�𝑡𝑡𝑗𝑗�;  𝑄𝑄��𝑡𝑡𝑗𝑗� + 1.96�𝑇𝑇�𝑡𝑡𝑗𝑗�� 
The pooled estimate of survival and its confidence interval at each time �𝑡𝑡𝑗𝑗� can be obtained 
by transformation: 
𝑆𝑆̅�𝑡𝑡𝑗𝑗� = 1 − 𝑒𝑒𝑒𝑒𝑒𝑒 �−𝑒𝑒𝑒𝑒𝑒𝑒 �𝑄𝑄��𝑡𝑡𝑗𝑗��� 
 95% 𝐶𝐶𝐶𝐶 𝑓𝑓𝑙𝑙𝑉𝑉 𝑆𝑆̅�𝑡𝑡𝑗𝑗� = �1 − 𝑒𝑒𝑒𝑒𝑒𝑒 �−𝑒𝑒𝑒𝑒𝑒𝑒 �𝑄𝑄��𝑡𝑡𝑗𝑗� ± 1.96�𝑇𝑇�𝑡𝑡𝑗𝑗���� 
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3. Rubin’s rules after log transformation  
Take the hazard ratio (HR) as the parameter of interest. After multiple imputation with 
m=55 imputations we have 55 imputed datasets. For each imputed data set, at each time 
𝑡𝑡𝑗𝑗 , 𝑗𝑗 = 1,⋯ , 𝐽𝐽 , we obtained the HR estimates  𝐻𝐻𝐻𝐻� 𝑖𝑖, 𝑖𝑖 = 1,⋯ ,𝑚𝑚, and the estimated variance 
of 𝐻𝐻𝐻𝐻� 𝑖𝑖 given by 𝑉𝑉�𝐻𝐻𝐻𝐻� 𝑖𝑖�, 𝑖𝑖 = 1,⋯ ,𝑚𝑚, for each imputed dataset. 
After log transformation, for 𝑖𝑖 = 1,⋯ ,𝑚𝑚 and  𝑗𝑗 = 1,⋯ , 𝐽𝐽, we define 
𝑄𝑄�𝑖𝑖 = 𝑙𝑙𝑙𝑙𝑙𝑙�𝐻𝐻𝐻𝐻� 𝑖𝑖�   
We define the variance of 𝑄𝑄�𝑖𝑖 as: 
𝑈𝑈𝑖𝑖 = 𝑉𝑉𝑉𝑉𝑉𝑉�𝑄𝑄�𝑖𝑖� = 𝑉𝑉𝑉𝑉𝑉𝑉�𝑙𝑙𝑙𝑙𝑙𝑙�𝐻𝐻𝐻𝐻� 𝑖𝑖�� = �𝑆𝑆𝑒𝑒�𝑙𝑙𝑙𝑙𝑙𝑙�𝐻𝐻𝐻𝐻� 𝑖𝑖���2 
with 
𝑆𝑆𝑒𝑒�𝑙𝑙𝑙𝑙𝑙𝑙�𝐻𝐻𝐻𝐻� 𝑖𝑖�� = �𝑙𝑙𝑙𝑙𝑙𝑙�𝑈𝑈_𝐻𝐻𝐻𝐻� 𝑖𝑖� − 𝑙𝑙𝑙𝑙𝑙𝑙�𝐿𝐿_𝐻𝐻𝐻𝐻� 𝑖𝑖�� (2 × 1.96)�  
In which 𝑈𝑈_𝐻𝐻𝐻𝐻� 𝑖𝑖 and 𝐿𝐿_𝐻𝐻𝐻𝐻� 𝑖𝑖  are the upper and lower bound of the 95% confidence interval 
for 𝐻𝐻𝐻𝐻� 𝑖𝑖. 
The pooled log transformed HR estimate is defined as: 
𝑄𝑄� = 1
𝑚𝑚
�𝑄𝑄�𝑖𝑖
𝑚𝑚
𝑖𝑖=1
 
(1) 
and the total variance for this estimate is 
𝑇𝑇 = 𝑈𝑈� + �1 + 1
𝑚𝑚
�𝐵𝐵 
(2) 
In which 
𝑈𝑈� = 1
𝑚𝑚
�𝑈𝑈𝑖𝑖
𝑚𝑚
𝑖𝑖=1
 
(3) 
is the pooled variance and 
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𝐵𝐵 = 1
𝑚𝑚 − 1��𝑄𝑄�𝑖𝑖 − 𝑄𝑄��2𝑚𝑚
𝑖𝑖=1
 
(4) 
is the between-imputation variance. 
By definition, the 95% confidence interval for the log transformation of HR is: 
�𝑄𝑄� − 1.96√𝑇𝑇;  𝑄𝑄� + 1.96√𝑇𝑇� 
The pooled estimate of HR and the corresponding confidence interval at each time �𝑡𝑡𝑗𝑗� are 
determined by transformation: 
𝐻𝐻𝐻𝐻�����𝑡𝑡𝑗𝑗� = 𝑒𝑒𝑒𝑒𝑒𝑒(𝑄𝑄�)  95%𝐶𝐶𝐶𝐶 𝑓𝑓𝑙𝑙𝑉𝑉 𝐻𝐻𝐻𝐻���� = �𝑒𝑒𝑒𝑒𝑒𝑒�𝑄𝑄� ± 1.96√𝑇𝑇�� 
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Appendix B. Associations between sociodemographic characteristics and “unknown” stage prostate cancer (n=76719) 
Variable Cases (“Unknown” NSWCR stage %) 
Bivariable model Multivariable modelb 
Unadjusted odds ratio (95% CI) Adjusted odds ratio (95% CI) 
Age at diagnosis           
One-year increase   1.04 (1.04 -1.04) p<0.0001 1.04 (1.04 -1.04) p<0.0001 
Survival time at the end of 2007           
One-year increase   1.02 (1.01 -1.02) p<0.0001 1.04 (1.03 -1.04) p<0.0001 
Survival status at the end of 2007      p<0.0001    p<0.0001 
Alive 42672 (40.1) 1.00    1.00 (1.00 -1.00)  
Died from prostate cancer 15866 (38.5) 0.93 (0.90 -0.97)  1.11 (1.06 -1.18)  
Died from other causes 18181 (45.2) 1.23 (1.19 -1.27)  1.18 (1.12 -1.24)  
Year of diagnosis      p<0.0001    p<0.0001 
1982-1986 5770 (19.5) 1.00    1.00    
1987-1991 8427 (31.0) 1.85 (1.71 -2.01)  1.83 (1.69 -1.98)  
1992-1996 17200 (49.5) 4.03 (3.75 -4.33)  4.20 (3.91 -4.52)  
1997-2001 16071 (50.4) 4.19 (3.89 -4.50)  5.09 (4.71 -5.50)  
2002-2007 29251 (38.0) 2.52 (2.35 -2.70)  3.86 (3.54 -4.22)  
Geographical locationa      p<0.0001    p<0.0001 
Major cities 52378 (39.1) 1.00    1.00    
Inner regional 16933 (45.5) 1.30 (1.25 -1.35)  1.23 (1.18 -1.28)  
Rural 7408 (44.3) 1.24 (1.18 -1.30)  1.19 (1.13 -1.26)  
Socio-economic statusa      p<0.0001    p<0.0001 
Least disadvantaged 26662 (35.4) 1.00    1.00    
Middle tertile 27246 (43.5) 1.40 (1.35 -1.45)  1.25 (1.20 -1.30)  
Most disadvantaged 22811 (44.5) 1.46 (1.41 -1.52)  1.35 (1.30 -1.41)  
Age-standardised incidence ratea      p<0.0001    p<0.0001 
High 18705 (41.7) 1.00    1.00    
Moderate 25827 (44.6) 1.12 (1.08 -1.17)  1.16 (1.11 -1.20)  
Low 32187 (37.8) 0.85 (0.82 -0.88)   0.88 (0.85 -0.92)   
a. Based on the patient’s place of residence at diagnosis. Prostate cancer incidence rate by 5-year period standardised to 2001 Australian standard population. 
b. Multivariable model includes all variables listed.  
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Chapter overview 
In this chapter, the aims of this program of research are reiterated and the main findings of 
the research studies described in this thesis are synthesised. The contribution to the cancer 
epidemiology literature made by each of the studies is highlighted, and the strengths and 
limitations of the research are discussed. The implications and some recommendations for 
public health management, cancer researchers and future research directions are provided.  
 
1 Summary of findings and contribution to the literature 
The principal aims of this research program were to: (1) illustrate the usefulness of historical 
cancer registry stage data in epidemiological studies by examining the geographical 
disparities in prostate cancer survival outcomes; (2) examine the characteristics and 
outcomes, including progression to metastatic disease, of men with “unknown” stage 
prostate cancer recorded in the New South Wales Cancer Registry (NSWCR); (3) investigate 
the possible reasons why these cases were recorded as “unknown” stage in the NSWCR; (4) 
validate the multiple imputation (MI) method to deal with this incomplete stage data; and 
then (5) evaluate the performance of the MI method when applied to the NSWCR 
incomplete stage data for prostate cancer. Each of these aims was addressed in detail in the 
previous chapters. The key findings, recommendations and suggested future research 
directions are summarised in Figure 1. In this section the integrated findings from the whole 
research program are discussed. As there has been no previous Australian study which has 
investigated the issues related to “unknown” stage being recorded in the NSWCR or 
validated methods to handle this incomplete data, this program of research provides a 
unique and important contribution to the cancer epidemiology literature. 
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Figure 1. Findings from and contributions of this research, and suggestions for future 
directions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Future research 
Findings from this research Patients 
Why is stage recorded as 
“unknown” in the cancer registry? 
Not suitable for staging 
Characteristics of cases 
with “unknown” stage 
Not receiving staging assessment was 
likely due to: 
• Difficulties with access to health 
services. 
• Possible differences between 
hospital services. 
• Older age and/or 
comorbid conditions. 
• Living in rural areas. 
• Living in more 
disadvantaged areas. 
  • Did not receive any 
hospital cancer 
procedure.  
• Received non-surgical 
treatment. 
  
Cancer notification system 
 Health facilities 
Potential reporting issue: 
• Stage information has been 
collated by non-notifying facilities. 
• Incomplete documentation. 
Cancer registry 
• This group is comprised 
of a mixture of stages, 
with the majority being 
localised stage. 
Known Unknown 
Validation of a practical method for handling “unknown” stage data 
• Using multiple imputation for “unknown” stage appears to 
provide valid estimates. 
• Complete-case analysis may produce biased results and should 
not be used to evaluate the validity of multiple imputation. 
 
Use of registry stage data 
 
• Survival and risk of 
metastatic progression 
were intermediate 
between that of cases 
with localised and 
regional stage. 
Stage coding rule:  
• Insufficient evidence for staging, 
e.g. low risk cases who were 
detected due to elevated PSA.  
• Received non-surgical treatment. 
• Staging occurred after the 4 
months reporting window used by 
the cancer registry. 
Stage data 
• Monitoring survival and 
stage distribution. 
• Informing health 
service planning.  
• Research on cancer 
outcomes. 
Improve patients’ 
outcome 
Recommendations: 
To cancer registries 
• Adopt the staging rule where low 
risk patients diagnosed only by a 
core needle biopsy after an elevated 
PSA can be classified as T1c stage.  
• Inclusion of all health care facilities 
in the cancer notification system. 
To researchers 
• Guidelines for implementing 
multiple imputation.  
• Grouping “unknown” stage with 
localised, regional or distant stage is 
inadvisable. 
• Investigations of 
“unknown” stage for 
other cancer sites 
recorded in the cancer 
registry. 
• Examine the potential 
impact of changes in PSA 
testing on stage migration 
and survival. 
• Examine the factors 
driving the urban-rural 
inequalities in patients’ 
outcomes. 
Urban-rural 
inequalities in cancer 
survival 
Reduce disparities in 
cancer outcomes 
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Usefulness of historical cancer registry stage data in epidemiological studies 
Population-based cancer registry stage data are widely used in epidemiological studies and 
health services research, with the main advantage being the population coverage with a 
long-term follow-up period. For simplicity and clarity, in this thesis the analysis of 
geographical inequalities in prostate cancer survival was selected to illustrate the value of 
historical cancer stage data in epidemiological studies, as there have been consistent 
reports of geographical disparities in cancer survival in Australia1-7 and other countries,8-15 
and stage of disease is a strong predictor of survival and is also associated with location of 
residence.16-19 This research is also presented in this thesis because in Chapter 6 the analysis 
is then repeated and the results are assessed after applying the validated multiple 
imputation method to handle “unknown” stage. The research described in Chapter 2 
showed that historical cancer registry stage data with sufficient long-term follow-up are 
required when examining disparities in survival outcomes for prostate cancer.20 Disparities 
in 10-year prostate cancer survival were observed by geographic location and socio-
economic status (SES) after adjustment for stage at diagnosis and the intensity of PSA 
testing within geographic areas.20 Men living in regional areas or low SES areas had poorer 
survival compared to their counterparts living in major cities or high SES areas.20 Despite 
efforts to reduce the geographical inequalities in prostate cancer survival outcomes over the 
past decade, the results of this research suggest that there is no evidence that geographic 
disparities in prostate cancer survival have reduced over time.20 Population-based studies 
using cancer registry data are considered to be a cost-effective method for examining 
patients’ long-term survival outcomes and can provide important information for health 
service planning.21 
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Systematic differences between prostate cancer patients with “unknown” and known 
stage recorded in the NSWCR 
Consistent with the findings from previous international studies of prostate cancer with 
“unknown” stage recorded in other cancer registries,16, 17, 22, 23 the research described in 
Chapter 3 confirmed that prostate cancer cases with “unknown” stage recorded in the 
NSWCR differed from cases with a known stage.21, 24-26 The proportion of prostate cancer 
cases with “unknown” stage recorded in the NSWCR was significantly higher for patients 
who were older at diagnosis, and was higher for those living in areas with low SES or which 
were geographically remote.25, 26 The results reported in of this thesis revealed that the risk 
of developing metastatic disease for those with “unknown” initial stage was intermediate 
between that for patients with localised and regional disease,21 and this pattern was 
consistent with the patterns of prostate cancer specific survival.21, 25 These findings indicate 
that “unknown” stage recorded in the NSWCR is not missing completely at random (MCAR), 
which means that a complete-case analysis will likely lead to biased results when examining 
prostate cancer patients’ disease outcomes using incomplete stage data.24 
 
Possible reasons for “unknown” stage being recorded in the NSWCR 
Several possible reasons that could contribute to a prostate cancer case being recorded as 
“unknown” stage in the NSWCR were identified in Chapter 4. Lack of definitive staging 
evidence is likely to be the key factor as to why a prostate cancer patient would be recorded 
as “unknown” stage in the NSWCR.26 This is particularly likely to occur when stage 
information has been collected by non-notifying facilities, including private consulting 
rooms,26 or when patients did not have a hospital-reported prostate cancer diagnosis, or 
received prostate cancer related procedures other than radical prostatectomy (RP) within 
Chapter 7 – Discussion 
 
Page 176 
 
four months after the initial diagnosis.26 Furthermore, this research revealed that older age 
at diagnosis and the presence of comorbidities were associated with more conservative 
treatment, which in turn results in limited staging information, and thus these patients were 
more likely to be recorded as having “unknown” stage.22, 26-28 Differences in the 
completeness of stage by geographical location of residence and SES were also observed, 
and point to possible disparities associated with hospital services in different SES areas and 
inequalities in accessibility to health services or diagnostic assessment, or differences in 
cancer notification practices.25, 26 These potential health service disparities are also likely to 
contribute to the geographical variation and SES differences in cancer outcomes observed, 
including differences in survival and metastatic progression.20, 21 
 
Validity of using MI to handle “unknown” stage data in the NSWCR 
MI has many advantages when correctly implemented. First, using MI to handle missing 
data allows researchers to use standard statistical methods to analyse each of these 
imputed datasets. Second, the imputation model is based on the observed data, therefore it 
has the ability to utilise the useful information in the observed data. Furthermore, MI 
reflects the uncertainty about the reasons for missingness, which consists of two types of 
uncertainties: sampling variation and the variation due to non-response.29 Another 
advantage of MI is that it can be implemented in most common statistical software 
packages using a ready to use command (e.g. ICE command in STATA), which is preferable to 
some other methods that require more extensive programming knowledge and skills. The 
main disadvantage of using MI is that the validity of this method depends on the 
specification of an imputation model which is based on appropriate assumptions about the 
missing data mechanism. While previous simulation studies have concluded that MI is a 
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useful method for dealing with “unknown” stage data for melanoma, breast cancer and 
colorectal cancer, to our knowledge the method has not been validated using real world 
data. One of the primary goals of this research was to assess the validity of MI as a method 
for handling real world “unknown” stage data for prostate cancer.24 Consistent with the 
findings of the previous simulation studies,30, 31 the validation study described in Chapter 5 
confirmed that MI was a valid method for handling incomplete prostate cancer stage data in 
the NSWCR.24 The reliability of MI for long-term historical NSWCR stage data was further 
demonstrated in Chapter 6 by comparing the stage distribution and stage-specific relative 
survival after imputation with corresponding statistics from the SEER database in the USA. 
While these results confirmed the reliability of MI in this situation, it is important to note 
that the validity of using MI is dependent on adherence to the guidelines provided in the 
literature.24, 32, 33 
 
The findings from this research demonstrated that assessing the differences between the 
results from complete-case analysis and MI can provide information on the missing data 
mechanism, but this comparison should not be used to evaluate the performance of MI.24 If 
the missing data are confirmed to be not MCAR then the estimates from analyses of the 
imputed data may differ from those from complete-case analysis, particularly if the 
missingness is associated with both the study outcome of interest and other study factors. 
Without knowing the mechanism leading to the missing data it is difficult to interpret 
comparisons of estimates from the analysis of imputed data with those from the complete-
case analysis. The findings from this research provide a good example of the potential for 
differences between estimates from the analysis of data from MI and those from complete-
case analysis.24 The results also show that complete-case analysis can provide biased 
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estimates. This highlights that comparisons of the results obtained from complete-case 
analysis and those obtained from MI should not be used to evaluate the validity of MI, and 
the differences should be interpreted with caution.24 
 
Understanding cases with “unknown” stage prostate cancer in the NSWCR 
More complete knowledge of the cases with “unknown” stage recorded in the cancer 
registry allows researchers to understand the potential biases involved in research based on 
this incomplete stage information, and helps them determine the most suitable and valid 
method to deal with these incomplete stage data when studying disparities in outcomes. 
Several component studies of this research program suggested that the group of cases with 
“unknown” stage prostate cancer recorded in the NSWCR actually included patients with a 
mixture of stages,21, 24-26 although the majority of these cases were likely to have localised 
stage.24, 26 Prostate cancer cases with “unknown” stage primarily consisted of patients who 
had low risk disease diagnosed by a core biopsy only, patients who did not receive definitive 
staging due to treatment decisions based on older age or the presence of comorbidities, or 
patients who did not undergo comprehensive staging assessment due to poorer accessibility 
to health services in rural or more disadvantaged areas.26 For patients aged less than 70 
years who had prostate cancer diagnosed in 2000-2002 and were registered as “unknown” 
stage in the NSWCR, clinical stage determined from a data source outside the cancer 
registry indicated that 82.6%, 11.1% and 6.2% of patients with “unknown” stage actually 
had localised, regional and distant disease, respectively (Chapter 5). After the validated 
imputation model was applied to the NSWCR stage data, including older patients diagnosed 
in 1982-2007 (Chapter 6), a similar stage distribution was observed (after imputation on 
average 81.8%, 8.7% and 9.5% of patients with “unknown” stage were categorised as 
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localised, regional and distant stage, respectively).  
 
Impact of “unknown” stage in analyses of patients’ outcomes 
Several component studies of this research program illustrated the impact of “unknown” 
stage in epidemiological studies when examining patients’ outcomes. Using record linkage 
with external clinical information on stage to determine the closest approximation to the 
“true” stage for cases with “unknown” stage recorded in the NSWCR, the analysis reported 
in Chapter 5 indicated that complete-case analysis in which cases with “unknown” stage are 
excluded can produce biased results.24 Past epidemiological studies using NSWCR stage data 
for prostate cancer have commonly categorised cases with “unknown” stage as a separate 
group.20, 21 By applying the validated MI to long-term NSWCR stage data as described in 
Chapter 6 it was demonstrated that there were some differences in the results from 
analyses using the imputed data compared with analyses using the original data in which 
those with “unknown” stage were included as a separate group, although the conclusions of 
the studies remained unchanged. However, as around 18% of cases with “unknown” stage 
were likely to actually have regional or distant stage prostate cancer, it is important that 
researchers or others using incomplete cancer registry stage data consider the potential 
residual confounding that could occur when categorising cases with “unknown” stage as a 
separate group. In addition, classifying those with “unknown” stage as having localised 
disease is not appropriate. Moreover, while “unknown” stage is a specific term as defined 
for use in the population-based cancer registries, it is not of relevance in other settings, and 
has little meaning for clinicians, patients or policy makers. As a result, it is difficult to 
translate research that categorises “unknown” stage as a group to clinical practice or 
decision making. 
Chapter 7 – Discussion 
2 Strengths and limitations 
The analyses reported in this thesis have some limitations which should be considered when 
interpreting the results and applying the methods in future research. These limitations have 
been discussed in detail in the relevant chapters and are summarised in this section. One of 
the major limitations of this research is that as it is limited to prostate cancer cases recorded 
in the NSWCR, the findings may not be generalisable to other jurisdictions or other cancer 
types. There is generally significant variation in the proportion of patients with “unknown” 
stage across the cancer types, probably due to the timing and complexity of the relevant 
staging procedures.27 This is particularly true for prostate cancer, as a relatively large 
proportion of prostate cancer patients are diagnosed with early stage cancer and a lower 
proportion of prostate cancer patients receive surgery than patients with other cancer 
types.34-37 In addition, no clinical treatment information such as PSA testing or non-surgical 
treatment was collected before the establishment of a centralised clinical registry in 2015. 
However, researchers can obtain inpatient hospital treatment information through record 
linkage between the NSWCR data and the NSW Admitted Patient Data Collection (APDC) 
from 2001 onward.38 However, this record linkage is limited to inpatient hospital services, 
which does not capture all non-surgical treatments or services, and under-enumerates 
comorbidities. For historical cancer registry data before 2001 there was no treatment and 
comorbidity data available for this study. Furthermore, there was no information on 
ethnicity available for this research and only area-level measurements of SES at diagnosis 
were used in these analyses, so there is the potential for misclassification of individuals. 
However, as area-level indicators for SES have increasingly been used in analyses of health 
inequalities,3, 20, 39, 40 it is suggested that these analyses are still of interest and the method is 
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sufficiently robust. A further limitation of this research is that MI was the only model-based 
method evaluated for dealing with “unknown” stage data, and MI was only compared with 
complete-case analysis and the approach of including cases with “unknown” stage as a 
separate group. However, given that MI has numerous advantages as previously discussed 
in this research, and this method can be implemented in most common statistical software 
packages, this research could help to improve the utilisation of incomplete data from other 
population-based cancer registries. 
 
This research has several strengths. First, data were obtained from a population-based 
cancer registry with high data quality which have met the requirements for inclusion in the 
Cancer Incidence in Five Continents (CI5) series since 1973.41 The research also used 
population-based linked records from routinely collected administrative health datasets. 
The primary advantage of these datasets is that they have full population coverage, which 
ensures that the results are representative of the study population. To our knowledge, this 
is the first study to formally examine the MAR assumption and to validate MI for “unknown” 
stage recorded in a population-based cancer registry using real data obtained from sources 
outside the cancer registry. The main strength of this method is that it has demonstrated 
and validated the performance of MI in a real-world setting. Moreover, the methods and 
processes that have been used in this research and some key findings reported in this thesis 
are applicable to other cancers and other settings. The use of population-based cancer 
registry data to examine risk of metastatic disease progression may be applicable elsewhere, 
and the method used to validate the application of MI in this thesis can be generalised to 
other population-based data, if the missing information in the population-based cancer 
registry is available from external sources. This could help to increase the utilisation of data 
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for other cancer types and from other cancer registries. 
 
3  Implications and recommendations 
Some of the findings from this thesis have implications for public health management in 
NSW. One of the issues identified as a factor in the registration of “unknown” stage prostate 
cancer cases was a result of receiving care in non-notifying health care facilities, as many 
primarily low risk prostate cancer patients diagnosed do not receive further staging 
assessment beyond a needle biopsy, and thus their stage information is held only by the 
private consulting rooms and is not notified to the NSWCR. The inclusion of these facilities in 
the cancer notification system could potentially increase the clinical information made 
available to the cancer registry and thus reduce the number of cases without enough 
information for stage to be assigned. 
 
The recent establishment of the NSW Prostate Clinical Cancer Registry, which is collecting 
TNM stage, PSA levels and cancer grade directly from clinicians’ medical notes, will result in 
extra clinical information being made available to the NSWCR,26 so that the issue of 
“unknown” stage may be somewhat alleviated in the future. However, previous research 
has reported that M stage is often the missing component which prevents a case from being 
staged, as M stage is not available if a patient did not receive surgical treatment or 
comprehensive diagnostic testing.42 Given that over 70% of prostate cancer cases may not 
receive surgery,26 it is likely that obtaining M stage will still be problematic. Therefore, 
effective methods for dealing with cancer patients with insufficient evidence for staging will 
still be of great importance. Fortunately, with the additional clinical information collected 
from clinicians’ medical notes being made available to the NSWCR, it should be possible to 
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identify low risk cases detected by elevated PSA. This would allow for the application of the 
staging rule used by the USA SEER system, where low risk patients diagnosed only by a core 
needle biopsy after an elevated PSA measurement can be classified as T1c stage.26, 43 Based 
on our finding that the majority of “unknown” cases had localised stage with good survival, 
it is likely that a significant proportion of cases with “unknown” stage fall into this category, 
so that allowing this method of classification would potentially result in a substantial 
reduction in the number of “unknown” stage prostate cancer cases in the NSWCR data. 
 
Cancer registry data are crucial for cancer epidemiological studies, and historical registry 
data is particularly necessary for studies examining patients’ outcomes over a long follow-up 
period. With around 40% of prostate cancer cases registered in the NSWCR not having a 
known stage of disease recorded, any study of prostate cancer outcomes using these data 
needs to be undertaken with an understanding of the possible impact of the differences 
between cases with known and “unknown” stage disease, and have an effective and reliable 
method of dealing with the incomplete data and the potential biases it may introduce. The 
investigations presented in this thesis explored the composition of the “unknown” stage 
group, which is important for understanding the direction of the possible bias resulting from 
the use of the incomplete stage data in epidemiological studies. As it was found that the 
group of cases with “unknown” stage prostate cancer is a heterogeneous group, although 
with the majority of these cases likely to have localised disease, using complete case 
analysis in studies examining cancer outcomes is potentially problematic and should be 
undertaken very cautiously, and grouping “unknown” stage with localised, regional or 
distant stage is inadvisable.24 As it is likely that similar missing data mechanisms and 
subsequent risks of bias will occur for other cancer types, investigations of “unknown” stage 
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recorded in the NSWCR for other cancer types are also required. 
 
Findings reported in this thesis also have implications for cancer research practice. While 
the results from this research program suggest that MI is a valid method for handling data 
with incomplete cancer registry stage, it is always important to note that the successful 
implementation of MI is very dependent on the strict adherence to the guidelines provided 
in the literature,24 and a cautious approach to the use of the MI method is recommended. 
Through careful review of the available literature, combined with the knowledge gained 
from the process of performing these analyses, a set of practical guidelines for the 
implementation of MI was synthesised and is presented in Table 1. To minimise the 
potential risks of MI the appropriate implementation of an imputation model needs to be 
carefully customised for each data set to be analysed.24, 44 It is hoped that as the method 
used to validate the application of MI in this thesis can be generalised to other population-
based data, as long as the missing information in the population-based cancer registry is 
available from external sources and is made available to the registry for verification of the 
missing values,24 the use of this validation method could help to improve the utilisation of 
incomplete data from other population-based cancer registries. 
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Table 1. Summary of guidelines from the literature for implementing and reporting 
analyses based on multiple imputation 
1. Before using MI 
 1.1 Data exploration Report the number and proportion of missing values for each 
variable involved in the analysis, and understand the type of each 
variable with missing data.24, 32 
 1.2 Investigate 
missing data 
mechanism 
Give reasons for missing values if possible, and indicate the 
association between missingness and the observed data. Clarify any 
differences between cases with complete and incomplete data.24, 32 
 1.3 Plan analysis of 
interest 
Determine the analysis to be conducted after imputation and list all 
the variables that will be included in the analysis model. 
 1.4 Consider 
potential methods to 
handle missing data 
Describe the method for handling the missing data and the 
assumptions that were made. For example, if the data are MCAR, 
then complete-case analysis may be used; if the data are likely to be 
MAR, then MI should be considered.24, 32 
2. Implementation of MI 
 2.1 Imputation step 
 2.1.1 Selection of 
variables to be 
included in the 
imputation model 
The imputation model must include the covariates and outcome for 
the planned analysis model determined in 1.3, together with all 
variables predictive of the missing data or influencing the process 
causing the missing data, even if these variables are not of interest 
in the intended analysis.24, 32, 33 
 2.1.2 Specify 
imputation model for 
each variable with 
missing data 
The correct method for the imputation model (e.g. linear 
regression, ordinal logistic regression or multinomial logistic 
regression) must be specified based on the type of variables to be 
imputed.33 Perform the appropriate transformation if required. 
 2.1.3 Select the 
number of 
imputations 
The number of imputations should be selected based on the 
statistical efficiency of the estimates, or as is often suggested, the 
number of imputations (m) should be at least equal to the 
percentage of cases with incomplete data.33, 45, 46 
 2.1.4 Imputation 
model diagnostics 
The imputation models must be checked for any potential perfect 
prediction problems when categorical variables are involved (i.e. 
when one or more observations has fitted probability exactly zero 
or one).24, 33 
 2.1.5 Justify MAR 
assumption 
Justification of the plausibility of the MAR assumption must be 
provided through consideration of all the possible reasons for 
missing data, and through assessing the differences between the 
results from complete-case analysis and analysis after MI.32, 33 
 2.1.6 Impute the 
missing data  
MI replaces the missing data with ‘plausible’ values multiple times 
(i.e. m times) using the selected imputation model based on steps 
2.1.1 to 2.1.5. This imputation process will generate m complete 
datasets. 
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Table 1. Summary of guidelines from the literature for implementing and reporting 
analyses based on multiple imputation (continued) 
 2.2 Data analysis step 
 2.2.1 Analyse each 
imputed dataset 
using a standard 
method 
The analysis of choice (e.g. survival analysis) is conducted 
separately for each imputed data set as if they were the real 
complete dataset, to generate m sets of estimates.29, 47  
 2.2.2 Produce pooled 
estimate using 
Rubin’s rules 
The m sets of estimates are then combined to produce one pooled 
estimate and standard error using Rubin’s rules.29, 47 Different 
transformations need to be considered when combining the 
estimates.48, 49 
 2.2.3 Compare 
results from analysis 
using MI with results 
from complete-case 
analysis 
Assess the differences between the results from complete-case 
analysis and MI.32, 33 However, comparisons of the results obtained 
from complete-case analysis and those obtained from MI should 
not be used to evaluate the performance of MI.24 
3. After analysis based on MI 
 3.1 Report details of 
the MI process 
Report details of the software used and specification of the 
imputation model defined in step 2 above. 
 3.2 Desirable 
sensitivity analyses 
It is also suggested that sensitivity analyses to investigate the 
robustness of inferences to estimate the parameters under MNAR 
mechanisms are desirable, although this requires ongoing research. 
32, 50 
MI: multiple imputation; MAR: missing at random; MCAR: missing completely at random; 
MNAR: missing not at random. 
 
Application of MI to the NSWCR stage data for prostate cancer allowed for a more complete 
examination of changes in stage distribution and 5-year stage-specific relative survival over 
a 25-year period than has previously been reported with “unknown” stage categorised as a 
separate group. This information is of particular use in evaluating prostate cancer diagnostic 
practices due to prostate specific antigen (PSA) testing. PSA testing was widely used in 
Australia from the early 1990s, however, in 2008 the USA Preventive Services Task Force 
issued clinical guidelines recommending against population-based PSA testing for prostate 
cancer diagnosis,51 and the Royal Australian College of General Practitioners (RACGP) issued 
similar guidelines not long after.52 It will be important that future research investigates any 
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potential impact of changes in PSA testing on stage migration and survival using more 
recent data with detailed information including patterns of PSA testing and treatment in the 
population. The use of MI could help to provide more detailed and accurate information for 
monitoring prostate cancer diagnostic practices and patients’ outcomes in the NSW 
population. 
 
The imputed long-term historical cancer registry stage data also allowed for potentially 
more reliable analyses of disparities in patients’ outcomes. This research highlighted that 
socioeconomic and urban-rural inequalities exist in both the completeness of stage 
information in the NSWCR25, 26 and in cancer patients’ outcomes.20, 21 After using the MI 
method to impute “unknown” stage, the differences in patients’ outcomes remained 
statistically significant after adjustment for stage at diagnosis. It is possible that potential 
disparities associated with cancer treatment and follow-up care are likely to contribute to 
the geographical variation in the risk of progression to metastatic disease and cancer 
survival.20, 21 At present, however, it is unclear to what extent limited accessibility to health 
services or shortages of cancer treatment facilities are actually contributing to incomplete 
staging. Further research should focus on confirming the factors driving these geographical 
inequalities in staging practices and cancer outcomes, and steps could then be taken 
towards reducing any variation in cancer management by location of residence or SES. 
 
This research represents an attempt to integrate a complex statistical method with 
epidemiological research practice. It is hoped that the finding that MI is a valid method for 
handling incomplete stage data, and the comprehensive summary of the practical guidelines 
for the appropriate implementation of MI that are provided, will make a significant 
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contribution to the practical application of MI in epidemiological studies.24, 32, 33 The findings 
of the research described in this thesis may also help to increase the utilisation of valuable 
historical cancer registry data.24  
Chapter 7 – Discussion 
 
Page 189 
 
References 
1.     Jong KE, Smith DP, Yu XQ, et al. Remoteness of residence and survival from cancer in 
New South Wales. Med J Aust 2004; 180: 618-622. 
2.     Hall SE, Holman CDAJ, Wisniewski ZS, et al. Prostate cancer: Socio-economic, 
geographical and private-health insurance effects on care and survival. BJU 
International 2005; 95: 51-58. 
3.     Baade PD, Youlden DR, Coory MD, et al. Urban-rural differences in prostate cancer 
outcomes in Australia: what has changed? Med J Aust 2011; 194: 293-296. 
4.     Cramb SM, Mengersen KL, Baade PD. Developing the atlas of cancer in Queensland: 
methodological issues. International Journal of Health Geographics 2011; 10: 9. 
5.     Australian Institute of Health and Welfare (AIHW). Cancer survival and prevalence in 
Australia: period estimates from 1982 to 2010. Asia Pac J Clin Oncol 2013; 9: 29-39. 
6.     Tervonen HE, Roder D, Morrell S, et al. Does exclusion of cancers registered only from 
death-certificate information diminish socio-demographic disparities in recorded 
survival? Cancer Epidemiol 2017; 48: 70-77. 
7.     Thomas AA, Pearce A, Sharp L, et al. Socioeconomic disadvantage but not remoteness 
affects short-term survival in prostate cancer: A population-based study using 
competing risks. Asia Pac J Clin Oncol 2017; 13: e31-e40. 
8.     Campbell NC, Elliott AM, Sharp L, et al. Rural factors and survival from cancer: analysis 
of Scottish cancer registrations. Br J Cancer 2000; 82: 1863-1866. 
9.     Gregorio DIPMS, Huang LP, DeChello LMMPH, et al. Place of Residence Effect on 
Likelihood of Surviving Prostate Cancer. Annals of Epidemiology 2007; 17: 520-524. 
Chapter 7 – Discussion 
 
Page 190 
 
10.     Jones AP, Haynes R, Sauerzapf V, et al. Travel times to health care and survival from 
cancers in Northern England. Eur J Cancer 2007; 44: 269-274. 
11.     Haynes R, Pearce J, Barnett R. Cancer survival in New Zealand: ethnic, social and 
geographical inequalities. Soc Sci Med 2008; 67: 928-937. 
12.     Robson B, Purdie G, Cormack D. Unequal Impact II: Māori and Non-Māori Cancer 
Statistics by Deprivation and Rural–Urban Status, 2002–2006. Wellington: Ministry of 
Health., 2010. 
13.     Schymura MJ, Kahn AR, German RR, et al. Factors associated with initial treatment and 
survival for clinically localized prostate cancer: Results from the CDC-NPCR Patterns of 
Care Study (PoC1). BMC Cancer 2010; 10: 152-152. 
14.     White A, Coker AL, Du XL, et al. Racial/ethnic disparities in survival among men 
diagnosed with prostate cancer in Texas. Cancer 2011; 117: 1080-1088. 
15.     Skyrud KD, Bray F, Eriksen MT, et al. Regional variations in cancer survival: Impact of 
tumour stage, socioeconomic status, comorbidity and type of treatment in Norway. 
Int J Cancer 2016; 138: 2190-2200. 
16.     Koroukian SM, Xu F, Beaird H, et al. Complexity of care needs and unstaged cancer in 
elders: a population-based study. Cancer Detect Prev 2007; 31: 199-206. 
17.     Liff JM, Chow WH, Greenberg RS. Rural-urban differences in stage at diagnosis. 
Possible relationship to cancer screening. Cancer 1991; 67: 1454-1459. 
18.     Watanabe-Galloway S, Watkins K, Duran T. Trends and Patterns of Late and Unstaged 
Lung, Colorectal, Female Breast, and Prostate Cancers among American Indians in the 
Northern Plains, 2002-2009. J Health Care Poor Underserved 2015; 26: 1048-1066. 
Chapter 7 – Discussion 
 
Page 191 
 
19.     Yu XQ, O'Connell DL, Gibberd RW, et al. Trends in survival and excess risk of death 
after diagnosis of cancer in 1980-1996 in New South Wales, Australia. Int J Cancer 
2006; 119: 894-900. 
20.     Yu XQ, Luo Q, Smith DP, et al. Geographic variation in prostate cancer survival in New 
South Wales. Med J Aust 2014; 200: 586-590. 
21.     Luo Q, Yu XQ, Smith DP, et al. A population-based study of progression to metastatic 
prostate cancer in Australia. Cancer Epidemiology 2015; 39: 617-622. 
22.     Klassen AC, Curriero F, Kulldorff M, et al. Missing stage and grade in Maryland 
prostate cancer surveillance data, 1992-1997. Am J Prev Med 2006; 30: S77-87. 
23.     Roetzheim RG, Pal N, Tennant C, et al. Effects of health insurance and race on early 
detection of cancer. J Natl Cancer Inst 1999; 91: 1409-1415. 
24.     Luo Q, Egger S, Yu XQ, et al. Validity of using multiple imputation for "unknown" stage 
at diagnosis in population-based cancer registry data. PLoS One 2017; 12: e0180033. 
25.     Luo Q, Yu XQ, Cooke-Yarborough C, et al. Characteristics of cases with unknown stage 
prostate cancer in a population-based cancer registry. Cancer Epidemiol 2013; 37: 813-
819. 
26.     Luo Q, Yu XQ, Smith DP, et al. Cancer-related hospitalisations and ‘unknown’ stage 
prostate cancer: a population-based record linkage study. BMJ Open 2017; 7:e014259. 
27.     Gurney J, Sarfati D, Stanley J, et al. Unstaged cancer in a population-based registry: 
Prevalence, predictors and patient prognosis. Cancer Epidemiol 2013; 37: 498-504. 
28.     Merrill RM, Sloan A, Anderson AE, et al. Unstaged cancer in the United States: a 
population-based study. BMC Cancer 2011; 11: 402. 
29.     Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and 
some applications. Stat Med 1991; 10: 585-598. 
Chapter 7 – Discussion 
 
Page 192 
 
30.     Eisemann N, Waldmann A, Katalinic A. Imputation of missing values of tumour stage in 
population-based cancer registration. BMC Med Res Methodol 2011; 11: 129. 
31.     Falcaro M, Nur U, Rachet B, et al. Estimating excess hazard ratios and net survival 
when covariate data are missing: strategies for multiple imputation. Epidemiology 
2015; 26: 421-428. 
32.     Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in 
epidemiological and clinical research: potential and pitfalls. BMJ 2009; 338: b2393. 
33.     White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues 
and guidance for practice. Stat Med 2011; 30: 377-399. 
34.     Young JM, Durcinoska I, DeLoyde K, et al. Patterns of follow up and survivorship care 
for people with colorectal cancer in new South Wales, Australia: a population-based 
survey. BMC Cancer 2018; 18: 339. 
35.     Currow DC, You H, Aranda S, et al. What factors are predictive of surgical resection 
and survival from localised non-small cell lung cancer? Med J Aust 2014; 201: 475-480. 
36.     Hayen A, Smith DP, Patel MI, et al. Patterns of surgical care for prostate cancer in NSW, 
1993-2002: rural/urban and socio-economic variation. Aust N Z J Public Health 2008; 
32: 417-420. 
37.     Kemp-Casey A, Roughead L, Saunders C, et al. Breast cancer recurrence following 
active treatment: determining its incidence in the NSW population. Public Health 
Research & Practice. 
38.     CHeReL. Data dictionaries, NSW Admitted Patient Data Collection (APDC), vol. 2018: 
Centre for health record linkage, 2017. 
39.     Yu XQ. Socioeconomic disparities in breast cancer survival: relation to stage at 
diagnosis, treatment and race. BMC Cancer 2009; 9: 364. 
Chapter 7 – Discussion 
 
Page 193 
 
40.     Yu XQ, O'Connell DL, Gibberd RW, et al. Assessing the impact of socio-economic status 
on cancer survival in New South Wales, Australia 1996-2001. Cancer Causes Control 
2008; 19: 1383-1390. 
41.     Forman D, Bray F, Brewster D, et al. Cancer Incidence in Five Continents, Vol. X 
(electronic version). Lyon: International Agency for Research on Cancer. Available from: 
http://ci5.iarc.fr, 2013. 
42.     Worthington JL, Koroukian SM, Cooper GS. Examining the characteristics of unstaged 
colon and rectal cancer cases. Cancer Detect Prev 2008; 32: 251-258. 
43.     Beahrs O, Henson D, Huntter R, et al., eds. Manual for Staging of Cancer, Fourth ed.: 
American Joint Committee on Cancer (AJCC). Philadelphia: Lippincott, 1992. 
44.     Falcaro M, Carpenter JR. Correcting bias due to missing stage data in the non-
parametric estimation of stage-specific net survival for colorectal cancer using 
multiple imputation. Cancer Epidemiol 2017; 48: 16-21. 
45.     Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? 
Some practical clarifications of multiple imputation theory. Prev Sci 2007; 8: 206-213. 
46.     Bodner TE. What improves with increased missing data imputations? Structural 
Equation Modeling 2008; 15: 5. 
47.     Rubin DB. Multiple Imputation for Nonresponse in Surveysed. New York: Wiley, 1987. 
48.     Morisot A, Bessaoud F, Landais P, et al. Prostate cancer: net survival and cause-
specific survival rates after multiple imputation. BMC Med Res Methodol 2015; 15: 54. 
49.     Marshall A, Altman DG, Holder RL, et al. Combining estimates of interest in prognostic 
modelling studies after multiple imputation: current practice and guidelines. BMC Med 
Res Methodol 2009; 9: 57. 
Chapter 7 – Discussion 
 
Page 194 
 
50.     Carpenter JR, Kenward MG, White IR. Sensitivity analysis after multiple imputation 
under missing at random: a weighting approach. Stat Methods Med Res 2007; 16: 259-
275. 
51.     Screening for prostate cancer: U.S. Preventive Services Task Force recommendation 
statement. Ann Intern Med 2008; 149: 185-191. 
52.     Practitioners TRACoG. Guidelines for preventive activities in general practice (red 
book), 7th edn. Melbourne: RACGP, 2009. 
 
Appendix A: Ethics clearance 
 
Page 195 
 
Appendix A: Ethics approvals 
The work presented in Chapters 2, 3 and 6 was approved by the NSW Population and Health 
Services Research Ethics Committee (Reference: HREC/09/CIPHS/16) and Cancer Institute 
NSW Ethics Committee (Reference: 2009/03/139). The work presented in Chapter 4 was 
approved by the NSW Population and Health Services Research Ethics Committee (AU RED 
Reference: HREC/10/CIPHS/21) and Cancer Institute NSW Ethics Committee (Reference: 
2010/04/223). The work presented in Chapter 5 was approved by the NSW Population and 
Health Services Research Ethics Committee (formerly known as the NSW Department of 
Health Ethics Committee) (Project No: 2005-11-017), Cancer Institute NSW Ethics 
Committee (Reference: 2004/05/024) and Cancer Council NSW (Reference: Project #298). 
De-identified data were used in all analyses. 
 
Appendix B: List of other research publications during PhD candidature 
 
Page 196 
 
Appendix B: List of other research publications during 
PhD candidature 
While undertaking my PhD research, I also made substantial contributions to the following 
cancer research publications, which are complementary to my research but do not form a 
part of the content of this thesis: 
1. Luo Q, Yu XQ, Wade S, Caruana M, Pesola F, Canfell K, O’Connell DL. Lung cancer 
mortality in Australia: Projected outcomes to 2040. Lung Cancer 2018; 125: 68-76. 
2. Yu XQ, Luo Q, Smith DP, O’Connell DL. Phase of care prevalence for prostate cancer 
in New South Wales, Australia: A population-based modelling study. PLOS One, 2017; 
39(1): 29–36. 
3. Luo Q, O’Connell DL, Kahn C, Yu XQ. Colorectal cancer metastatic disease 
progression in Australia: a population-based analysis. Cancer Epidemiol 2017; 49C: 
92-100. 
4. Yu XQ, Luo Q, Kahn C, Cahill C, Weber M, Grogan P, Jemal A, O’Connell DL. Widening 
socioeconomic disparity in lung cancer incidence among men in New South Wales, 
Australia, 1987-2011. Chin J Cancer Res 2017; 29 (5): 395-401. 
5. Yu XQ, Luo Q, Kahn C, Grogan P, O’Connell DL, Jemal A. Contrasting temporal trends 
in lung cancer incidence by socioeconomic status among women in New South 
Wales, Australia, 1985-2009. Lung Cancer 2017; 108: 55-61. 
6. Chapman S, Azizi L, Luo Q, Sitas F. Response from the authors to correspondence 
related to ‘Has the incidence of brain cancer risen in Australia since the introduction 
of mobile phones 29 years ago?’ Cancer Epidemiol 2016; 44: 138–140. 
Appendix B: List of other research publications during PhD candidature 
 
Page 197 
 
7. Chapman S, Azizi L, Luo Q, Sitas F. Has the incidence of brain cancer risen in Australia 
since the introduction of mobile phones 29 years ago? Cancer Epidemiol 2016; 42: 
199-205. 
8. He Y, Yu XQ, Luo Q, et al. Patterns of care of non-small cell lung cancer patients in 
China and implications for survival. Journal of Cancer Research and Therapeutics, 
2018; 14(9): 410-415.  
9. Yu XQ, Kahn C, Luo Q, Sitas F, O’Connell DL. Lung cancer prevalence in New South 
Wales (Australia): Analysis of past trends and projection of future estimates. Cancer 
Epidemiol 2015; 39(4): 534-538. 
10. Sitas F, Neale RE, Weber MF, Luo Q. Pancreatic cancer: gradual rise, increasing 
relevance. Med J Aust 2015; 202(8): 401-402. 
11. Yu XQ, Luo Q, Kahn C, O'Connell DL and Houssami N. Temporal trends show 
improved breast cancer survival in Australia but widening urban-rural differences. 
Breast 2015; 24(4): 524-527. 
12. Yu XQ, Luo Q, Smith DP, Clements MS, O’Connell DL. Prostate cancer prevalence in 
New South Wales Australia: A population-based study. Cancer Epidemiol 2014; 39(1): 
29–36. 
13. Yu XQ, De Angelis R, Luo Q, Kahn C, Houssami N and O'Connell DL. A population-
based study of breast cancer prevalence in Australia: predicting the future health 
care needs of women living with breast cancer. BMC Cancer 2014; 14: 936. 
 
 
Appendix C: List of other conference presentations during PhD candidature 
 
Page 198 
 
Appendix C: List of other conference presentations 
during PhD candidature 
Oral presentations: 
1. Luo Q, O'Connell DL, Kahn C, Yu XQ. Progression to metastatic colorectal cancer in an 
Australian population. International Association of Cancer Registries (IACR) 39th 
Annual Scientific Meeting, 16-19 October 2017, Utrecht, the Netherlands. 
2. Luo Q, O'Connell DL, Kahn C, Yu XQ. Progression to metastatic colorectal cancer in an 
Australian population. Oral presentation, AEA 2016 Annual Scientific Meeting, 14-16 
September 2016, Canberra, Australia. 
 
Poster presentations: 
1. Luo Q, Steinberg J, O’Connell D, Yu XQ, Caruana M, Wade S, Canfell K. Impact of 
tobacco control on lung cancer mortality in Australia up to 2100: how many deaths 
can be averted? Australian Lung Cancer Conference 2018, Sydney, NSW, Australia, 5-
7 Apr 2018. 
2. Luo Q, O'Connell DL, Kahn C, Yu XQ. Progression to metastatic colorectal cancer in an 
Australian population. Poster presentation, Sydney Cancer Conference, 22-23 
September 2016, Sydney, Australia. 
 
Contribution to conference presentations: 
1. Rankin N, Weber M, Luo Q, Wade S, Hughes S, Fong K, Canfell K. Lung cancer 
pathways: a five-year program to reduce impact through epidemiological modelling 
Appendix C: List of other conference presentations during PhD candidature 
 
Page 199 
 
and investment in prioritized interventions. World Conference on Lung Cancer 2017, 
Yokohama, Japan, 16 Oct 2017. 
2. Rankin N, Weber M, Luo Q, Caruana M, Wade S, Yap S, Hughes S, Fornusek, J, 
Murray J, Vaneckova P, Canfell K, in collaboration with the Lung Cancer Pathways 
Scientific Advisory Committee. Lung cancer ‘Pathways’: a five-year program to 
reduce the impact of lung cancer through epidemiological modelling and investment 
in prioritised interventions. Australian Lung Cancer Conference 2018, Sydney NSW, 
Australia, 5-7 Apr 2018. 
3. Yu XQ, Luo Q, Smith DP, Clements M, O’Connell DL. Challenges in projecting 
prevalence for prostate cancer. Poster presentation, 13th Australasian Prostate 
Cancer Conference, 31 July-3 August 2012, Melbourne, Australia 
4. Yu XQ, Luo Q, Smith DP, Clements M, O’Connell DL. Challenges in projecting 
prevalence for prostate cancer. Poster Presentation, 34th IACR (International 
Association of Cancer Registries) annual meeting 2012, 17-19 September 2012, 
Ireland 
5. Yu XQ, Luo Q, Smith DP, Clements M, O’Connell DL. A method to project prevalence 
by phase of care for prostate cancer. Best of the best oral presentation, the 38th 
COSA annual meeting 2012, 13-15 November 2012, Brisbane, Australia  
6. Yu XQ, Luo Q, Smith DP, Clements M, O’Connell DL. Challenges in projecting 
prevalence for prostate cancer. Best of the best oral presentation, the 38th COSA 
2011 annual meeting , 15-17 November 2011, Perth, Australia 
 
 
 
 
 
